Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.1.11.1 - exodeoxyribonuclease I

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
abc-type xenobiotic transporter deficiency
ABCC4, a plasma membrane transporter modulating platelet aggregation.
Abortion, Habitual
Phosphodiesterase 8B gene polymorphism in women with recurrent miscarriage: a retrospective case control study.
Abscess
The Role of Phosphodiesterase Inhibitors in the Management of Cavernositis With Multifocal Abscesses: A Report of Case Series.
Acidosis
Effects of olprinone, a new phosphodiesterase inhibitor, on gastric intramucosal acidosis and systemic inflammatory responses following hypothermic cardiopulmonary bypass.
Influence of Acidosis on Cardiotonic Effects of Colforsin and Epinephrine: A Dose-Response Study.
Acquired Immunodeficiency Syndrome
A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review.
Prenatal diagnosis of cystic fibrosis by assay of amniotic fluid microvillar enzymes.
The fine-structural distribution of G-protein receptor kinase 3, beta-arrestin-2, Ca2+/calmodulin-dependent protein kinase II and phosphodiesterase PDE1C2, and a Cl(-)-cotransporter in rodent olfactory epithelia.
Acute Coronary Syndrome
A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers.
Cilostazol and Primary-PCI: Mirage or Good Alternative?
Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease--a randomized placebo-controlled study.
Acute Kidney Injury
Effects of olprinone, a phosphodiesterase III inhibitor, on ischemic acute renal failure.
Further characterization of the protective effect of 8-cyclopentyl-1,3-dipropylxanthine on glycerol-induced acute renal failure in the rat.
Inhibition of cytokine release by and cardiac effects of type IV phosphodiesterase inhibition in early, profound endotoxaemia in vivo.
Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure.
Lipopolysaccharide-induced acute renal failure in conscious rats: effects of specific phosphodiesterase type 3 and 4 inhibition.
Phosphodiesterase (1, 3 & 5) inhibitors attenuate diclofenac-induced acute kidney toxicity in rats.
Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine.
Zaprinast accelerates recovery from established acute renal failure in the rat.
Acute Lung Injury
Development and assessment of countermeasure formulations for treatment of lung injury induced by chlorine inhalation.
Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung.
Induced nitric oxide impairs relaxation but not contraction in endotoxin-exposed rat pulmonary arteries.
LPS-induced acute lung injury is attenuated by phosphodiesterase inhibition: effects on proinflammatory mediators, metalloproteinases, NF-kappaB, and ICAM-1 expression.
Mitigation of chlorine lung injury by increasing cyclic AMP levels.
Nitration of protein kinase G-I? modulates cyclic nucleotide crosstalk via phosphodiesterase 3A: Implications for acute lung injury.
Phosphodiesterase inhibition overcomes pulmonary vasomotor dysfunction in acute lung injury.
Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?
Short-term cardiovascular effects of selective phosphodiesterase 3 inhibitor olprinone versus non-selective phosphodiesterase inhibitor aminophylline in a meconium-induced acute lung injury.
Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury.
Adenocarcinoma
Adenosine 3' , 5'-cyclic monophsphate phosphodiesterase activities in the x-irradiation induced rat small bowel adenocarcinoma.
Collecting data through high throughput in vitro early toxicity and off-target liability assays to rapidly identify limitations of novel thyromimetics.
Inhibition of experimental metastasis of human adenocarcinoma by cilostazol, a platelet phosphodiesterase inhibitor.
Parallel activation of cyclic AMP phosphodiesterase and cyclic AMP-dependent protein kinase in two human gut adenocarcinoma cells (HT 29 and HRT 18) in culture, by vasoactive intestinal peptide (VIP) and other effectors activating the cyclic AMP system.
Adenocarcinoma of Lung
Exonuclease 1 (EXO1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Lung Adenocarcinoma.
Adenoma
Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population.
Comparative study of cyclic AMP-generation system, steroid biosynthesis and lipid metabolism in vitro in ACTH responsive and unresponsive adrenal tumors.
Constitutively active Gs alpha is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas.
How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues?
Identification of gene expression profiles associated with cortisol secretion in adrenocortical adenomas.
Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations.
Adenoma, Islet Cell
Isolation and characterization of calmodulin from an insulin-secreting tumour.
Adenomatous Polyposis Coli
Advances in the study of Lynch syndrome in China.
Adrenocortical Carcinoma
Stimulation of guanosine 3',5'-monophosphate-phosphodiesterase activity by adrenocorticotropic hormone-activated increase of guanosine 3',5'-monophosphate in isolated adrenocortical carcinoma cells.
Airway Obstruction
Evaluation of the effect of phosphodiesterase on equine platelet activation and the effect of antigen challenge on platelet phosphodiesterase activity in horses with recurrent airway obstruction.
Albuminuria
Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-alpha stimulation, and effects of a phosphodiesterase inhibitor.
Alopecia
Comment on 'Androgenetic alopecia is associated with increased scalp hardness': role of phosphodiesterase inhibitors?
The use of phosphodiesterase inhibitors for the treatment of alopecia.
Alopecia Areata
Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases.
Alstrom Syndrome
Birt-Hogg-Dubé syndrome associated with chorioretinopathy and nyctalopia: a case report and review of the literature.
Alzheimer Disease
A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers.
Alterations of selected enzymes of phospholipid metabolism in Alzheimer's disease brain tissue as compared to non-Alzheimer's demented controls.
Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization.
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.
Bioinformatic Analysis Reveals Phosphodiesterase 4D-Interacting Protein as a Key Frontal Cortex Dementia Switch Gene.
Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
Cilostazol, a Phosphodiesterase 3 Inhibitor, Moderately Attenuates Behaviors Depending on Sex in the Ts65Dn Mouse Model of Down Syndrome.
Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer's Disease.
Design and Synthesis of Novel Aminoalkanamides Targeting Neurodegeneration and Symptoms of Alzheimer's Disease.
Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease.
Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease.
Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.
Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study.
Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Ferulic acid alleviates A?25-35- and lipopolysaccharide-induced PC12 cellular damage: a potential role in Alzheimer's disease by PDE inhibition.
Inhibition of PDE2A, but not PDE9A, modulates presynaptic short-term plasticity measured by paired-pulse facilitation in the CA1 region of the hippocampus.
Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Multifunctional Ligands Targeting Phosphodiesterase as the Future Strategy for the Symptomatic and Disease-Modifying Treatment of Alzheimer's Disease.
Neurovascular Protective Function of Endothelial Nitric Oxide?- Recent Advances.
New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment.
Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview.
Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.
Phosphodiesterase inhibitors say NO to Alzheimer's disease.
Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1-42-mediated cytotoxicity.
Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.
Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer's Disease.
Targeting New Pharmacological Approaches for Alzheimer's Disease: Potential for Statins and Phosphodiesterase Inhibitors.
Zaprinast and rolipram enhances spatial and emotional memory in the elevated plus maze and passive avoidance tests and diminishes exploratory activity in naive mice.
Amebiasis
Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer.
Amnesia
Brain cyclic AMP and memory in mice.
Testing cyclic AMP mediation of memory: reversal of alpha-methyl-p-tyrosine-induced amnesia.
Amyloidosis
Combined treatment with terbutaline and aminophylline inhibits experimental amyloidosis in mice.
Amyotrophic Lateral Sclerosis
Calcium, calmodulin and 3',5'-cyclic nucleotide phosphodiesterase activity in human muscular disorders.
Anaphylaxis
Effect of the lipoxygenase inhibitor N-hydroxy-N-(6-methoxy-3,4-dihydro-2-naphthylmethyl)urea on bronchoconstriction and lung vascular permeability in anaphylactic guinea pigs.
In vivo anaphylaxis in the rat: effects of phosphodiesterase inhibitors.
Studies with two new phosphodiesterase inhibitors (ICI 58, 301 and ICI 63, 197) on anaphylaxis in guinea pigs, mice and rats.
[Changes in the cyclic nucleotide system in experimental anaphylaxis and approaches to their correction]
[Effect of thymagen, thymalin and vilosen on the cAMP and cGMP levels and phosphodiesterase activity in spleen lymphocytes during sensitization and anaphylactic shock]
Anemia
Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals.
Anemia, Hemolytic
Pulmonary hypertension in patients with hematological disorders following splenectomy.
Anemia, Sickle Cell
Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.
Increased adhesive properties of platelets in sickle cell disease: roles for alphaIIb beta3-mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity.
Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals.
PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study.
Sildenafil promotes eNOS activation and inhibits NADPH oxidase in the transgenic sickle cell mouse penis.
Testosterone replacement in transgenic sickle cell mice controls priapic activity and upregulates PDE5 expression and eNOS activity in the penis.
Angina Pectoris
Co-crystal structures of PKG I? (92-227) with cGMP and cAMP reveal the molecular details of cyclic-nucleotide binding.
Anosmia
Aetiological relationships of nasal mucus cyclic nucleotides in patients with taste and smell dysfunction.
Relative resistance to oral theophylline treatment in patients with hyposmia manifested by decreased secretion of nasal mucus cyclic nucleotides.
Anthrax
Synergic TiO2 photocatalysis and guanine photoreduction for silver deposition amplification: an ultrasensitive and high-throughput visualized colorimetric analysis strategy for anthrax DNAs in blood using a wettable microwells array.
Apnea
Adenosine analogues depress ventilation in rabbit neonates. Theophylline stimulation of respiration via adenosine receptors?
Arrhythmias, Cardiac
Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.
Multiorgan Drug Action of Levosimendan in Critical Illnesses.
Nitroxyl (HNO) for treatment of acute heart failure.
PDE1 Inhibition Modulates Cav1.2 Channel to Stimulate Cardiomyocyte Contraction.
Use of levosimendan in patients with ischemic heart disease following mechanical reperfusion.
[Progress in treatment of chronic heart failure in Western medicine and treatment strategies in traditional Chinese medicine]
Arterial Occlusive Diseases
Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction.
Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles.
Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.
Arteritis
Characterization of the arteritis induced by infusion of rats with UK-61,260, an inodilator, for 24 h. A comparison with the arteritis induced by fenoldopam mesylate.
Arthralgia
A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period.
Arthritis
Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram.
Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity.
Difference in preventive effects between the phosphodiesterase iv inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice.
Effect of phosphodiesterase-5 inhibition on joint and muscle damage in rats with adjuvant arthritis
Effects of the phosphodiesterase inhibitor rolipram on streptococcal cell wall-induced arthritis in rats.
Tadalafil analgesia in experimental arthritis involves suppression of intra-articular TNF release.
Arthritis, Experimental
Combination therapy with DMARDs and biological agents in collagen-induced arthritis.
Effects of pentoxifylline and nabumetone on the serum levels of IL-1beta and TNFalpha in rats with adjuvant arthritis.
Arthritis, Infectious
Inhibiting the inflammatory response in joint sepsis.
Arthritis, Psoriatic
Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections.
Apremilast in psoriatic arthritis.
Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Proximal Renal Tubular Acidosis (Fanconi syndrome) Induced by Apremilast: A Case Report.
Worsening of Lymphopenia during Apremilast Treatment.
Arthritis, Rheumatoid
Differential effect of phosphodiesterase IV inhibitor RP73401 on various inflammatory and immune responses relevent to rheumatoid arthritis.
Drugs, inflammation and cell adhesion receptors.
Potential of phosphodiesterase type of IV inhibitors in the treatment of rheumatoid arthritis.
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.
Vardenafil and cilostazol can improve vascular reactivity in rats with diabetes mellitus and rheumatoid arthritis co-morbidity.
[Effect of selective phosphodiesterase 4 inhibitors on nuclear factor kappa B, tumor necrosis factor-? and interleukin-8 expression in peripheral blood mononuclear cells in rheumatoid arthritis with interstitial lung disease].
Asthma
Protective effects of phosphodiesterase inhibitors on lung function and remodeling in a murine model of chronic asthma.
A comparison of the relaxant effects of olprinone and aminophylline on methacholine-induced bronchoconstriction in dogs.
A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-? Signaling and Activation of cAMP/PKA Signaling.
A review on herbal antiasthmatics.
Airway smooth muscle as a target of asthma therapy: history and new directions.
Ariflo (SmithKline Beecham plc).
Asthma and airway inflammation: potential anti-inflammatory activities of phosphodiesterase inhibitors.
Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients.
Bronchodilatory and anti-inflammatory properties of inhaled selective phosphodiesterase inhibitors in a guinea pig model of allergic asthma.
Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma.
Bronchoprotective effects of KF-19514 and cilostazol in guinea pigs in vivo.
CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.
Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
Chemotherapeutic potential of phosphodiesterase inhibitors.
Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Comparison of Effect of Leukotriene Biosynthesis Blockers and Inhibitors of Phosphodiesterase Enzyme in Patients with Bronchial Hyperreactivity.
Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.
Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors.
Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.
Effect of aerosolized administration of KF19514, a phosphodiesterase 4 inhibitor, on bronchial hyperresponsiveness and airway inflammation induced by antigen inhalation in guinea-pigs.
Effect of T-440, a novel type IV phosphodiesterase inhibitor, on allergen-induced immediate and late asthmatic reaction and leukocyte infiltration into the airways of guinea pigs.
Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma.
Effect of theophylline on CD11b and L-selectin expression and density of eosinophils and neutrophils in vitro.
Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma.
Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence.
Effects of intracellular cyclic AMP modulators on human eosinophil survival, degranulation and CD11b expression.
Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung.
Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig.
Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines.
Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma.
Elevated leukocyte phosphodiesterase as a basis for depressed cyclic adenosine monophosphate responses in the Basenji greyhound dog model of asthma.
Enantiomer Discrimination Illustrated by the High Resolution Crystal Structures of Type 4 Phosphodiesterase.
Evidence of oxidative stress in asthma and COPD: potential inhibitory effect of theophylline.
Experimental and investigational phosphodiesterase inhibitors in development for asthma.
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Future developments in the pharmacotherapy of lung disease.
Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies.
Hesperetin, a Selective Phosphodiesterase 4 Inhibitor, Effectively Suppresses Ovalbumin-Induced Airway Hyperresponsiveness without Influencing Xylazine/Ketamine-Induced Anesthesia.
Hesperidin-3'-o-methylether is more potent than hesperidin in phosphodiesterase inhibition and suppression of ovalbumin-induced airway hyperresponsiveness.
Human alveolar macrophage activation: inhibition by forskolin but not beta-adrenoceptor stimulation or phosphodiesterase inhibition.
Hypertrophic osteopathy in rats following chronic administration of SDZ MNS 949, an isoquinoline.
Ibudilast inhibits chemokine expression in rheumatoid synovial fibroblasts and exhibits immunomodulatory activity in experimental arthritis.
Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats.
Ibudilast: a non?selective phosphodiesterase inhibitor in brain disorders.
Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease.
In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor.
Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma.
Inhibition of phosphodiesterase activity, airway inflammation and hyperresponsiveness by PDE4 inhibitor and glucocorticoid in a murine model of allergic asthma.
Inhibition of phosphodiesterase suppresses allergic lung inflammation by regulating MCP-1 in an OVA-induced asthma murine model with co-exposure to lipopolysaccharide.
Investigating the effect of sildenafil on improving lung function and quality of life in the patients with severe asthma.
Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker.
Lack of involvement of type 7 phosphodiesterase in an experimental model of asthma.
Low-dose theophylline: a new anti-inflammatory role in asthma management?
Modulation of Cytokine Production by Cyclic Adenosine Monophosphate Analogs in Human Leukocytes.
New Avenues for Phosphodiesterase Inhibitors in Asthma.
New cassane-type diterpenoids from kernels of Caesalpinia bonduc (Linn.) Roxb. and their inhibitory activities on phosphodiesterase (PDE) and nuclear factor-kappa B (NF-?B) expression.
Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models.
Olprinone, a phosphodiesterase III inhibitor, does not affect hypoxia-induced pial arteriolar dilatation in rabbits.
Pharmacologic modification of induced asthma.
Pharmacologic modulation of experimentally induced allergic asthma.
Pharmacological Basis for Medicinal Use of Lens culinaris in Gastrointestinal and Respiratory Disorders.
Pharmacological explanation for the medicinal use of Juniperus excelsa in hyperactive gastrointestinal and respiratory disorders.
Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.
Phosphodiesterase 3 inhibition and cough in elderly asthmatics.
Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis.
Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs.
Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.
Phosphodiesterase Type 4D Gene Polymorphism: Association with the Response to Short-Acting Bronchodilators in Paediatric Asthma Patients.
Potent suppressive effects of 3-O-methylquercetin 5,7,3',4'-O-tetraacetate on ovalbumin-induced airway hyperresponsiveness.
Potential and novel therapies for asthma.
Potential use of selective phosphodiesterase inhibitors in the treatment of asthma.
Pretreatment with antiasthmatic drug ibudilast ameliorates A?1-42-induced memory impairment and neurotoxicity in mice.
Relationships between adenosine, cyclic nucleotides, and xanthines in asthma.
S-Petasin, the Main Sesquiterpene of Petasites formosanus, Inhibits Phosphodiesterase Activity and Suppresses Ovalbumin-induced Airway Hyperresponsiveness.
Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease.
Selective phosphodiesterase type 4 inhibitors reduce the prolonged survival of eosinophils stimulated by granulocyte-macrophage colony-stimulating factor.
Selective type IV phosphodiesterase inhibitors prevent IL-4-induced IgE production by human peripheral blood mononuclear cells.
Studies on Bronchodilator Activity of Salvia officinalis (Sage): Possible Involvement of K(+) Channel Activation and Phosphodiesterase Inhibition.
Studies on the chemical composition and possible mechanisms underlying the antispasmodic and bronchodilatory activities of the essential oil of Artemisia maritima L.
Synthesis and biological activity of Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.
Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.
Targeting the mast cell in asthma.
The Calcium Channel Blocking and Phosphodiesterase Inhibitory Activities of the Extract of Andropogon muricatus Explains its Medicinal Use in Airways Disorders.
The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma.
The effect of zardaverine, an inhibitor of phosphodiesterase isoenzymes III and IV, on endotoxin-induced airway changes in rats.
The granulocyte response to the phosphodiesterase inhibitor RO 20-1724 in asthma.
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
The potential role of phosphodiesterase inhibitors in the management of asthma.
The rabbit as a model to study asthma and other lung diseases.
The role of phosphodiesterase enzymes in allergy and asthma.
The study of pathogenetic basis of asthma using biostatistic models.
Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants.
Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma.
Theophylline attenuates Ca2+ sensitivity and modulates BK channels in porcine tracheal smooth muscle.
Theophylline exerts complex anti-ageing and anti-cytotoxicity effects in human skin ex vivo.
Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma.
Therapeutic responses in asthma and COPD. Bronchodilators.
Treatment of asthma with theophylline and beta adrenergic agents.
Two new isoxazolines from the husks of Xanthoceras sorbifolia Bunge.
Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells.
Update on the pharmacodynamics and pharmacokinetics of theophylline.
Vinpocetine alleviates lung inflammation via macrophage inflammatory protein-1? inhibition in an ovalbumin-induced allergic asthma model.
[Cyclic nucleotides phosphodiesterase activity in a rat lung model of asthma]
Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome
Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review.
Astrocytoma
Cyclic AMP phosphodiesterase in cloned astrocytoma cells: norepinephrine induces a specific enzyme form.
Identification of the phosphodiesterase regulated by muscarinic cholinergic receptors of 1321N1 human astrocytoma cells.
Multiple forms of cyclic 3',5'-AMP phosphodiesterase of rat cerebrum and cloned astrocytoma and neuroblastoma cells.
Pertussis toxin differentiates between two mechanisms of attenuation of cyclic AMP accumulation by muscarinic cholinergic receptors.
Receptor reserve in the calcium-dependent cyclic AMP response of astrocytoma cells to muscarinic receptor stimulation: demonstration by agonist-induced desensitization, receptor inactivation, and phorbol ester treatment.
Ataxia
Central adenosinergic system involvement in ethanol-induced motor incoordination in mice.
Atherosclerosis
Changes of cyclic-AMP and cycic-AMP phosphodiesterase in the progression and regression of experimental atherosclerosis.
Cilostazol Reduces PAC-1 Expression on Platelets in Ischemic Stroke.
Cilostazol, a phosphodiesterase III inhibitor: future perspectives in atherosclerosis.
Cyclic nucleotide phosphodiesterase 3 expression in vivo: evidence for tissue-specific expression of phosphodiesterase 3A or 3B mRNA and activity in the aorta and adipose tissue of atherosclerosis-prone insulin-resistant rats.
Drugs and foods on contraction of endothelial cells as a key mechanism in atherogenesis and treatment of atherosclerosis with endothelial-cell relaxants (cyclic AMP phosphodiesterase inhibitors).
Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: a randomised, double-blind, placebo-controlled, crossover trial.
Effects of phthalazinol (EG 626) on arterial lipolytic enzyme activities in the rat.
Hyperreactive arterial endothelial cells in atherogenesis and cyclic AMP phosphodiesterase inhibitor in prevention and treatment of atherosclerotic disorders.
Hyperreactive arterial endothelial cells: a clue for the treatment of atherosclerosis.
PDE5 inhibitors for LUTS.
Preparation of ophthalmic formulations containing cilostazol as an anti-glaucoma agent and improvement in its permeability through the rabbit cornea.
Role of sGC-dependent NO signalling and myocardial infarction risk.
The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial.
The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 Inhibitors.
[Effect of cortisol on adenylate cyclase and 3',5'-AMP phosphodiesterase activity and 3',5'-AMP concentration in tissues and biological fluids in experimental atherosclerosis]
Atrial Fibrillation
A Double-Blind Placebo-Controlled Study of the Effects of Olprinone, a Specific Phosphodiesterase III Inhibitor, for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer.
Various subtypes of phosphodiesterase inhibitors differentially regulate pulmonary vein and sinoatrial node electrical activities.
Autoimmune Diseases
Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease.
Phosphodiesterase 4-targeted treatments for autoimmune diseases.
Phosphodiesterase inhibitors in the management of autoimmune disease.
SAMHD1 is a nucleic-acid binding protein that is mislocalized due to aicardi-goutières syndrome-associated mutations.
Systemic lupus erythematosus overlapping dermatomyositis owing to a heterozygous TREX1 Asp130Asn missense mutation.
T Cells Produce IFN-? in the TREX1 D18N Model of Lupus-like Autoimmunity.
The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system.
TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner.
Axial Spondyloarthritis
Beyond the TNF-? Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology.
Bacterial Infections
Rolipram inhibits staphylococcal enterotoxin B-mediated induction of the human skin-homing receptor on T lymphocytes.
Blindness
AIPL1, a protein associated with childhood blindness, interacts with {alpha}-subunit of rod phosphodiesterase (PDE6) and is essential for its proper assembly.
Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors.
Phosphodiesterase dysfunction, cyclic GMP accumulation, and visual cell degeneration in early-onset inherited blindness.
Bloom Syndrome
A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1.
DNA End Resection: Facts and Mechanisms.
Microhomology-mediated End Joining and Homologous Recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells.
RPA Phosphorylation Inhibits DNA Resection.
Bone Diseases, Metabolic
KMUP-1 promotes osteoblast differentiation through cAMP and cGMP pathways and signaling of BMP-2/Smad1/5/8 and Wnt/?-catenin.
Bone Resorption
Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture.
Comparative study of the effects of cyclic nucleotide phosphodiesterase inhibitors on bone resorption and cyclic AMP formation in vitro.
Delayed stimulation of bone resorption in vitro by phosphodiesterase inhibitors requires the presence of adenylate cyclase stimulation.
Delayed stimulatory effect of cyclic AMP on bone resorption in vitro.
Inhibition of bone resorption and lysosomal enzyme release from calvarial bones cultured for 24 hours: synergism between cyclic AMP analogues and phosphodiesterase inhibitors.
Platelet-derived growth factor stimulates bone resorption via a prostaglandin-mediated mechanism.
Brachydactyly
Clinical and Molecular Perspectives of Monogenic Hypertension.
Clinical Effects of Phosphodiesterase 3A Mutations in Inherited Hypertension With Brachydactyly.
Mutations causing acrodysostosis-2 facilitate activation of phosphodiesterase 4D3.
PDE3A mutations cause autosomal dominant hypertension with brachydactyly.
Bradycardia
Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias.
Brain Diseases
Ibudilast: a non?selective phosphodiesterase inhibitor in brain disorders.
Brain Infarction
A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes.
Brain Injuries
Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats.
Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone.
Ibudilast, a phosphodiesterase inhibitor with anti-inflammatory activity, protects against ischemic brain injury in rats.
Neuroprotective effects of cilostazol are mediated by multiple mechanisms in a mouse model of permanent focal ischemia.
Pentoxifylline Alleviates Early Brain Injury After Experimental Subarachnoid Hemorrhage in Rats: Possibly via Inhibiting TLR 4/NF-?B Signaling Pathway.
Pentoxifylline attenuates hypoxic-ischemic brain injury in immature rats.
Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.
Brain Injuries, Traumatic
Detection of single- and double-strand DNA breaks after traumatic brain injury in rats: comparison of in situ labeling techniques using DNA polymerase I, the Klenow fragment of DNA polymerase I, and terminal deoxynucleotidyl transferase.
Phosphodiesterase inhibition rescues chronic cognitive deficits induced by traumatic brain injury.
Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.
Phosphodiesterase isoform-specific expression induced by traumatic brain injury.
Traumatic Brain Injury Upregulates Phosphodiesterase Expression in the Hippocampus.
Brain Ischemia
A Novel Phosphodiesterase Type 4 Inhibitor, HT-0712, Enhances Rehabilitation-Dependent Motor Recovery and Cortical Reorganization After Focal Cortical Ischemia.
Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia.
Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone.
Effect of propentofylline on cerebral blood flow in a gerbil focal cerebral ischemia.
Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia.
In situ detection of neuronal DNA strand breaks using the Klenow fragment of DNA polymerase I reveals different mechanisms of neuron death after global cerebral ischemia.
Pentoxifylline treatment improves neurological and neurochemical deficits in rats subjected to transient brain ischemia.
Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia.
Protection against blood-brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: a quantitative study.
Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil.
The effects of the phosphodiesterase inhibitor olprinone on global cerebral ischemia.
The phosphodiesterase type 2 inhibitor BAY 60-7550 reverses functional impairments induced by brain ischemia by decreasing hippocampal neurodegeneration and enhancing hippocampal neuronal plasticity.
Therapeutic Benefit of Cilostazol in Patients with Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized and Nonrandomized Studies.
Brain Neoplasms
Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo.
Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors.
Phosphodiesterase inhibitors control A172 human glioblastoma cell death through cAMP-mediated activation of protein kinase A and Epac1/Rap1 pathways.
Potential role of calmodulin-dependent phosphodiesterase in human brain tumor (review).
Breast Neoplasms
A new electrochemical method for the detection of cancer cells based on small molecule-linked DNA.
Atacamycins A-C, 22-membered antitumor macrolactones produced by Streptomyces sp. C38.
Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition.
Evaluation of PDE5 and PDE9 Expression in Benign and Malignant Breast Tumors.
Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells.
Implementation of micromethods to resolve problems of human breast tumor heterogeneity in analysis of cyclic 3':5'-nucleotide phosphodiesterase.
Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell-like Property and Metastasis in Breast Cancer.
Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.
[Effect of soy isoflavones on cAMP/PKA pathway in breast cancer cells of the rat.]
Bronchial Hyperreactivity
Comparison of Effect of Leukotriene Biosynthesis Blockers and Inhibitors of Phosphodiesterase Enzyme in Patients with Bronchial Hyperreactivity.
Effects of inhibitors of phosphodiesterase, on antigen-induced bronchial hyperreactivity in conscious sensitized guinea-pigs and airway leukocyte infiltration.
Effects of isoenzyme selective phosphodiesterase inhibitors on bacterial lipopolysaccharide-induced bronchial hyperreactivity in guinea pigs.
Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs.
Bronchial Spasm
Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.
Effect of theophylline administered intratracheally as a dry powder formulation on bronchospasm and airway microvascular leakage in the anesthetized guinea-pig.
Bronchitis, Chronic
Clinical Considerations for Roflumilast: A New Treatment for COPD.
Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review.
Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review.
Bronchopulmonary Dysplasia
Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia.
Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats.
Brugada Syndrome
Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome.
Carcinogenesis
EXO1 overexpression is associated with poor prognosis of hepatocellular carcinoma patients.
Increased cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in the epidermis of phorbol ester-treated mouse skin and in papillomas.
Phosphodiesterase type 5 inhibitors use and risk of colorectal cancer: a systematic review and meta-analysis.
Study of post-natal effect of chemopreventive agents on ethylnitrosourea-induced transplacental carcinogenesis in rats. III. Inhibitory action of indomethacin, voltaren, theophylline and epsilon-aminocaproic acid.
Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.
Carcinoma
A phosphodiesterase from ascites carcinoma Krebs II cells specifically cleaves the bond between VPg and RNA of encephalomyocarditis virus.
Adenosine-3',5'-cyclic monophosphate levels and adenosine-3',5'-cyclic monophosphate phosphodiesterase activity in metastasizing and nonmetastasizing rat mammary carcinomas.
Adenylate cyclase, cyclic adenosin 3':5'-monophosphate phosphodiesterase, and regression of Walker 256 mammary carcinoma.
Association of DNA repair gene polymorphisms with response to cisplatin-based concurrent chemoradiotherapy in patients with cervical carcinoma.
Atacamycins A-C, 22-membered antitumor macrolactones produced by Streptomyces sp. C38.
Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Characterisation of cyclic adenosine 3':5'-monophosphate phospodiesterase from Walker carcinoma sensitive and resistant to bifunctional alkylating agents.
Cyclic AMP phosphodiesterase activity in human gingival carcinoma.
Cyclic nucleotide phosphodiesterase and protein activator in human cancer cell lines and Brown-Pearce carcinoma.
Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Expression and role of phosphodiesterase 3 in human squamous cell carcinoma KB cells.
Inhibition of cyclic adenosine 3',5'-monophosphate phosphodiesterase from Walker carcinoma by ascorbic and dehydroascorbic acids.
Inhibition of growth of primary and metastatic Lewis lung carcinoma cells by the phosphodiesterase inhibitor isobutylmethylxanthine.
Isolation from ascites carcinoma Krebs II cells of an unlinking enzyme hydrolyzing a covalent bond between picornavirus RNA and VPg.
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells.
Modulation of glucocorticoid-regulated transcription by purines: novel characteristics and implications for tissue specificity of steroid responses.
Phosphodiesterase in human colon carcinoma cell line CaCo-2 in culture.
Reduced DNA synthesis and cell viability in small cell lung carcinoma by treatment with cyclic AMP phosphodiesterase inhibitors.
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP.
[Effect of polysaccharides on the cyclic nucleotide content and phosphodiesterase activity in the organs of mice with Lewis lung carcinoma]
Carcinoma, Ehrlich Tumor
Guanine nucleotides activate cytosolic phospholipase C of ascites tumour cells stimulated by 1-oleoyl-2-acetyl-sn-glycerol.
Quercetin inhibition of the induction and function of cytotoxic T lymphocytes.
Carcinoma, Hepatocellular
A simple procedure for the purification of calmodulin bound to membranes; calmodulin bound to the particulate fraction of AH-66 hepatoma ascites cells.
An effect of dexamethasone on adenosine 3',5'-monophosphate content and adenosine 3',5'-monophosphate phosphodiesterase activity of cultured hepatoma cells.
Associations between single-nucleotide polymorphisms of human exonuclease 1 and the risk of hepatocellular carcinoma.
Calcium-activatable phosphodiesterase and calcium-dependent modulator protein in transplantable hepatoma tissues.
Cyclic 3',5'-nucleotide monophosphate phosphodiesterase activity in hepatomas of different growth rates.
Cyclic AMP phosphodiesterase activity in three Morris hepatomas.
Decreased activities of cyclic cytidine 3',5'-monophosphate phosphodiesterase in Morris hepatomas having varying growth rates.
Dynamics of calmodulin and cyclic AMP phosphodiesterase in plasma membranes of rat livers and ascites hepatomas.
EXO1 overexpression is associated with poor prognosis of hepatocellular carcinoma patients.
Increased activity of low-Km cyclic adenosine 3':5'-monophosphate phosphodiesterase in plasma membranes of Morris hepatoma 5123tc (h).
Inhibition of hepatoma cell growth by analogs of adenosine and cyclic AMP and the influence of enzymes in mammalian sera.
No Association of the Exonuclease 1 T439M Polymorphism and Risk of Hepatocellular Carcinoma Development in the Turkish Population: a Case-control Study.
Partial purification from hepatoma cells of an intracellular substance which mediates the effects of insulin on pyruvate dehydrogenase and low Km cyclic AMP phosphodiesterase.
Phosphodiesterase 3/4 Inhibitor Zardaverine Exhibits Potent and Selective Antitumor Activity against Hepatocellular Carcinoma Both In Vitro and In Vivo Independently of Phosphodiesterase Inhibition.
Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma.
Phosphodiesterase and ribonuclease activities of plasma membrane of rat liver and hepatoma.
Phospholipase C (EC 3.1.4.11): a malignancy linked signal transduction enzyme.
Positive correlation between calmodulin content and hepatoma growth rates.
Studies on responsiveness of hepatoma cells to catecholamines. I. Lack of beta-adrenergic responsiveness in rat ascites hepatoma AH13 cells.
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
The action of mitomycin C on the induction of cyclic AMP phosphodiesterase and the development of desensitization of adenylate cyclase by isoproterenol in rat ascites hepatoma AH130 cells.
The antitumour agent 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) inhibits rat liver cAMP phosphodiesterase and amplifies hormone effects in hepatocytes and hepatoma cells.
The significance of Exonuclease 1 K589E polymorphism on hepatocellular carcinoma susceptibility in the Turkish population: a case-control study.
[Adenosine cyclic-3',5'-monophosphate phosphodiesterase in hepatomas with different growth rates]
[Concentration of cyclic nucleotides, activity of adenylate cyclase, 3',5'-AMP phosphodiesterase and guanylate cyclase in plasma membranes from liver and hepatomas of different degrees of malignancy]
Carcinoma, Lewis Lung
Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Inhibition of growth of primary and metastatic Lewis lung carcinoma cells by the phosphodiesterase inhibitor isobutylmethylxanthine.
[Effect of polysaccharides on the cyclic nucleotide content and phosphodiesterase activity in the organs of mice with Lewis lung carcinoma]
Carcinoma, Renal Cell
Stimulation by cAMP of erythropoietin secretion by an established human renal carcinoma cell line.
Carcinoma, Squamous Cell
Expression and role of phosphodiesterase 3 in human squamous cell carcinoma KB cells.
Protein kinase A regulates Rac and is required for the growth factor-stimulated migration of carcinoma cells.
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Cardiac Output, Low
Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery -- a systematic literature review.
Catecholamine and volume therapy for cardiac surgery in Germany--results from a postal survey.
Clinical and haemodynamic effects of milrinone in the treatment of low cardiac output after cardiac surgery.
Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery.
Current practice of hemodynamic monitoring and vasopressor and inotropic therapy in post-operative cardiac surgery patients in Germany: results from a postal survey.
Efficacy of phosphodiesterase inhibitor enoximone in management of postcardiotomy cardiogenic shock.
Inotropic support of the critically ill patient. A review of the agents.
[Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery]
[Hemodynamic effects of new phosphodiesterase inhibitors in patients with coronary heart disease. A comparison between enoximone and R80122]
[The effects of milrinone on hemodynamics in patients undergoing cardiac surgery]
[Treatment of low cardiac output by phosphodiesterase inhibitors]
Cardio-Renal Syndrome
Evolving treatment strategies for management of cardiorenal syndrome.
Pharmacologic Management of the Cardio-renal Syndrome.
Cardiomegaly
Cyclic AMP synthesis and hydrolysis in the normal and failing heart.
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Decreased activity of the Na+/H+ exchanger by phosphodiesterase 5A inhibition is attributed to an increase in protein phosphatase activity.
Function of myocardial alpha-adrenoceptors.
Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats.
Myocardial effects of cyclic AMP phosphodiesterase inhibition are dampened in thyroxine-induced cardiac hypertrophy.
Myocardial energetics: experimental and clinical studies to address its determinants and aerobic limit.
Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes.
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
Cardiomyopathies
An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety.
Chemotherapeutic efficacy of phosphodiesterase inhibitors in chagasic cardiomyopathy.
Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice.
Influence of phosphodiesterase inhibition on myocardial energetics in dilative cardiomyopathy.
Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
The activity of adenylate cyclase and phosphodiesterase in the isoproterenol-damaged cardiac muscle of spontaneously hypertensive rats.
[Enoximone as an alternative to mechanical circulatory support prior to heart transplantation]
[Enoximone as pharmacologic "bridging" to heart transplantation]
Cardiomyopathy, Dilated
Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy.
Augmentation of diastolic function with phosphodiesterase inhibition in congestive heart failure.
Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment.
Effect of dobutamine and OPC-18790 on diastolic chamber stiffness in patients with idiopathic dilated cardiomyopathy.
Effects of intravenous milrinone on left ventricular function in ischemic and idiopathic dilated cardiomyopathy.
Immunomodulatory effect of pentoxifylline in suppressing experimental autoimmune myocarditis.
Influence of enoximone and UDCG-115 on coronary hemodynamics in idiopathic dilated cardiomyopathy.
Marked and prompt hemodynamic improvement by carperitide in refractory congestive heart failure due to dilated cardiomyopathy.
Myocardial energetics and efficiency in patients with idiopathic cardiomyopathy: response to dobutamine and amrinone.
Phosphodiesterase inhibition and positive inotropic effects.
Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure.
[Anesthetic management of a patient with dilated cardiomyopathy using olprinone]
[Vasodilatation and positive inotropic effect of the phosphodiesterase inhibitor enoximone]
Cardiomyopathy, Hypertrophic
Cyclic AMP-dependent phosphodiesterase isozyme-specific potentiation by protein kinase C in hypertrophic cardiomyopathic hamster hearts.
Cardiotoxicity
A synopsis of research in cardiac apoptosis and its application to congestive heart failure.
Anagrelide-induced cardiomyopathy.
Apoptosis: pathophysiology and therapeutic implications for the cardiac surgeon.
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Epinephrine induced myocardial necrosis: effects of aminophylline and adrenergic blockade.
Cardiovascular Diseases
A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases.
Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease.
Beneficial effects of tetramethylpyrazine, an active constituent of Chinese herbs, on rats with endotoxemia.
Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.
Chronic treatment with Sildenafil has no effect on folliculogenesis or fertility in C57BL/6 and C57BL/6 knockout for iNOS mice.
Clinical studies of phosphodiesterase inhibitors for cardiovascular disease.
Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease.
Drug interactions: the new phosphodiesterase inhibitor enoximone and the calcium channel blocker nifedipine in coronary surgery patients--influence on hemodynamics and plasma concentrations.
Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study.
Effect of Andrographolide on Gene Expression Profile and Intracellular Calcium in Primary Rat Myocardium Microvascular Endothelial Cells.
Effects of heterologous expression of human cyclic nucleotide Phosphodiesterase 3A (hPDE3A) on redox regulation in yeast.
Efficacy of B-Type Natriuretic Peptide Is Coupled to Phosphodiesterase 2A in Cardiac Sympathetic Neurons.
Erectile dysfunction.
Flavonoids attenuate cardiovascular disease, inhibit phosphodiesterase, and modulate lipid homeostasis in adipose tissue and liver.
Penile blood cyclic guanosin monophosphate level is associated with penile Doppler ultrasound findings.
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease.
Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).
Sexual dysfunction and cardiac Risk (the Second Princeton Consensus Conference).
Structure of Human Phosphodiesterase 5A1 Complexed with Avanafil Reveals Molecular Basis of Isoform Selectivity and Guidelines for Targeting ?-Helix Backbone Oxygen by Halogen Bonding.
Upregulation of Myocardial and Vascular Phosphodiesterase 9A in A Model of Atherosclerotic Cardiovascular Disease.
Carney Complex
Frequent Phosphodiesterase 11A Gene (PDE11A) Defects in Patients with Carney Complex (CNC) Caused by PRKAR1A Mutations: PDE11A May Contribute to Adrenal and Testicular Tumors in CNC as a Modifier of the Phenotype.
Carotid Artery Diseases
The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial.
Carotid Artery Thrombosis
Ibudilast, a Phosphodiesterase Inhibitor, in Combination with Low-dose Aspirin Potently Inhibits Guinea Pig Carotid Artery Thrombosis without Extending Bleeding Time and Causing Gastric Mucosal Injury.
Catalepsy
Effect of cyclo(Leu-Gly) on cyclic GMP-phosphodiesterase activity changes associated with development of tolerance to morphine-induced antinociception, catalepsy, respiratory depression and mydriasis.
[Effect of phosphodiesterase inhibitors on neuroleptic-induced catalepsy and apomorphine-induced stereotypic movements in rats]
Central Nervous System Diseases
A Novel Inhibition Modality for Phosphodiesterase 2A.
Phosphodiesterase 7(PDE7): A unique drug target for central nervous system diseases.
Phosphodiesterases as a New Therapeutic Targets for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases.
Central Serous Chorioretinopathy
Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil).
Cerebral Hemorrhage
A PDE1 inhibitor reduces adipogenesis in mice via regulation of lipolysis and adipogenic cell signaling.
Cerebral Infarction
Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage.
Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model.
Dose-Dependent Inhibitory Effects of Cilostazol on Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage.
Tenascin-C in brain injuries and edema after subarachnoid hemorrhage: Findings from basic and clinical studies.
Cerebral Small Vessel Diseases
Antiplatelet Therapy in Cerebral Small Vessel Disease.
Cerebrovascular Disorders
A PDE1 inhibitor reduces adipogenesis in mice via regulation of lipolysis and adipogenic cell signaling.
Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats.
Macro- and microrheological parameters of blood in patients with cerebral and peripheral atherosclerosis: the molecular change mechanisms after pentoxifylline treatment.
Mixed Cerebrovascular Disease and the Future of Stroke Prevention.
Progress in the Mechanism and Clinical Application of Cilostazol.
The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation.
Chagas Disease
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and implications for the design of parasite selective inhibitors.
Chemical validation of phosphodiesterase C as a chemotherapeutic target in Trypanosoma cruzi, the etiological agent of Chagas' disease.
Cholecystitis
Hemorrhagic cholecystitis in an elderly patient taking aspirin and cilostazol.
Cholera
5-Hydroxytryptamine type 2A receptors regulate cyclic AMP accumulation in a neuronal cell line by protein kinase C-dependent and calcium/calmodulin-dependent mechanisms.
Acetylcholine inhibits positive inotropic effect of cholera toxin in ventricular muscle.
Action of cAMP on expression and release of adhesion molecules in human endothelial cells.
Actions of peptide YY and neuropeptide Y on chief cells from guinea pig stomach.
Activators of adenylate cyclase and cyclic AMP prolong calcium-dependent action potentials of mouse sensory neurons in culture by reducing a voltage-dependent potassium conductance.
Adenosine 3:5' cyclic monophosphate synthesis by human tracheal epithelial cells.
Alpha 2-adrenergic regulation of arylalkylamine N-acetyltransferase in organ-cultured chick pineal gland: characterization with agonists and modulation of experimentally stimulated enzyme activity.
Antilipolytic effects of insulin and adenylate cyclase inhibitors on isolated human fat cells.
Calcitonin stimulates plasminogen activator in porcine renal tubular cells: LLC-PK1.
Calcium and cyclic nucleotide interaction in secretion of amylase from rat pancreas in vitro.
Calcium ion and cyclic adenosine 3',5'-monophosphate regulate proopiomelanocortin messenger ribonucleic acid levels in rat intermediate and anterior pituitary lobes.
cAMP up-regulates IL-4 and IL-5 production from activated CD4+ T cells while decreasing IL-2 release and NF-AT induction.
Cholinergic inhibition of catecholamine-stimulable cyclic AMP accumulation in murine atria.
Control of monocyte C2 production by cyclic AMP.
Cyclic adenosine-3',5'-monophosphate stimulates the acute release of placental lactogen from human trophoblast cells.
Cyclic AMP is a likely mediator of ovulation in the tsetse fly.
Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils.
Cyclic nucleotides and their relationship to complement-component-C2 synthesis by human monocytes.
Cyclic nucleotides, possible intracellular mediators of macrophage activation and secretory processes.
Decrease in cAMP levels promoted by CD48-CD2 interaction correlates with inhibition of apoptosis in B cells.
Decreased phosphodiesterase activity in cholera toxin-induced hypersecretion in suckling rats.
Desensitization of the cAMP system in mouse Leydig cells by hCG, cholera toxin, dibutyryl cAMP and cAMP: localization of the 'lesion' to the guanine nucleotide regulatory protein-adenylate cyclase complex.
Differences in the beta-adrenergic responsiveness between high and low passage rat glioma C6 cells.
Discrepancy between effects of cholera toxin on net fluid movement and cAMP levels in rat jejunum, ileum, and colon.
Effect of adenylyl cyclase activation on intracellular and extracellular cAMP and cGMP in preimplantation cattle blastocysts.
Effects of cholera toxin and isobutylmethylxanthine on growth of human fibroblasts.
Effects of cholera toxin and phosphodiesterase inhibitors on fluid transport and cyclic adenosine 3',5'-monophosphate concentrations in rabbit gallbladder.
Effects of cholera toxin on cyclic AMP accumulation and bone resorption in cultured mouse calvaria.
Effects of cholinergic and adrenergic agonists on phosphorylation of a 165,000-dalton myofibrillar protein in intact cardiac muscle.
Effects of cyclic adenosine 3':5'-monophosphate upon glycoprotein and carcinoembryonic antigen synthesis and release by human colon cancer cells.
Effects of GnRH and drugs that affect cAMP levels on LH synthesis and release.
Effects of prostaglandins and cAMP levels on monocyte IL-1 production.
Effects of sera, basic fibroblast growth factor, heparin and cyclic AMP-stimulation on proliferation of human vascular endothelial cells.
Epidermal growth factor stimulates formation of inositol phosphates in BALB/c/3T3 cells pretreated with cholera toxin and isobutylmethylxanthine.
Estradiol receptor and cyclic nucleotide phosphodiesterase: functional relationship, possible role of guanine nucleotide binding proteins.
Forskolin does not activate sperm adenylate cyclase.
Hormonal control of phosphodiesterase activity in cultured rat Sertoli cells.
Hormonal regulation of inhibin production by cultured Sertoli cells.
In ovo growth hormone alters growth and adipose tissue development of chickens.
Induction of refractoriness to isoproterenol by prior treatment of C6-2B rat astrocytoma cells with cholera toxin.
Inhibition of follicle-stimulating hormone- and adenosine-3',5'-cyclic monophosphate-induced progesterone production by calcium and protein kinase C in the rat ovary.
Inhibition of human mammary carcinoma cell proliferation by retinoids and intracellular cAMP-elevating compounds.
Inhibition of ornithine decarboxylase and S-adenosylmethionine decarboxylase activities of S49 lymphoma cells by agents increasing cyclic AMP.
Inhibition of the proliferation of Nb2 cells by femtomolar concentrations of cholera toxin and partial reversal of the effect by 12-O-tetradecanoyl-phorbol-13-acetate.
Insulin stimulation of cyclic AMP phosphodiesterase is independent from the G-protein pathways involved in adenylate cyclase regulation.
Involvement of calcium in the release of immunoreactive beta-endorphin-like peptide from dispersed cells of the neurointermediate lobe of the rat pituitary gland.
Isolation of a mutant LLC-PK1 cell line defective in hormonal responsiveness. A pleiotropic lesion in receptor function.
Isolation of nontoxinogenic mutants of Vibrio cholerae in a colorimetric assay for cholera toxin using the S49 mouse lymphosarcoma cell line.
Mechanism of erythropoietin action on the erythroid progenitor cells induced from murine erythroleukemia cells (TSA8).
Modulation of in vitro erythropoiesis: enhancement of erythroid colony growth by cyclic nucleotides.
Multiple signal transduction mechanisms leading to the secretion of 5-hydroxytryptamine by MTC cells, a neurectodermally derived cell line.
Oxidized-low density lipoprotein inhibits cyclic AMP production by porcine luteal cells.
Partial reversal of doxorubicin resistance by forskolin and 1,9-dideoxyforskolin in murine sarcoma S180 variants.
Pharmacological elevation of cyclic AMP and transmitter release at the mouse neuromuscular junction.
Photoreactive (caged) cyclic AMP analogs induce DNA synthesis in mammary epithelial cells.
Potentiation between intracellular cyclic-AMP-elevating agents and inducers of leukemic cell differentiation.
Regulation by butyrate of the cAMP response to cholera toxin and forskolin in pituitary GH1 cells.
Regulation of dome formation in differentiated epithelial cell cultures.
Regulation of interleukin 2 synthesis by cAMP in human T cells.
Regulation of oocyte maturation in the rainbow trout,Salmo gairdneri: role of cyclic AMP in the mechanism of action of the maturation inducing steroid (MIS), 17?-hydroxy, 20?-dihydroprogesterone.
Relation between cyclic adenosine monophosphate and prostaglandin output by dispersed cells from human amnion and decidua.
Role of cyclic nucleotides in the inhibition of growth-hormone secretion by somatostatin.
Role of cytokines in the modulation of nitric oxide production by cyclic AMP.
Role of protein kinase C in transforming growth factor-beta 1 induction of carcinoembryonic antigen in human colon carcinoma cells.
Somatic genetic analysis of cyclic AMP action: characterization of unresponsive mutants.
Stimulatory and inhibitory effects of cyclic AMP on pancreatic glucagon release from monolayer cultures and the controlling role of calcium.
Studies on the mechanisms of somatostatin action on insulin release. IV. effect of somatostatin on cyclic AMP levels and phosphodiesterase activity in isolated rat pancreatic islets.
Suppression of granulocyte/macrophage colony-stimulating factor release from human monocytes by cyclic AMP-elevating drugs: role of interleukin-10.
Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Synthesis of interleukin 6 (interferon-beta 2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP.
The phorbol ester TPA prevents the expression of both glucagon desensitisation and the glucagon-mediated block of insulin stimulation of the peripheral plasma membrane cyclic AMP phosphodiesterase in rat hepatocytes.
The phorbol ester, TPA inhibits glucagon-stimulated adenylate cyclase activity.
The relationship between intracellular cyclic AMP concentrations and the in vitro growth of macrophages.
Thyrotropin-releasing hormone activates a Ca2+-dependent polyphosphoinositide phosphodiesterase in permeable GH3 cells. GTP gamma S potentiation by a cholera and pertussis toxin-insensitive mechanism.
Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line.
[Mechanism of beta-endorphin release regulation--evaluation using dispersed cells of the pituitary intermediate lobe]
[Role of phosphodiesterase in the changes of cyclic adenosine-3',5'-monophosphate in the rabbit jejunal mucosa after treatment with cholera enterotoxin]
[The effects of cholera toxin in the release of beta-endorphin from the dispersed cells of the rat neurointermediate lobe]
Chondrosarcoma
Regulation of chondrosarcoma metabolism by cyclic adenosine 3'5'-monophosphate.
Choroideremia
Regional expression of disease-related genes in human and monkey retina.
Cleft Palate
Developmental pattern of cAMP, adenyl cyclase, and cAMP phosphodiesterase in the palate, lung, and liver of the fetal mouse: alterations resulting from exposure to methylmercury at levels inhibiting palate closure.
Colic
Pathophysiology and symptoms of renal colic in children - a case report.
Pharmacological explanation for the medicinal use of Juniperus excelsa in hyperactive gastrointestinal and respiratory disorders.
Studies on the chemical composition and possible mechanisms underlying the antispasmodic and bronchodilatory activities of the essential oil of Artemisia maritima L.
Treatment of loin pain suspected to be renal colic with papaverine hydrochloride: a prospective double-blind randomised study.
Colitis
Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways.
Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice.
The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice.
The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice.
Colitis, Ulcerative
Clinical utility of plecanatide in the treatment of chronic idiopathic constipation.
In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.
Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP.
Colonic Neoplasms
Adenosine 3',5'-cyclic monophosphate and guanosine 3',5'-cyclic monophosphate phosphodiesterase activities in 1,2-dimethylhydrazine induced colon adenocarcinoma.
Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.
Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility.
Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility.
Positionally cloned human disease genes: patterns of evolutionary conservation and functional motifs.
Therapeutic opportunities in colon cancer: Focus on phosphodiesterase inhibitors.
Color Vision Defects
A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked to mutations in the PDE6C gene.
Decreased catalytic activity and altered activation properties of PDE6C mutants associated with autosomal recessive achromatopsia.
Mutations in the gene PDE6C encoding the catalytic subunit of the cone photoreceptor phosphodiesterase in patients with achromatopsia.
Colorectal Neoplasms
Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS.
Clinical utility of plecanatide in the treatment of chronic idiopathic constipation.
ETHE1 overexpression promotes SIRT1 and PGC1? mediated aerobic glycolysis, oxidative phosphorylation, mitochondrial biogenesis and colorectal cancer.
Functional alterations of human exonuclease 1 mutants identified in atypical hereditary nonpolyposis colorectal cancer syndrome.
Germline deletions of EXO1 do not cause colorectal tumors and lesions which are null for EXO1 do not have microsatellite instability.
Hereditary non-polyposis colorectal cancer and the role of hPMS2 and hEXO1 mutations.
Impact of EXO1 polymorphism in susceptibility to colorectal cancer.
Nuclear localization of human DNA mismatch repair protein exonuclease 1 (hEXO1).
Prognostic and clinicopathological insights of phosphodiesterase 9A gene as novel biomarker in human colorectal cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Advances in the study of Lynch syndrome in China.
Functional alterations of human exonuclease 1 mutants identified in atypical hereditary nonpolyposis colorectal cancer syndrome.
Nuclear localization of human DNA mismatch repair protein exonuclease 1 (hEXO1).
Positionally cloned human disease genes: patterns of evolutionary conservation and functional motifs.
Coma
Controlling anoxic tolerance in adult Drosophila via the cGMP-PKG pathway.
Cone-Rod Dystrophies
A new PDE6A missense variant p.Arg544Gln in rod-cone dystrophy.
Confusion
[Cyclic nucleotide phosphodiesterase in vertebrates]
Connective Tissue Diseases
Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension.
Contracture
Effects of dibutyryl cyclic AMP, ouabain, and xanthine derivatives on crossbridge kinetics in rat cardiac muscle.
Reactivity of the human internal thoracic artery to vasodilators in coronary artery bypass grafting.
[Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone]
Coronary Artery Disease
Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor.
Effects of enoximone and R 80122, a new selective phosphodiesterase III inhibitor, on hemodynamics and myocardial energetics in patients with ischemic heart disease.
Molecular genetics of coronary artery disease.
Some aspects of the cardiovascular pharmacology of UK 14,275 in patients with coronary artery disease.
[Continuous beta-block with esmolol in combination with enoximone : Influence on cardiac function in high risk patients undergoing vascular surgery.]
[Cyclic adenosine monophosphate and atherogenic factors]
[Pharmacodynamic effects of the phosphodiesterase inhibitor enoximone during exposure to the volatile anesthetics halothane and isoflurane in coronary surgery patients]
Coronary Disease
Cardiovascular effects of a new inotropic agent, U. K. 14275, in patients with coronary heart disease.
Cardiovascular effects of forskolin and phosphodiesterase-III inhibitors.
Features of coronary heart disease development in emergency workers of the Chornobyl accident depending on the action of radiation and non radiation risk factors and genotypes of single nucleotide polymorphism rs966221 of phosphodiesterase 4D gene.
[Enoximone as pharmacologic "bridging" to heart transplantation]
[Hemodynamic effects of new phosphodiesterase inhibitors in patients with coronary heart disease. A comparison between enoximone and R80122]
[Hemodynamic, anti-ischemic, metabolic and neurohumoral effects of enoximone (MDL 17,043) in patients with coronary disease]
Coronary Stenosis
Treatment of ischaemic left ventricular dysfunction with milrinone or dobutamine administered during coronary artery stenosis in the presence of beta blockade in pigs.
Coronary Thrombosis
Potentiation of phosphodiesterase inhibitor antithrombotic activity with alpha-2 adrenergic blockade.
Cough
Efficacy and safety profile of roflumilast in a real-world experience.
Studies on Bronchodilator Activity of Salvia officinalis (Sage): Possible Involvement of K(+) Channel Activation and Phosphodiesterase Inhibition.
COVID-19
Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19).
COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors.
Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.
Pentoxifylline or theophylline use in hospitalized COVID-19 patients requiring oxygen support.
Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
Crohn Disease
Cytokine-based therapies in inflammatory bowel disease.
In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.
Cushing Syndrome
A stop-codon of the phosphodiesterase 11A gene is associated with elevated blood pressure and measures of obesity.
Carney complex.
Familial micronodular adrenocortical disease, Cushing syndrome, and mutations of the gene encoding phosphodiesterase 11A4 (PDE11A).
Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors.
Cystic Fibrosis
Activation of endogenous deltaF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition.
Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells.
Adrenergic secretory responses of submandibular tissues from control subjects and cystic fibrosis patients.
Altered calmodulin activity in buccal epithelial cells from cystic fibrosis patients.
Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors.
Isobutylmethylxanthine fails to stimulate chloride secretion in cystic fibrosis airway epithelia.
Mechanisms of anion secretion in Calu-3 human airway epithelial cells by 7,8-benzoquinoline.
Potassium release in labial glands from controls and patients with cystic fibrosis.
Prenatal diagnosis of cystic fibrosis by assay of amniotic fluid microvillar enzymes.
The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects.
Cystitis
Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats.
Type 4 phosphodiesterase inhibitor suppresses experimental bladder inflammation.
Uroprotective effect of pentoxifylline in cyclophosphamide-induced hemorrhagic cystitis in rats.
Death, Sudden, Cardiac
Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.
Decompression Sickness
Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog.
Dementia
Bioinformatic Analysis Reveals Phosphodiesterase 4D-Interacting Protein as a Key Frontal Cortex Dementia Switch Gene.
Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: implication of cilostazol for diabetes mellitus-induced dementia.
Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.
Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.
Propentofylline for dementia.
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.
Dementia, Vascular
Bioinformatic Analysis Reveals Phosphodiesterase 4D-Interacting Protein as a Key Frontal Cortex Dementia Switch Gene.
Demyelinating Diseases
Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model.
Drop in relapse rate of MS by combination therapy of three different phosphodiesterase inhibitors.
Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor.
Dermatitis
Adenosine 3':5'-cyclic monophosphate phosphodiesterase in skin. II. Levels in atopic dermatitis.
Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
Dermatitis, Atopic
2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults.
A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves.
Adenosine 3':5'-cyclic monophosphate phosphodiesterase in skin. II. Levels in atopic dermatitis.
Altered leukocyte protein kinase activity in atopic dermatitis.
Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis
Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.
Cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from patients with atopic dermatitis: correlation with respiratory atopy.
Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes.
Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.
Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study.
Elevated cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from children with atopic dermatitis.
Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness.
gamma-interferon production in atopic dermatitis shows differential modification by phosphodiesterase and prostaglandin inhibition.
Immunopharmacology of the atopic diseases.
Impaired lymphocyte cyclic adenosine monophosphate responses in atopic eczema.
In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Increased leukocyte sensitivity to phosphodiesterase inhibitors in atopic dermatitis: tachyphylaxis after theophylline therapy.
Inositol metabolism in mononuclear leucocytes from patients with atopic dermatitis.
Modulation of leukocyte cyclic AMP phosphodiesterase activity by recombinant interferon-gamma: evidence for a differential effect on atopic monocytes.
Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis.
Peripheral blood mononuclear leukocyte cyclic adenosine monophosphate specific phosphodiesterase activity in childhood atopic dermatitis.
Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis.
Phosphodiesterase and immune dysfunction in atopic dermatitis.
Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro.
Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis.
Response of mononuclear leukocyte cyclic adenosine monophosphate-phosphodiesterase activity to treatment with topical fluorinated steroid ointment in atopic dermatitis.
Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis.
The ACVD task force on canine atopic dermatitis (XXII): nonsteroidal anti-inflammatory pharmacotherapy.
The effect of in vitro exposure to histamine on mononuclear leucocyte phosphodiesterase activity in atopic dermatitis.
Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis.
[Changed phosphodiesterase activity of leukocytes in atopic eczema]
[Papaverin--effective in therapy of pruritus of atopic dermatitis?]
[Topical therapy for atopic eczema].
Diabetes Insipidus
Renal medullary adenylate cyclase in rats with hypothalamic diabetes insipidus.
Diabetes Insipidus, Nephrogenic
Rolipram, a phosphodiesterase inhibitor, in the treatment of two male patients with congenital nephrogenic diabetes insipidus.
Diabetes Mellitus
Analysis of the insulin-sensitive phosphodiesterase 3B gene in type 2 diabetes.
Cilostazol protects against microvascular brain injury in a rat model of type 2 diabetes.
Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM.
Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.
Could chronic Vardenafil administration influence the cardiovascular risk in men with type 2 diabetes mellitus?
Does radical nephrectomy increase the risk of erectile dysfunction compared with partial nephrectomy? A cohort analysis.
Effect of cilostazol on the neuropathies of streptozotocin-induced diabetic rats.
Effects of chronic administration of the phosphodiesterase inhibitor vardenafil on serum levels of adrenal and testicular steroids in men with type 2 diabetes mellitus.
Increased PC-1 phosphodiesterase activity and inhibition of glucose uptake in adipocytes of type 2 diabetic rats.
Phosphodiesterase activity in human subcutaneous adipose tissue in insulin- and noninsulin-dependent diabetes mellitus.
Phosphodiesterase III Inhibition Increases cAMP Levels and Augments the Infarct Size Limiting Effect of a DPP-4 Inhibitor in Mice with Type-2 Diabetes Mellitus.
Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
Temporal changes in vascular reactivity in early diabetes mellitus in rats: role of changes in endothelial factors and in phosphodiesterase activity.
The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial.
Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis.
Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension.
[Treatment of erectile dysfunction of neurogenic genesis with inhibitors of phosphodiesterase of type 5 in patients with diabetes mellitus]
Diabetes Mellitus, Experimental
The response of cyclic 3',5'-AMP and cyclic 3',5'-GMP phosphodiesterases to experimental diabetes.
Diabetes Mellitus, Lipoatrophic
Analysis of the insulin-sensitive phosphodiesterase 3B gene in type 2 diabetes.
Diabetes Mellitus, Type 2
Analysis of the insulin-sensitive phosphodiesterase 3B gene in type 2 diabetes.
Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM.
Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.
Common variants in the ENPP1 gene are not reproducibly associated with diabetes or obesity.
Could chronic Vardenafil administration influence the cardiovascular risk in men with type 2 diabetes mellitus?
Decreased glucagon-stimulated cyclic AMP production by isolated liver cells of rats with type 2 diabetes.
Effects of chronic administration of the phosphodiesterase inhibitor vardenafil on serum levels of adrenal and testicular steroids in men with type 2 diabetes mellitus.
Effects of cilostazol, a phosphodiesterase inhibitor, on urinary excretion of albumin and prostaglandins in non-insulin-dependent diabetic patients.
ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes in North Indians.
Increased PC-1 phosphodiesterase activity and inhibition of glucose uptake in adipocytes of type 2 diabetic rats.
Pancreatic ?-cell dysfunction, expression of iNOS and the effect of phosphodiesterase inhibitors in human pancreatic islets of type 2 diabetes.
Phosphodiesterase activity in human subcutaneous adipose tissue in insulin- and noninsulin-dependent diabetes mellitus.
Systematic search for single nucleotide polymorphisms in the 5' flanking region of the human phosphodiesterase 3B gene: absence of evidence for major effects of identified polymorphisms on susceptibility to Japanese type 2 diabetes.
The absence of evidence for major effects of the frequent SNP +299G>A in the resistin gene on susceptibility to insulin resistance syndrome associated with Japanese type 2 diabetes.
The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial.
Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis.
Diabetic Angiopathies
Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F.
Diabetic Nephropathies
Effect of phosphodiesterase inhibitor on diabetic nephropathy.
Evaluation of Drug Interaction of Glimepiride with Phosphodiesterase Inhibitors Type V in Diabetic Nephropathy.
Diabetic Neuropathies
Effect of cilostazol on experimental diabetic neuropathy in the rat.
Sexual dysfunction in men and women with endocrine disorders.
Drug-Related Side Effects and Adverse Reactions
Phosphodiesterase inhibitors in inflammatory bowel disease.
Dry Eye Syndromes
Cilostazol reduces dry eye symptoms and improve walking distance in patients with peripheral artery disease.
PDE4 inhibition suppresses IL-17-associated immunity in dry eye disease.
Dyskinesias
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism?
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
Dyslipidemias
Xanthine-based KMUP-1 improves HDL via PPAR?/SR-B1, LDL via LDLRs, and HSL via PKA/PKG for hepatic fat loss.
Dysostoses
Mutations causing acrodysostosis-2 facilitate activation of phosphodiesterase 4D3.
Dyspnea
Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure.
Isolated unilateral absence of pulmonary artery in adulthood: a clinical analysis of 65 cases from a case series and systematic review.
Migraine with aura following atrial septostomy for pulmonary arterial hypertension.
Embolism
Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats.
Encephalitis
Virus-induced alterations in cyclic adenosine monophosphate generation in hamster islets of Langerhans.
Encephalomyelitis
Heat shock proteins and experimental autoimmune encephalomyelitis (EAE): I. Immunization with a peptide of the myelin protein 2',3' cyclic nucleotide 3' phosphodiesterase that is cross-reactive with a heat shock protein alters the course of EAE.
Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats.
Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats.
Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats.
Sildenafil Inhibits Myelin Expression and Myelination of Oligodendroglial Precursor Cells.
The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents.
Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors.
Encephalomyelitis, Autoimmune, Experimental
Heat shock proteins and experimental autoimmune encephalomyelitis (EAE): I. Immunization with a peptide of the myelin protein 2',3' cyclic nucleotide 3' phosphodiesterase that is cross-reactive with a heat shock protein alters the course of EAE.
Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats.
Phosphodiesterase activity of nervous tissue in experimental allergic encephalomyelitis.
Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats.
Postulated vasoactive neuropeptide immunopathology affecting the blood-brain/blood-spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment?
Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats.
Sildenafil Inhibits Myelin Expression and Myelination of Oligodendroglial Precursor Cells.
The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents.
Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors.
Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: sequential gene expression analysis of cytokines, adhesion molecules and the inducible nitric oxide synthase.
End Stage Liver Disease
NMDA receptors in hyperammonemia and hepatic encephalopathy.
The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation.
Endocrine System Diseases
Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis.
Endotoxemia
Amrinone combined with dobutamine improves hemodynamics and oxygen delivery without down-regulation of cardiac beta-adrenergic receptor density in porcine endotoxemia.
Effects of olprinone on hepatosplanchnic circulation and mitochondrial oxidation in a porcine model of endotoxemia.
Enoximone maintains intestinal villus blood flow during endotoxemia.
Influence of amrinone on intestinal villus blood flow during endotoxemia.
Milrinone improves intestinal villus blood flow during endotoxemia.
Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia.
Phosphodiesterase inhibition decreases nuclear factor-kappaB activation and shifts the cytokine response toward anti-inflammatory activity in acute endotoxemia.
Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 independent.
The effects of olprinone (a phosphodiesterase III inhibitor) on hepatic vascular bed in a porcine model of endotoxemia.
Enteritis
Necrotic enteritis locus 1 diguanylate cyclase and phosphodiesterase (cyclic-di-GMP) gene mutation attenuates virulence in an avian necrotic enteritis isolate of Clostridium perfringens.
Eosinophilia
Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in brown-Norway rats.
The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways.
The potential roles of cytokines, IL-5 and IL-8, and plasma cortisol in the anti-inflammatory actions of phosphodiesterase inhibitors in sensitized guinea-pig airways.
Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia.
Epistaxis
Epistaxis after PDE-5 inhibitors misuse.
Erectile Dysfunction
A case report of pudendal arteries angioplasty with sirolimus drug-coated balloon and drug-eluting stent associated with intracavernous autologous peripheral blood mononuclear cells injection for untreatable vasculogenic erectile dysfunction.
A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
A validated LC-MS/MS assay for the quantification of phosphodiesterase-5 inhibitors in human plasma.
Administration of daily 5?mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia.
Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies.
Association Between Infertility and Sexual Dysfunction in Men and Women.
Atrial fibrillation after vardenafil therapy.
Avanafil for the treatment of erectile dysfunction.
Chronic inhibition of nitric-oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil.
Cialis (tadalafil): a new treatment for erectile dysfunction.
Ciprofloxacin-Induced Antibacterial Activity Is Attenuated by Phosphodiesterase Inhibitors.
Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.
Clinical responses to sildenafil in Waldenstrom's macroglobulinemia.
Co-crystal structures of PKG I? (92-227) with cGMP and cAMP reveal the molecular details of cyclic-nucleotide binding.
Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.
Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease.
Correlations With Satisfaction Measures in Men Treated With Phosphodiesterase Inhibitors for Erectile Dysfunction.
Current and future trends in the oral pharmacotherapy of male erectile dysfunction.
Cutaneous microcirculatory function predicts the responsiveness to tadalafil in patients with erectile dysfunction and coronary artery disease.
Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract.
Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms.
Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling.
Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function.
Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease.
Effect of sildenafil on renin secretion in human subjects.
Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males.
Effects of sildenafil on retinal blood flow and flicker-induced retinal vasodilatation in healthy subjects.
Effects of the specific phosphodiesterase inhibitors on alloxan-induced diabetic rabbit cavernous tissue in vitro.
Erectile dysfunction drugs altered the activities of antioxidant enzymes, oxidative stress and the protein expressions of some cytochrome P450 isozymes involved in the steroidogenesis of steroid hormones.
Erectile dysfunction drugs and oxidative stress in the liver of male rats.
Erectile dysfunction.
Erectile dysfunction: management update.
Erectile dysfunction: on the efficacy of a phosphodiesterase inhibitor in patients with multiple risk factors.
Erectile dysfunction: on the efficacy of a phosphodiesterase inhibitor with concurrent sex therapy.
Evaluation and treatment of autonomic disorders of the urogenital system.
Evaluation and treatment of erectile dysfunction in men with diabetes mellitus.
Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men.
FRS 1000, an extract of red onion peel, strongly inhibits phosphodiesterase 5A (PDE 5A).
Future strategies for treating erectile dysfunction.
Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat.
Local Treatment of Penile Prosthesis Infection as Alternative to Immediate Salvage Surgery.
Management of male sexual dysfunction after cancer treatment.
Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
Metabolism of aildenafil in vivo in rats and in vitro in mouse, rat, dog, and human liver microsomes.
Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.
Might erectile dysfunction be due to the thermolabile variant of methylenetetrahydrofolate reductase?
MONOTHERAPY FOR COMORBID ERECTILE DYSFUNCTION AND LOWER URINARY TRACT SYMPTOMS: PHOSPHODIESTERASE INHIBITOR OR ?-ADRENOCEPTOR ANTAGONIST?
Myocardial Impact of NHE1 Regulation by Sildenafil.
Neuropeptides and central control of sexual behaviour from the past to the present: A review.
New immunophenotype of circulating endothelial progenitor cells and endothelial microparticles in patients with erectile dysfunction and metabolic syndrome: effects of tadalafil administration.
New phosphodiesterase inhibitors in the treatment of erectile dysfunction.
Nitrergic-noradrenergic interaction in penile erection: a new insight into erectile dysfunction.
Nonarteritic ischaemic optic neuropathy (NAION) after 36 h of intake of sildenafil citrate: first Egyptian case.
Novel therapies for cyclic GMP control of vascular smooth muscle growth.
Novel treatment options for overlapping yet distinct erectile dysfunction and andropause syndromes.
Obesity, An Enemy of Male Fertility: A Mini Review.
Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction.
PDE-5 and NOS II mRNA expression in menopausal women: a molecular biology study.
PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy.
PDE5 inhibitor treatment persistence and adherence in Brazilian men: post-hoc analyses from a 6-month, prospective, observational study.
Penile prosthetic surgery and its role in the treatment of end-stage erectile dysfunction - an update.
Performance and safety of treatment options for erectile dysfunction in patients with spinal cord injury: A review of the literature.
Pharmacologic treatment of erectile dysfunction.
Pharmacology of phosphodiesterase-5 inhibitors.
Pharmacotherapy for erectile dysfunction.
Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application models.
Pharmacotherapy of sexual dysfunctions : current status.
Phosphodiesterase (PDE5) inhibition assay for rapid detection of erectile dysfunction drugs and analogs in sexual enhancement products.
Phosphodiesterase inhibition: erectile dysfunction is only part of the story.
Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Phosphodiesterase inhibitors in female sexual dysfunction.
Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men.
Phosphodiesterase inhibitors in the treatment of erectile dysfunction.
Phosphodiesterase inhibitors in vascular ischemia: A case report and review of their use in ischemic conditions.
Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction.
Phosphodiesterase Type 5 Inhibitors in Postprostatectomy Erectile Dysfunction: A Critical Analysis of the Basic Science Rationale and Clinical Application.
Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor, in dogs.
Re: JinQiu Yuan, RenJie Zhang, ZuYao Yang, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013;63:902-12.
Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction.
Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
Safety of Phosphodiesterase-5 Inhibitors in Valvular Heart Disease.
Sexual disorders in men with multiple sclerosis: evaluation and management.
Should phosphodiesterase 5 selective inhibitors be used for uterine relaxation?
Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease.
Sildenafil citrate for female sexual arousal disorder: a future possibility?
Sildenafil for erectile dysfunction.
Sildenafil for selective serotonin reuptake inhibitor-induced erectile dysfunction in elderly male depressed patients.
Sildenafil increases the force of right atrial contractions in vitro via the NO-guanylyl cyclase pathway involving beta-adrenoceptor linked mechanisms.
Sildenafil obviates ischemia-reperfusion injury-induced acute kidney injury through peroxisome proliferator-activated receptor ? agonism in rats.
Sildenafil reduces alcohol-induced gastric damage: just say 'NO'.
Sildenafil Use and Increased Risk of Incident Melanoma in US Men: A Prospective Cohort Study.
Sildenafil, a novel effective oral therapy for male erectile dysfunction.
Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.
Soluble guanylate cyclase beta1-subunit expression is increased in mononuclear cells from patients with erectile dysfunction.
Structure of Human Phosphodiesterase 5A1 Complexed with Avanafil Reveals Molecular Basis of Isoform Selectivity and Guidelines for Targeting ?-Helix Backbone Oxygen by Halogen Bonding.
Technical advances in penile prostheses.
The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction.
The effect of sildenafil citrate (Viagra) on visual sensitivity.
The effect of sildenafil on ocular blood flow.
The effects of tadalafil on axial-pattern skin flap survival in rats.
The evaluation of the effects of renal failure on erectile dysfunction in a rabbit model of chronic renal failure.
The future of the oral pharmacotherapy of male erectile dysfunction: things to come.
The Global Online Sexuality Survey (GOSS): the United States of America in 2011 chapter II: phosphodiesterase inhibitors utilization among English speakers.
The Phosphodiesterase 5-Inhibitors (PDE-5i) for ERECTILE DYSFUNCTION (ED): A Therapeutic Challenge For Psychiatrists.
The phosphodiesterase type-5 inhibitor, tadalafil, improves depressive symptoms, ameliorates memory impairment, as well as suppresses apoptosis and enhances cell proliferation in the hippocampus of maternal-separated rat pups.
The regulation of transient receptor potential canonical 4 (TRPC4) channel by phosphodiesterase 5 inhibitor via the cyclic guanosine 3'5'-monophosphate.
The Role of Initial Success Rates and Other Factors in Determining Reliability of Outcomes of Phosphodiesterase Inhibitor Therapy for Erectile Dysfunction: A Pooled Analysis of 17 Placebo-Controlled Trials of Tadalafil for Use as Needed.
The role of phosphodiesterase inhibitors in impotence.
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.
The use of antimuscarinics, phosphodiesterase type V inhibitors and phytotherapy for lower urinary tract symptoms in men.
Therapy of ED: PDE-5 Inhibitors.
Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors.
Treatments for erectile dysfunction in spinal cord lesioned patients. Are there alternatives to phosphodiesterase type 5 inhibitors?
Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels.
Udenafil: efficacy and tolerability in the management of erectile dysfunction.
Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future.
Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity.
Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma.
Vardenafil Bayer Yakuhin.
Where cost, medical necessity, and morality meet: should US government insurance programs pay for erectile dysfunction drugs?
Words of wisdom. Re: The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. Paick J-S, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY, Choi HK, Suh J-K, Kim SC.
Words of Wisdom. RE: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Words of Wisdom. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
[Choice of treatment in erectile dysfunction associated with hypogonadism].
[Efficacy and safety of phosphodiesterase inhibitors for erectile dysfunction in diabetic men: A meta analysis].
[Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
[Efficacy of phosphodiesterase inhibitors in the treatment of patients with organic erectile dysfunction: a comparative study]
[Nebido in the treatment of hypogonadism syndrome and its complications in men].
[New features of pharmacologic treatment of erectile dysfunction]
[PDE-5 inhibitors: patients preferences].
[Phosphodiesterase inhibitor for erectile dysfunction. No less effective in the diabetic patient]
[Phosphodiesterase inhibitors are effective in treating erectile dysfunction in diabetic men]
[Phosphodiesterase inhibitors in clinical practice. The present and the future. Part I]
[Prediction of clinical efficacy of levitra (vardenafil) in patients with arteriogenic erectile dysfunction]
[Psychogenic erectile dysfunction and phosphodiesterase inhibitors type 5].
[Recurrence-free survival after radical prostatectomy and PDE-5 inhibitor intake].
[Sexual activity and cardiovascular risks].
[Should we prescribe phosphodiesterase inhibitors for the treatment of symptomatic benign prostatic hyperplasia].
[Tadalafil in patients with benign prostatic hyperplasia during conservative combined therapy].
[Treatment of erectile dysfunction in patients with plastic induration of the penis]
[Treatment of erectile dysfunction of neurogenic genesis with inhibitors of phosphodiesterase of type 5 in patients with diabetes mellitus]
[Type V phosphodiesterase inhibitor erection-provoking test with audio-visual sexual stimulation for the diagnosis of erectile dysfunction]
Escherichia coli Infections
An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
Esophageal Motility Disorders
Phosphodiesterase inhibitors are viable options for treating esophageal motility disorders: A case report and literature review.
exodeoxyribonuclease i deficiency
Fibroblast phosphodiesterase deficiency in Niemann-Pick disease.
Indirect suppression of recB and recC mutations by exonuclease I deficiency.
Trimethoprim-induced DNA polymerase I deficiency in Escherichia coli K-12.
exodeoxyribonuclease vii deficiency
Pyrimidine dimer excision in Escherichia coli strains deficient in exonucleases V and VII and in the 5' leads to 3' exonuclease of DNA polymerase I.
Familial Primary Pulmonary Hypertension
Evidence-based pharmacologic management of pulmonary arterial hypertension.
Levosimendan is not effective in reducing pulmonary pressures in patients with idiopathic pulmonary arterial hypertension: report of two cases.
Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.
Phosphodiesterase inhibitors in the management of primary pulmonary hypertension.
[Aerosolized iloprost combined with a phosphodiesterase inhibitor in the treatment of primary pulmonary hypertension]
Fatigue Syndrome, Chronic
The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system.
Fatty Liver
Combined treatments with metformin and phosphodiesterase inhibitors alleviate non-alcoholic fatty liver disease in high-fat diet-fed rats: A comparative study.
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.
Theophylline-Based KMUP-1 Improves Steatohepatitis via MMP-9/IL-10 and Lipolysis via HSL/p-HSL in Obese Mice.
Fetal Alcohol Spectrum Disorders
Acute administration of vinpocetine, a phosphodiesterase type 1 inhibitor, ameliorates hyperactivity in a mice model of fetal alcohol spectrum disorder.
Phosphodiesterase inhibition increases CREB phosphorylation and restores orientation selectivity in a model of fetal alcohol spectrum disorders.
Fibromyalgia
The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system.
Fibrosarcoma
Pentoxifylline potentiates nitric oxide production and growth suppression in interferon-gamma-treated L929 fibroblasts.
Toxicity to tumour cells of diethylaminoreserpine.
Fissure in Ano
Manometric study of topical sildenafil (Viagra) in patients with chronic anal fissure: sildenafil reduces anal resting tone.
Phosphodiesterase inhibitors cause relaxation of the internal anal sphincter in vitro.
Friedreich Ataxia
Phosphodiesterase Inhibitors Revert Axonal Dystrophy in Friedreich's Ataxia Mouse Model.
Frontotemporal Dementia
Bioinformatic Analysis Reveals Phosphodiesterase 4D-Interacting Protein as a Key Frontal Cortex Dementia Switch Gene.
Ganglioneuroma
Distinct isozyme patterns of cyclic nucleotide phosphodiesterase in human neuroblastoma and ganglioneuroma; a possible marker of differentiation of neural crest-derived tumors and Schwann cells.
Gastrointestinal Diseases
Relationship between phosphodiesterase inhibition induced by several Kampo medicines and smooth muscle relaxation of gastrointestinal tract tissues of rats.
Gastrointestinal Stromal Tumors
Phosphodiesterase 3A: a new player in development of interstitial cells of Cajal and a prospective target in gastrointestinal stromal tumors (GIST).
Genetic Diseases, Inborn
TDP1 serine 81 promotes interaction with DNA ligase IIIalpha and facilitates cell survival following DNA damage.
The role of SOS and flap processing in microsatellite instability in Escherichia coli.
Glaucoma
Use of phosphodiesterase inhibitors and prevalence of self-reported glaucoma in the United States.
Glioblastoma
Molecular cloning and expression of a human phosphodiesterase 4C.
Phosphodiesterase inhibitors control A172 human glioblastoma cell death through cAMP-mediated activation of protein kinase A and Epac1/Rap1 pathways.
Transcriptomics-Based Phenotypic Screening Supports Drug Discovery in Human Glioblastoma Cells.
Glioma
beta Adrenergic receptor-mediated regulation of cyclic nucleotide phosphodiesterase in C6 glioma cells: vinblastine blockade of isoproterenol induction.
Beta-adrenergic receptor regulation of a cyclic AMP phosphodiesterase in C6 glioma cells.
C-6 glioma growth in rats: suppression with a beta-adrenergic agonist and a phosphodiesterase inhibitor.
Cyclic AMP-mediated induction of the cyclic AMP phosphodiesterase of C-6 glioma cells.
delta-Opioid receptor activates cAMP phosphodiesterase activities in neuroblastoma x glioma NG108-15 hybrid cells.
Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma.
Regulation by a beta-adrenergic receptor of a Ca2+-independent adenosine 3',5'-(cyclic)monophosphate phosphodiesterase in C6 glioma cells.
Regulation of cAMP levels by protein kinase C in C6 rat glioma cells.
Response of C-6 glioma to isoproterenol and papaverine in vivo depends on beta-adrenergic receptor density.
RNA polymerase II in C6 glioma cells. Alpha-amanitin blockade of cAMP phosphodiesterase induction by beta-adrenergic stimulation.
Sensitivity of the Natriuretic Peptide/cGMP System to Hyperammonaemia in Rat C6 Glioma Cells and GPNT Brain Endothelial Cells.
The beta-adrenergic receptor system in human glioma-derived cell lines: the mode of phosphodiesterase induction and the macromolecules phosphorylated by cyclic AMP-dependent protein kinase.
The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells.
Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas.
Valproate activates phosphodiesterase-mediated cAMP degradation: relevance to C6 glioma G1 phase progression.
[3H]Rolipram binding and phosphodiesterase activity in neuroblastoma N18TG-2 and glioma C6Bu-1.
[Treatment of rat glioma with a beta-adrenergic agonist and a phosphodiesterase inhibitor in vivo]
Glomerulonephritis
Pentoxifylline attenuated the renal disease progression in rats with remnant kidney.
Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis.
Glomerulonephritis, Membranous
Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann Nephritis.
Glucose Intolerance
Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology.
Early and rapid development of insulin resistance, islet dysfunction and glucose intolerance after high-fat feeding in mice overexpressing phosphodiesterase 3B.
Hearing Loss
An Update on Phosphodiesterase Mutations Underlying Genetic Etiology of Hearing Loss and Retinitis Pigmentosa.
Heart Arrest
The effects of the phosphodiesterase inhibitor olprinone on global cerebral ischemia.
Heart Defects, Congenital
Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment.
[Enoximone in the treatment of postoperative low cardiac output syndrome in pediatric heart surgery. Open study in tetralogy of Fallot]
Heart Diseases
Comparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseases human heart.
Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
Identification of Murine Phosphodiesterase 5A Isoforms and their Functional Characterization in HL-1 Cardiac Cell Line.
Myocardial Response to Milrinone in Single Right Ventricle Heart Disease.
Pharmacological activity of cardiovascular agents from herbal medicine.
Phosphodiesterase 5A as a target in cardiac disease.
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease.
[Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery]
[Enoximone as pharmacologic "bridging" to heart transplantation]
Heart Failure
A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus.
A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period.
A review of the role of statins in heart failure treatment.
Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure.
Acute effects of intravenous phosphodiesterase inhibition in chronic heart failure: simultaneous pre- and afterload reduction with a single agent.
Acute hemodynamic and hormonal effects of CI-930, a new phosphodiesterase inhibitor, in severe congestive heart failure.
Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure.
Acute hemodynamic effects of adibendan, a new phosphodiesterase inhibitor, for severe congestive heart failure.
Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure.
Acute neurohormonal and hemodynamic response to a new peak III phosphodiesterase inhibitor (ICI 153,110) in patients with chronic heart failure.
Acute positive inotropic intervention: the phosphodiesterase inhibitors.
Addition of enoximone to adrenergic agents in the management of severe heart failure.
Addition of phosphodiesterase inhibitors to adrenergic agents in acutely ill patients.
Additive haemodynamic effects of piroximone and prostacyclin in severe chronic heart failure.
Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations.
Amrinone suppresses the synthesis of tumor necrosis factor-alpha in human mononuclear cells.
Amrinone, a phosphodiesterase III inhibitor, and arachidonic acid metabolism in humans.
Amrinone, a selective phosphodiesterase III inhibitor, improves microcirculation and flap survival: a comparative study with prostaglandin E1.
Amrinone: is it the inotrope of choice?
Analysis of responses to a selective phosphodiesterase III inhibitor, SK&F 94120, on isolated myocardium, including human ventricular myocardium from "end-stage" failure patients.
Analysis on outcome of 5284 patients with coronary artery disease: The role of integrative medicine.
Arterial baroreflex sensitivity is a good predictor of inotropic responses to a phosphodiesterase inhibitor in human heart failure.
Augmentation of cardiac function in end-stage heart failure by combined use of dobutamine and amrinone.
Augmentation of diastolic function with phosphodiesterase inhibition in congestive heart failure.
Baroreflex sensitivity might predict responders to milrinone in patients with heart failure.
Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.
Calmodulin kinase II inhibition limits the pro-arrhythmic Ca2+ waves induced by cAMP-phosphodiesterase inhibitors.
Cardiac and hemodynamic effects of intravenous R80122, a new phosphodiesterase III inhibitor, in a canine model of myocardial ischemia and heart failure.
Cardiac contractility modulation with the impulse dynamics signal: studies in dogs with chronic heart failure.
Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties.
Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.
Cardiovascular effects of milrinone.
Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.
Central and regional hemodynamic effects of oral enoximone in congestive heart failure: a double-blind, placebo-controlled study.
Changes in cyclic nucleotide phosphodiesterase activity and calmodulin concentration in heart muscle of cardiomyopathic hamsters.
Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts.
CI-930, a new cardiotonic and vasodilating agent: hemodynamic comparison to dobutamine and long-term clinical effects.
Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.
Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study.
Clinical pharmacokinetics of vasodilators. Part II.
Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.
Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression.
Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure.
Comparative hemodynamic and hormonal response of enoximone and dobutamine in severe congestive heart failure.
Comparative hemodynamic effects of intravenous digoxin and enoximone in severe chronic heart failure.
Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients.
Comparison between the positive inotropic effects of enoximone, a cardiac phosphodiesterase III inhibitor, and dobutamine in patients with moderate to severe congestive heart failure. A study using the end-systolic pressure-volume relationship method.
Comparison of the effects of captopril and enoximone in patients with severe heart failure: a placebo controlled double-blind study.
Comparison of the initial hospitalization costs between the patients treated with dobutamine and the patients treated with amrinone for acute decompensated heart failure in a Japanese institute.
Compartmentalization of beta-adrenergic signals in cardiomyocytes.
Contractile responses to selective phosphodiesterase inhibitors following chronic beta-adrenoreceptor activation.
Contrasting preload-dependent hemodynamic and neurohumoral effects of isomazole, a partial phosphodiesterase inhibitor and calcium sensitizer.
Control of arteriolar resistance in heart failure. Partial attenuation of specific phosphodiesterase inhibitor-mediated vasodilation by digitalis glycosides.
Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicine.
Could Ca2+ sensitizers rescue patients from chronic congestive heart failure?
Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure.
Design and Development of Novel 4-(4-(1H-Tetrazol-5-yl)-1H-pyrazol-1-yl)-6-morpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine as Cardiotonic Agent via Inhibition of PDE3.
Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A.
Diastolic function in patients with severe heart failure: comparison of the effects of enoximone and nitroprusside.
Differential effects of dobutamine and a phosphodiesterase inhibitor on early diastolic filling in patients with congestive heart failure.
Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.
Difficult cases in heart failure: Bridge to beta blockade in severe heart failure: the use of phosphodiesterase inhibitors.
Disposition kinetics of orally administered enoximone in patients with moderate to severe heart failure.
Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure.
Does ventricular fibrillation cause myocardial stunning during defibrillator implantation?
Downregulation of right ventricular phosphodiesterase PDE-3A mRNA and protein before the development of canine heart failure.
Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling.
Drug treatment of patients with decompensated heart failure.
Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension.
Effect of flosequinan upon isoenzymes of phosphodiesterase from guinea-pig cardiac and vascular smooth muscle.
Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs.
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Effect of phosphodiesterase III inhibitor (Olprinone) on thoracic duct lymph flow in anesthetized sheep with experimentally induced heart failure by endothelin-1.
Effect of phosphodiesterase III inhibitor on plasma concentrations of endothelin-1 and tumour necrosis factor in patients with acute heart failure.
Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow.
Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure.
Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
Effect of the phosphodiesterase inhibitor UK 61260 on human myocardial inotropy and diastolic relaxation.
Effectiveness of imazodan for treatment of chronic congestive heart failure. The Imazodan Research Group.
Effects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failure.
Effects of piroximone on the right ventricular function in severe heart failure patients.
Effects of serotonin in failing cardiac ventricle: Signalling mechanisms and potential therapeutic implications.
Effects of the new cardiotonic phosphodiesterase inhibitor 1,2-dihydro-5- imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3-pyridine-carbonitrile hydrochloride monohydrate on aortic input impedance.
Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators.
Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure.
Enhanced relaxation and reduced positive inotropic effects of amrinone in ventricular muscle from cats with subacute heart failure. Implications for drug therapy.
Enhancement of the effectiveness of milrinone to increase force of contraction by stimulation of cardiac beta-adrenoceptors in the failing human heart.
Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
Enoximone as a bridge to heart transplantation: the Utah experience.
Evaluation of phosphodiesterase 9A as a novel biomarker in heart failure with preserved ejection fraction.
Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis.
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Heart failure: therapeutic challenges and strategies and the role of phosphodiesterase inhibitors. 31 August 1988, Vienna, Austria.
Hemodynamic and neuroendocrine response to acute administration of the phosphodiesterase inhibitor BM14.478 in patients with congestive heart failure.
Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failure.
Hemodynamic effects of a novel sodium channel activator in dogs with chronic heart failure.
Hemodynamic efficacy of E-1020 in comparison with dopamine on acute mitral regurgitation in anesthetized dogs.
Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
Hemodynamic, pharmacokinetic and clinical response to CI-930 in congestive heart failure due to ischemic or dilated cardiomyopathy.
Increased messenger RNA level of the inhibitory G protein alpha subunit Gi alpha-2 in human end-stage heart failure.
Influence of isoproterenol and ouabain on excitation-contraction coupling, cross-bridge function, and energetics in failing human myocardium.
Innovations in the pharmacologic management of heart failure.
Inodilator therapy for heart failure. Early, late, or not at all?
Inotropes and beta-blockers: is there a need for new guidelines?
Inotropic and chronotropic effects of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives in isolated rat atria.
Inotropic and energetic effects of altering the force-calcium relationship: mechanisms, experimental results, and potential molecular targets.
Inotropic effect of enoximone in patients with severe heart failure: demonstration by left ventricular end-systolic pressure-volume analysis.
Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction.
Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition.
Intravenous milrinone in treatment of advanced congestive heart failure.
Ion channel modulators as potential positive inotropic compound for treatment of heart failure.
IV milrinone for cardiac output increase and maintenance: comparison in nonhyperdynamic SIRS/sepsis and congestive heart failure.
Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure.
Levosimendan in perioperative and critical care patients.
Levosimendan, a New Inotropic and Vasodilator Agent.
Long-term effects of an inotropic phosphodiesterase inhibitor (ICI 153,110) on the rat salivary gland, harderian gland, and intestinal mucosa.
Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group.
Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.
Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors.
Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group.
Low-dose enoximone in subjects awaiting cardiac transplantation. Clinical results and effects on beta-adrenergic receptors.
Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents.
Marked and prompt hemodynamic improvement by carperitide in refractory congestive heart failure due to dilated cardiomyopathy.
Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type v phosphodiesterase inhibition and exogenous natriuretic Peptide: a novel strategy to improve renal function in experimental overt heart failure.
Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure.
Milrinone: basic and clinical pharmacology and acute and chronic management.
miRNA expression in pediatric failing human heart.
Models of dilated cardiomyopathy in small animals and novel positive inotropic therapies.
Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group.
Myocardial energetics: experimental and clinical studies to address its determinants and aerobic limit.
Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease.
Neuroendocrine changes in heart failure and their clinical relevance.
New pharmacologic interventions to increase cardiac contractility: challenges and opportunities.
New therapies for the management of acute heart failure.
Newer oral inotropic agents: phosphodiesterase inhibitors.
Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction.
Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure.
Olprinone, a phosphodiesterase III inhibitor, does not affect hypoxia-induced pial arteriolar dilatation in rabbits.
Olprinone, phosphodiesterase III inhibitor, is useful for patients with severe acute heart failure due to takotsubo cardiomyopathy accompanied by subarachnoid hemorrhage.
Patient Attributes Associated With Better Long-Term Outcomes on Palliative Milrinone.
PDE5 inhibitor sildenafil in the treatment of heart failure: A meta-analysis of randomized controlled trials.
Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure.
Pharmacokinetics of single oral dose of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis).
Pharmacological comparison of CK-2289, an inodilator agent, with milrinone and enoximone.
Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors.
Pharmacology of bipyridine phosphodiesterase III inhibitors.
Pharmacology of positive inotropic phosphodiesterase III inhibitors.
Pharmacology of SCH00013: a novel Ca2+ sensitizer.
Pharmacotherapy of dilated cardiomyopathy.
Phosphodiesterase 4 in the human heart - major player or little helper?
Phosphodiesterase 5a Inhibition with Adenoviral Short Hairpin RNA Benefits Infarcted Heart Partially through Activation of Akt Signaling Pathway and Reduction of Inflammatory Cytokines.
Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure.
Phosphodiesterase III inhibitors for heart failure.
Phosphodiesterase III inhibitors: long-term risks and short-term benefits.
Phosphodiesterase inhibition and positive inotropic effects.
Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts.
Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.
Phosphodiesterase inhibition in heart failure.
Phosphodiesterase inhibitors in refractory heart failure: bridge to beta-blockade?
Phosphodiesterase inhibitors piroximone and enoximone inhibit platelet aggregation in vivo and in vitro.
Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation.
Phosphodiesterase inhibitors. Do the risks outweight the benefits?
Phosphodiesterase inhibitors. Its role in heart failure therapy.
Phosphodiesterase inhibitors: haemodynamic effects related to the treatment of cardiac failure.
Physiologic response to the inotropic and vasodilator properties of enoximone.
Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
Positive inotropic/vasodilator agents.
Possible contribution of acetylamrinone and its enhancing effects on platelet aggregation under shear stress conditions in the onset of thrombocytopenia in patients treated with amrinone.
Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors.
Potential mechanisms of improved left ventricular function with enoximone in severe congestive heart failure.
Preventing LVAD implantation by early short-term mechanical support and prolonged inodilator therapy : A case series with acute refractory cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation and optimised medical strategy.
Randomized trial of phosphodiesterase inhibitors versus catecholamines in patients with acutely decompensated heart failure.
Rationale for the short term use of intravenous milrinone under hemodynamic guidance in patients with severe systolic heart failure.
Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease.
Relaxant effects of the selective phosphodiesterase inhibitors milrinone and OPC 3911 on isolated human mesenteric vessels.
Renal and hormonal effects of phosphodiesterase III inhibition in congestive heart failure.
Risks and benefits of the treatment of heart failure. Current status.
Separation between vasodilation and positive inotropism by assessment of myocardial energetics in patients with dilated cardiomyopathy.
Severe transient cardiac failure caused by placental chorangiosis.
Solid-phase synthesis and evaluation of libraries of substituted 4,5-dihydropyridazinones as vasodilator agents.
Some new positive inotropic agents.
Specific phosphodiesterase inhibition and maximal and submaximal exercise performance in patients with congestive heart failure.
Stability of Milrinone Lactate in 5% Dextrose Injection and 0.9% Sodium Chloride Injection at Concentrations of 400, 600, and 800 micrograms/mL.
T-wave alternans in a case with systemic lupus erythematosus-related myocarditis.
The acute effect of an oral "inotropic" placebo on the exercise capacity of patients with chronic cardiac failure.
The effect of positive inotropes on the failing human myocardium.
The effects of olprinone, a phosphodiesterase 3 inhibitor, on systemic and cerebral circulation.
The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.
The role of phosphodiesterase inhibitors in heart failure.
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.
The vasorelaxatory effect of the milrinone on the preconstricted rat aorta.
The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History.
Therapeutic achievements of phosphodiesterase inhibitors and the future.
Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors.
Topical application of amrinone (a selective phosphodiesterase III inhibitor) for relief of vasospasm.
Treatment of heart failure with enoximone, a new phosphodiesterase inhibitor. Düsseldorf, Federal Republic of Germany. September 25-27, 1987. Proceedings.
Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.
Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS.
Use of levosimendan in patients with ischemic heart disease following mechanical reperfusion.
Various subtypes of phosphodiesterase inhibitors differentially regulate pulmonary vein and sinoatrial node electrical activities.
Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
What do the newer inotropic drugs have to offer?
[Current treatment of chronic heart failure]
[Effects of amrinone on renal blood flow and cardiac function, in comparison with those of milrinone and olprinone, in anesthetized dog]
[Effects of R80122. The influence of a new phosphodiesterase inhibitor on global and intestinal hemodynamics in coronary surgery patients]
[Efficacy of intravenous milrinone in the treatment of acute congestive cardiac failure. Results of a French multicenter study]
[Enoximone/dobutamine comparison in chronic congestive cardiac insufficiency with low cardiac output]
[Infusion therapy at outpatient clinic in chronic end-stage heart failure]
[Inotropic therapy in heart failure: general aspects and clinical results]
[Long-term therapy of chronic cardiac insufficiency using enoximone]
[Monitoring and treatment of patients with shock in the intensive care unit]
[New positive inotropic drugs in acute and chronic heart failure]
[Pathophysiologic aspects and modern treatment of congestive heart failure]
[Phosphodiesterase inhibitors--a new therapeutic principle in heart failure]
[Phosphodiesterase inhibitors]
[Positive inotropic substances in therapy of heart failure: digitalis, catecholamines, phosphodiesterase inhibitors]
[Potentialitis of phosphodiesterase inhibitors in management of patients with chronic heart failure complicating cardiac ischemia]
[The hemodynamic profile of amrinone and enoximone in patients with severe heart failure]
[Therapy of verapamil poisoning with noradrenaline and the phosphodiesterase inhibitor enoximone]
[Treatment of chronic heart failure in the child]
[Treatment of chronic heart failure: current views]
[Use of new inotropic agents in the treatment of acute cardiac failure]
[Usefulness of exercise tests in the evaluation of the effects of treatment in chronic cardiac insufficiency]
[Vasodilatation and positive inotropic effect of the phosphodiesterase inhibitor enoximone]
Heart Failure, Systolic
Nonglycoside inotropes in congestive heart failure. Are they beneficial or harmful?
Role of nonglycosidic inotropic agents: indications, ethics, and limitations.
Hepatic Veno-Occlusive Disease
A phosphodiesterase III inhibitor protects rat liver from sinusoidal obstruction syndrome through heme oxygenase-1 induction.
A Phosphodiesterase III Inhibitor Protects Rat Liver From Sinusoidal Obstruction Syndrome Through Heme Oxygenase-1 Induction.
Phosphodiesterase III inhibitor attenuates rat sinusoidal obstruction syndrome through inhibition of platelet aggregation in Disse's space.
Hepatitis
Anticalmodulin autoantibody in liver diseases: a new antibody against a cytoskeleton-related protein.
Crystal structure of the mouse hepatitis virus ns2 phosphodiesterase domain that antagonizes RNase L activation.
Inhibition of phosphodiesterase 7A ameliorates Concanavalin A-induced hepatitis in mice.
[Clinical significance of serum phosphodiesterase activities in viral hepatitis]
Hepatitis B
Exonuclease I and III improve the detection efficacy of hepatitis B virus covalently closed circular DNA.
Hepatitis E
Detection of negative sense RNA in packaged hepatitis E virions using improved strand specific RT-PCR method.
Hepatitis, Autoimmune
PK/PD Modeling of the PDE7 Inhibitor-GRMS-55 in a Mouse Model of Autoimmune Hepatitis.
Hepatitis, Chronic
Anticalmodulin autoantibody in liver diseases: a new antibody against a cytoskeleton-related protein.
Hepatorenal Syndrome
[Is there a role for pentoxifylline in the treatment of alcoholic hepatitis?]
Hernias, Diaphragmatic, Congenital
Nitric oxide activity through guanylate cyclase and phosphodiesterase modulation is impaired in fetal lambs with congenital diaphragmatic hernia.
Herpes Simplex
Herpes Simplex Virus 1 DNA Polymerase RNase H Activity Acts in a 3'-to-5' Direction and Is Dependent on the 3'-to-5' Exonuclease Active Site.
Involvement of eucaryotic deoxyribonucleic acid polymerases alpha and gamma in the replication of cellular and viral deoxyribonucleic acid.
Herpes Zoster
Calmodulin-like activity and calcium-dependent phosphodiesterase in purified cells of the rat zona glomerulosa and zona fasciculata.
Effects of atrial natriuretic factor on the renin-aldosterone system: in vivo and in vitro studies.
HIV Infections
Inhibition of cytotoxicity and cytokine release of CD8+ HIV-specific cytotoxic T lymphocytes by pentoxifylline.
Mass spectrometric phosphoproteome analysis of HIV-infected brain reveals novel phosphorylation sites and differential phosphorylation patterns.
Hodgkin Disease
t(4;8)(q27;q24) in Hodgkin lymphoma cells targets phosphodiesterase PDE5A and homeobox gene ZHX2.
Huntington Disease
Application of neurophysiological biomarkers for Huntington's disease: evaluating a phosphodiesterase 9A inhibitor.
Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition.
Exclusion of DNA changes in the beta-subunit of the c-GMP phosphodiesterase gene as the cause for Huntington's disease.
Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
Pharmacological investigation of biochemical and behavioral effects resembling Huntington's disease utilizing selective calcium and calmodulin dependent phosphodiesterase inhibitor.
Phosphodiesterase 9A Inhibition Facilitates Corticostriatal Transmission in Wild-Type and Transgenic Rats That Model Huntington's Disease.
Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
Hydrocephalus
Preventive effects of cilostazol against the development of shunt-dependent hydrocephalus after subarachnoid hemorrhage.
Hydronephrosis
Analyses of renal medullary lipid droplets from normal, hydronephrotic, and indomethacin treated rabbits.
Hyperalgesia
A Novel Compound Analgesic Cream (Ketamine, Pentoxifylline, Clonidine, DMSO) for Complex Regional Pain Syndrome Patients.
Alpha 1-adrenoceptor-mediated sympathetically dependent mechanical hyperalgesia in the rat.
Direct cutaneous hyperalgesia induced by adenosine.
Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia.
Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats.
Mediation of serotonin hyperalgesia by the cAMP second messenger system.
Multiple second messenger systems act sequentially to mediate rolipram-induced prolongation of prostaglandin E2-induced mechanical hyperalgesia in the rat.
Sildenafil and glyceryl trinitrate reduce tactile allodynia in streptozotocin-injected rats.
Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain.
The effects of local pentoxifylline and propentofylline treatment on formalin-induced pain and tumor necrosis factor-alpha messenger RNA levels in the inflamed tissue of the rat paw.
Topical combinations aimed at treating microvascular dysfunction reduce allodynia in rat models of CRPS-I and neuropathic pain.
Topical combinations to treat microvascular dysfunction of chronic postischemia pain.
Hypercalcemia
Thiazide diuretics do not potentiate cAMP response to parathyroid hormone.
Hyperglycemia
Selective reversal of hyperglycemia-evoked gastric myoelectric dysrhythmias by nitrergic stimulation in healthy humans.
The mechanism of chlorothiazide-induced carbohydrate intolerance.
Hyperlipidemias
A review of the role of statins in heart failure treatment.
Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.
The absence of evidence for major effects of the frequent SNP +299G>A in the resistin gene on susceptibility to insulin resistance syndrome associated with Japanese type 2 diabetes.
Hyperprolactinemia
Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study.
Hypersensitivity
1,25-Dihydroxyvitamin D3 potentiates the decreased response of lymphocytes from atopic subjects to agents that increase intracellular cyclic adenosine monophosphate.
Complementary roles for exonuclease 1 and Flap endonuclease 1 in maintenance of triplet repeats.
Interaction of the antiallergic agent AA-344 with biogenic amines and prostaglandins in production of cyclic AMP in rat mast cells.
Studies on anti-allergic action of AH 21-132, a novel isozyme-selective phosphodiesterase inhibitor in airways.
The action of phosphodiesterase inhibitors on the hypersensitivity of frog photoreceptor.
The role of phosphodiesterase enzymes in allergy and asthma.
Zaprinast diminished pain and enhanced opioid analgesia in a rat neuropathic pain model.
Hypertension
A phosphodiesterase inhibitor promotes the premature development of adverse cardiac remodelling mediated by beta-adrenergic activation in hypertension.
Advances in the medical treatment of pulmonary hypertension.
Analysis of short-term treatment with the phosphodiesterase type 5 inhibitor tadalafil on long bone development in young rats.
Association of phosphodiesterase 4 polymorphism (rs702553) with blood pressure in the African American Study of Kidney Disease and Hypertension Genomics Study.
Autosomal-dominant hypertension with type E brachydactyly is caused by rearrangement on the short arm of chromosome 12.
Cardiovascular effects of Juniperus excelsa are mediated through multiple pathways.
Chronic inhibition of nitric-oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil.
Clinical and Molecular Perspectives of Monogenic Hypertension.
Clinical Effects of Phosphodiesterase 3A Mutations in Inherited Hypertension With Brachydactyly.
Comparative Effectiveness of Pharmacological Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis.
Contrasting effects of hypoglycemia on plasma renin activity and cyclic adenosine 3',5'-monophosphate (cyclic AMP) in low renin and normal renin essential hypertension.
COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors.
Curcumin analogues inhibit phosphodiesterase-5 and dilate rat pulmonary arteries.
Discovery of pyridoindole derivatives as potential inhibitors for phosphodiesterase 5A: in silico and in vivo studies.
Discovery of two novel hetero-tricyclic lead scaffolds as PDE5A inhibitor: virtual screening, molecular docking and pharmacophore modeling approach.
Does radical nephrectomy increase the risk of erectile dysfunction compared with partial nephrectomy? A cohort analysis.
Endothelin receptor antagonists for pulmonary arterial hypertension.
Evidence-based pharmacologic management of pulmonary arterial hypertension.
Evolution of aortic and cardiac cyclic AMP phosphodiesterase during the onset of mineralpcorticoid hypertension in the rat [proceedings].
Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors.
Excessive nitric oxide function and blood pressure regulation in patients with autonomic failure.
Further evidence for the involvement of cAMP in central blood pressure regulation.
Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
Increased inositol trisphosphate in erythrocytes of spontaneously hypertensive rats.
Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration.
Intravenous pentoxifylline does not affect the exercise-induced pulmonary arterial, capillary or venous hypertension in Thoroughbred horses.
Levosimendan is not effective in reducing pulmonary pressures in patients with idiopathic pulmonary arterial hypertension: report of two cases.
Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.
Long-term inhaled iloprost use in children with pulmonary arterial hypertension.
Low-dose systemic phosphodiesterase III inhibitor pimobendan combined with prostacyclin therapy in a patient with severe primary pulmonary y hypertension.
New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine.
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
Outcomes of Liver Transplantation for Porto-Pulmonary Hypertension in Model for End-Stage Liver Disease Era.
PDE3A mutations cause autosomal dominant hypertension with brachydactyly.
Phosphodiesterase 3A and Arterial Hypertension.
Phosphodiesterase type V: a novel therapeutic target for hypertension.
Platelet cyclic AMP in essential hypertension.
Pulmonary arterial hypertension secondary to chronic lung diseases: pathogenesis and medical treatment.
Pulmonary hypertension and right ventricular function in advanced heart failure.
Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension.
Relaxant effect and possible mechanism of 17-nor-subincanadine E in rabbit corpora cavernosa.
Renal phosphodiesterase 4B is activated in the Dahl salt-sensitive rat.
Retraction: Urdaneta F, Willert JL, Beaver T, Naik B, Kirby DS, Lobato EB. Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension. Ann Thorac Surg 2004;78:1433–7.
RNA Sequencing Reveals Novel Transcripts from Sympathetic Stellate Ganglia During Cardiac Sympathetic Hyperactivity.
Scleroderma - new aspects in pathogenesis and treatment.
Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats.
Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca2+ entry.
Sildenafil reduces alcohol-induced gastric damage: just say 'NO'.
Tadalafil as treatment for idiopathic pulmonary arterial hypertension.
The absence of evidence for major effects of the frequent SNP +299G>A in the resistin gene on susceptibility to insulin resistance syndrome associated with Japanese type 2 diabetes.
The activity of adenylate cyclase and phosphodiesterase in the isoproterenol-damaged cardiac muscle of spontaneously hypertensive rats.
[Phosphodiesterase characteristics of the fat cells in spontaneous hypertension in rats]
[Pulmonary arterial hypertension-specific drugs - current status]
[Pulmonary hypertension and right ventricular failure. Part XII. Nitrous oxide and phosphodiesterase inhibitors in the treatment of primary pulmonary arterial hypertension]
[Pulmonary hypertension in COPD and interstitial lung diseases]
[Pulmonary hypertension. Pathophysiology and current concepts of medication therapy]
[Transport of calcium and distribution of calmodulin in the erythrocytes in primary arterial hypertension]
[Update in the diagnosis and therapy for pulmonary arterial hypertension]
Hypertension, Portal
Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Hypertension, Pregnancy-Induced
Control of vascular reactivity in pregnancy.
Hypertension, Pulmonary
3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass.
A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease.
A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.
Additive effect of phosphodiesterase inhibitors in control of pulmonary hypertension after congenital cardiac surgery in children.
Advances in the medical treatment of pulmonary hypertension.
Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension.
Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.
Cellular pathophysiology and therapy of pulmonary hypertension.
Chronic treatment with Sildenafil has no effect on folliculogenesis or fertility in C57BL/6 and C57BL/6 knockout for iNOS mice.
Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity.
Contrasting effects of isoproterenol and phosphodiesterase III inhibitor on intracellular calcium transients in cardiac myocytes from failing hearts.
Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease.
E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats.
Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension.
Effects of low-dose milrinone on weaning from cardiopulmonary bypass and after in patients with mitral stenosis and pulmonary hypertension.
Efficacy of tadalafil in chronic hypobaric hypoxia-induced pulmonary hypertension: possible mechanisms.
Heart Failure Treated with Low-dose Milrinone in a Full-term Newborn.
Hemodynamic effects of inhaled nitric oxide and phosphodiesterase inhibitor (dipyridamole) on secondary pulmonary hypertension following heart valve surgery in adults.
High-dose enoximone to evaluate reversibility of pulmonary hypertension: is there a diagnostic value of neurohormonal measurements?
Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Intravenous Sildenafil in the Treatment of Neonates with Persistent Pulmonary Hypertension.
Isolated unilateral absence of pulmonary artery in adulthood: a clinical analysis of 65 cases from a case series and systematic review.
Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.
Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors.
Milrinone attenuates serotonin-induced pulmonary hypertension and bronchoconstriction in dogs.
Nitric oxide and pulmonary hypertension.
Nitric oxide in conjunction with milrinone better stabilized pulmonary hemodynamics after Fontan procedure.
Novel peptide for attenuation of hypoxia-induced pulmonary hypertension via modulation of nitric oxide release and phosphodiesterase -5 activity.
Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition.
Phosphodiesterase III and V inhibitors on pulmonary artery from pulmonary hypertensive rats: differences between early and established pulmonary hypertension.
Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review.
Phosphodiesterase inhibitors for pulmonary hypertension.
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.
Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension.
Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension.
Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension.
Recent Advances in Chronic Thromboembolic Pulmonary Hypertension.
Retraction: Urdaneta F, Willert JL, Beaver T, Naik B, Kirby DS, Lobato EB. Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension. Ann Thorac Surg 2004;78:1433–7.
Right ventricular function and failure: a review.
Selective pulmonary vasodilatory effect of ZSY-27 in dogs with pulmonary hypertension due to pulmonary embolism.
Sildenafil and an early stage of chronic hypoxia-induced pulmonary hypertension in newborn piglets.
Sildenafil for pulmonary hypertension.
Sildenafil inhibits chronically hypoxic upregulation of canonical transient receptor potential expression in rat pulmonary arterial smooth muscle.
Sildenafil suppresses the proliferation and enhances the apoptosis of hemangioma endothelial cells.
Site-specific effect of guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition in isolated lamb lungs.
Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease.
The Potential Role of Aerosolized Phosphodiesterase 3 Inhibitor Enoximone in the Management of Coronavirus Disease 2019 Hypoxemia: A Case Report.
The vasorelaxatory effect of the milrinone on the preconstricted rat aorta.
Therapeutic methods used in patients with Eisenmenger syndrome.
Treatment initiation in paediatric pulmonary hypertension: insights from a multinational registry.
Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension.
Type V phosphodiesterase inhibition modulates endogenous immunoreactivities of endothelin-1 and endothelial nitric oxide synthase in pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension.
Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone.
[Anesthesia for heart transplantation in newborn and suckling infants. Special aspects of the hypoplastic left heart syndrome]
[Endothelin receptor antagonist, phosphodiesterase inhibitor, thromboxane inhibitor]
[Postoperative management for severe pulmonary hypertension in a patient with congenital mitral stenosis and patent ductus arteriosus]
[Pregnant woman with pulmonary hypertension].
[Pulmonary hypertension and right ventricular failure. Part XII. Nitrous oxide and phosphodiesterase inhibitors in the treatment of primary pulmonary arterial hypertension]
Hyperthyroidism
Adrenergic regulation of lipolysis in fat cells from hyperthyroid and hypothyroid patients.
Phosphodiesterase activity in human subcutaneous adipose tissue in hyper- and hypothyroidism.
Serum cyclic 3',5'-nucleotide phosphodiesterase in patients with various thyroid disorders.
The atrial natriuretic peptide- and catecholamine-induced lipolysis and expression of related genes in adipose tissue in hypothyroid and hyperthyroid patients.
Thyroid hormone modulation of epinephrine-induced lipolysis in rat adipocytes: a possible role of calcium.
Hypertrophy, Right Ventricular
The xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinase.
Hypogonadism
Effects of tadalafil treatment combined with physical activity in patients with low onset hypogonadism: results from a not-randomized single arm phase 2 study.
Hypogonadism in the man with erectile dysfunction: what to look for and when to treat.
Pharmacologic Therapy in Men's Health: Hypogonadism, Erectile Dysfunction, and Benign Prostatic Hyperplasia.
Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study.
[Choice of treatment in erectile dysfunction associated with hypogonadism].
[The role of testosterone drugs in combined therapy of erectile dysfunction in patients with metabolic syndrome]
Hypokinesia
Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors.
[Catecholamine concentration and adenyl cyclase and phosphodiesterase activities of the sarcolemma of myocardial cells during hypokinesia and in experimental information neuroses]
Hypotension
Cardiomegaly of the larger twin in monochorionic twin pregnancies warrants neonatal intensive care even without twin-to-twin transfusion syndrome.
Combination therapy with albumin and pentoxifylline protects against acute kidney injury during endotoxemic shock in mice.
Combined use of adenosine and amrinone inhibits reperfusion injury of rat liver.
Effect of phosphodiesterase III inhibitor on contractility, afterload, and vascular capacitance during right heart bypass preparation.
Levosimendan does not improve survival time in a rat model of verapamil toxicity.
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Pharmacokinetics and pharmacodynamics of olprinone after cardiac surgery.
Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.
Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension.
Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
[Therapy of verapamil poisoning with noradrenaline and the phosphodiesterase inhibitor enoximone]
Hypotension, Orthostatic
Interaction between udenafil and tamsulosin in rats: non-competitive inhibition of tamsulosin metabolism by udenafil via hepatic CYP3A1/2.
Hypothyroidism
Adrenergic regulation of lipolysis in fat cells from hyperthyroid and hypothyroid patients.
Frequency and effect on serum TSH of phosphodiesterase 8B (PDE8B) gene polymorphisms in patients with sporadic nonautoimmune subclinical hypothyroidism.
Genetic association study of phosphodiesterase 8B gene with subclinical hypothyroidism in pregnant women.
Local and systemic alterations in cyclic 3',5' AMP phosphodiesterase activity in relation to tail regeneration under hypothyroidism and T4 replacement in the lizard, Mabuya carinata.
Mutations in the c-erbA beta 1 gene: do they underlie euthyroid fibromyalgia?
Phosphodiesterase 8B Gene Polymorphism Is Associated with Subclinical Hypothyroidism in Pregnancy.
Phosphodiesterase activity in human subcutaneous adipose tissue in hyper- and hypothyroidism.
Idiopathic Pulmonary Fibrosis
Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.
Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis.
Immune System Diseases
PK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response.
Impotence, Vasculogenic
Purification of a dimethyladenosine compound from silkworm pupae as a vasorelaxation substance.
Infarction, Middle Cerebral Artery
Cilostazol attenuates ischemic brain injury and enhances neurogenesis in the subventricular zone of adult mice after transient focal cerebral ischemia.
Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia.
PDE5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism.
Protection against blood-brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: a quantitative study.
Infections
A rapid procedure for isolation of large quantities of Escherichia coli DNA polymerase I utilizing a lambdapolA transducing phage.
Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options.
An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
Associations between single-nucleotide polymorphisms of human exonuclease 1 and the risk of hepatocellular carcinoma.
Characterization of lambdapolA transducing phages; effective expression of the E. coli polA gene.
Deletion of the cyclic di-AMP phosphodiesterase gene (cnpB) in Mycobacterium tuberculosis leads to reduced virulence in a mouse model of infection.
Derivation of Pre-oligodendrocytes from Human Endometrial Stromal Cells by Using Overexpression of MicroRNA 338.
Efficient cloning of hepatitis B virus DNA from single-stranded replicative intermediates and its application to S1 mapping of viral RNA in human liver tissue.
Genetic variation in Trex1 affects HIV-1 disease progression.
HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection.
Involvement of the beta-adrenergic system in the cardiac chronic form of experimental Trypanosoma cruzi infection.
Isolation and characterization of a lambdapolA transducing phage.
Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
Rotavirus Controls Activation of the 2'-5'-Oligoadenylate Synthetase/RNase L Pathway Using at Least Two Distinct Mechanisms.
The Bacterial Second Messenger Cyclic di-GMP Regulates Brucella Pathogenesis and Leads to Altered Host Immune Response.
The EAL domain containing protein STM2215 (rtn) is needed during Salmonella infection and has cyclic di-GMP phosphodiesterase activity.
The effect of rolipram, a type IV phosphodiesterase inhibitor, on Pseudomonas aeruginosa infection of respiratory mucosa.
TREX1 531C>T Polymorphism is Associated with High Proviral Load Levels in HTLV-1-Infected Persons.
[Activity of the cyclic adenosine monophosphate phosphodiesterase of the blood lymphocytes in patients with a Lamblia infection susceptible and resistant to lambliacides]
Infertility
Novel in situ gelling vaginal sponges of sildenafil citrate-based cubosomes for uterine targeting.
Phosphodiesterase 8B Polymorphism rs4704397 Is Associated with Infertility in Subclinical Hypothyroid Females: A Case-Control Study.
Infertility, Female
Inactivation of Exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility.
Phosphodiesterase 8B Polymorphism rs4704397 Is Associated with Infertility in Subclinical Hypothyroid Females: A Case-Control Study.
Regulation of meiotic maturation.
Inflammatory Bowel Diseases
Phosphodiesterase inhibitors in inflammatory bowel disease.
Influenza, Human
Interaction of plasma membranes with influenza virus. VII. Effect on 3',5'-cyclic adenosine monophosphate phosphodiesterase activity.
Role of calcium dependent regulator protein (CDR) in inhibition of 3',5'-c AMP-phosphodiesterase by influenza virus. I. Isolation and purification of CDR and CDR-dependent 3',5'-c' AMP-phosphodiesterase from chick embryos.
Role of calcium-dependent regulator protein (CDR) in inhibition of 3',5'-c AMP-phosphodiesterase by influenza virus. II. Kinetic studies on inhibition of CDR-dependent phosphodiesterase by influenza virus.
Insulin Resistance
A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice.
Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM.
Discriminative insulin antagonism of stimulatory effects of various cAMP analogs on adipocyte lipolysis and hepatocyte glycogenolysis.
Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor alpha and cAMP.
Early and rapid development of insulin resistance, islet dysfunction and glucose intolerance after high-fat feeding in mice overexpressing phosphodiesterase 3B.
Effect of phosphodiesterase inhibition on insulin resistance in obese individuals.
Effects of Chinese Medicinal Formula BNG-1 on Phosphodiesterase 3B Expression, Hepatic Steatosis, and Insulin Resistance in High Fat Diet-induced NAFLD Mice.
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.
Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice.
In vivo effects of phosphodiesterase III inhibitors on glucose metabolism and insulin sensitivity.
Insulin resistance of fat cells from spontaneously diabetic KK mice. Analysis of insulin-sensitive phosphodiesterase.
Insulin-sensitive adenosine 3',5'-cyclic monophosphate phosphodiesterase of hepatocyte plasma membrane.
Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B.
Metabolic consequences of ENPP1 over-expression in adipose tissue.
Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions.
Pharmaceutical reversal of insulin resistance.
Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.
The absence of evidence for major effects of the frequent SNP +299G>A in the resistin gene on susceptibility to insulin resistance syndrome associated with Japanese type 2 diabetes.
Urinary PC-1 activity in patients with type 1 diabetes mellitus.
Intellectual Disability
Phosphodiesterase activity is regulated by CC2D1A that is implicated in non-syndromic intellectual disability.
Restoration of neuronal plasticity by a phosphodiesterase type 1 inhibitor in a model of fetal alcohol exposure.
Intermittent Claudication
A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease.
A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy.
Analysis of the cilostazol safety database.
Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication.
Cilostazol for treatment of cerebral infarction.
Cilostazol increases tissue blood flow in contracting rabbit gastrocnemius muscle.
Cilostazol Inhibits Cytokine-Induced Tetrahydrobiopterin Biosynthesis in Human Umbilical Vein Endothelial Cells.
Cilostazol may improve outcome in critical limb ischemia.
Cilostazol promotes production of melanin by activating the microphthalmia-associated transcription factor (MITF).
Cilostazol reduces proliferation through c-Myc down-regulation in MDCK cells.
Cilostazol.
Cilostazol: a Review of Basic Mechanisms and Clinical Uses.
Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.
Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.
Drug treatment of peripheral arterial disease in the elderly.
Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.
Induction of Angiogenesis by a Type III Phosphodiesterase Inhibitor, Cilostazol, Through Activation of Peroxisome Proliferator-Activated Receptor-? and cAMP Pathways in Vascular Cells.
Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication.
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Medical therapy for intermittent claudication.
Metabolic inertia in contracting skeletal muscle: a novel approach for pharmacological intervention in peripheral vascular disease.
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
Optimization, ex vivo permeation, and stability study of lipid nanocarrier loaded gelatin capsules for treatment of intermittent claudication.
Oral administration of cilostazol improves survival rate after rat liver ischemia/reperfusion injury.
Oral dosing of pentoxifylline, a pan-phosphodiesterase inhibitor restores bone mass and quality in osteopenic rabbits by an osteogenic mechanism: A comparative study with human parathyroid hormone.
Pharmacokinetic modeling analysis of cilostazol and its active metabolites (OPC-13015 and OPC-13213) after multiple oral doses of cilostazol in healthy Korean volunteers.
Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease.
Regulation of intestinal hPepT1 (SLC15A1) activity by phosphodiesterase inhibitors is via inhibition of NHE3 (SLC9A3).
Reversal of Osteopenia in Ovariectomized Rats by Pentoxifylline: Evidence of Osteogenic and Osteo-Angiogenic Roles of the Drug.
Treating peripheral arterial disease in patients with diabetes.
[Potential therapeutic approaches for prevention and treatment of diabetic nephropathy and neuropathy: evidences of cilostazol]
Ischemic Attack, Transient
Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte-endothelial cell interactions.
Ischemic Stroke
A haplotype of the phosphodiesterase 4D (PDE4D) gene is associated with myocardial infarction and with cardiometabolic parameters: the GEA study.
Advances in the genetic basis of coronary artery disease.
Association between PDE4D polymorphism and ischemic stroke in young population.
Cilostazol Reduces PAC-1 Expression on Platelets in Ischemic Stroke.
Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function.
Influence of Genetic Variation in PDE3A on Endothelial Function and Stroke.
Molecular genetics of coronary artery disease.
Phosphodiesterase 4 D gene polymorphism in relation to intracranial and extracranial atherosclerosis in ischemic stroke.
[Plasma levels of cyclic nucleotides, phosphodiesterase, thyroid hormones and insulin in patients with ischemic stroke]
Kidney Diseases, Cystic
Caffeine Accelerates Cystic Kidney Disease in a Pkd1-Deficient Mouse Model.
Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases.
Kidney Failure, Chronic
Advances in the medical treatment of pulmonary hypertension.
The effect of chronic renal failure on phosphodiesterase inhibitor-induced relaxation responses in rabbit cavernosal strips.
Leber Congenital Amaurosis
Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors.
Leiomyoma
Changes in beta(2)-adrenoceptor expression and in adenylyl cyclase and phosphodiesterase activity in human uterine leiomyomas.
Characterization of soluble cyclic AMP phosphodiesterases and partial purification of a major form in human leiomyoma of the uterus.
Leukemia
Beta 2 receptor-mediated stimulation of Friend erythroleukemia cell growth by thyroid hormones.
Comparison of two methods of staining apoptotic cells of leukemia cell lines. Terminal deoxynucleotidyl transferase and DNA polymerase I reactions.
Cyclic AMP phosphodiesterase in human lymphocytes and lymphoblasts.
Demonstration, in leukemia L-1210 cells, of a phosphodiesterase acting on 3':5'-cyclic CMP but not on 3':5'-cyclic AMP or 3':5'-cyclic GMP.
Differential inhibition of various deoxyribonucleic acid polymerases by Evans blue and aurintricarboxylic acid.
Drug repurposing for targeting cyclic nucleotide transporters in acute leukemias - A missed opportunity.
Effects of VP-16 on cell growth and metabolism of nucleic acids in mouse leukemia L-1210 cells and on the activity of DNA polymerase I of E. coli.
Fidelity of HIV-1 reverse transcriptase copying RNA in vitro.
Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.
Influence of DNA sequence on the nature of mispairing during DNA synthesis.
Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxyuridine-5'-triphosphate.
Systematic validation of hypothesis-driven candidate genes for cervical cancer in a genome-wide association study.
Terminal deoxynucleotidyltransferase. Serological studies and radioimmunoassay.
[Construction of a cDNA library from liver tissue of rhesus monkey, Macaca mulatta]
Leukemia, Erythroblastic, Acute
Beta 2 receptor-mediated stimulation of Friend erythroleukemia cell growth by thyroid hormones.
Regulation of cyclic 3',5'-adenosine monophosphate phosphodiesterase in Friend erythroleukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis.
Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors.
Cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in normal and chronic lymphocytic leukemia lymphocytes.
Excision of beta-D- and beta-L-nucleotide analogs from DNA by the human cytosolic 3'-to-5' exonuclease.
Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease.
Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells.
The cAMP signaling pathway as a therapeutic target in lymphoid malignancies.
Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders.
Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia.
Leukemia, Lymphoid
Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells.
Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activity of cyclic nucleotide phosphodiesterases in granulocytes of chronic myelogenous leukemia (CML). A preliminary report.
Leukemia, Myeloid
Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways.
Leukemia, Myeloid, Acute
Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death.
Leukodystrophy, Globoid Cell
Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model.
Leukoencephalopathies
TREX1 is expressed by microglia in normal human brain and increases in regions affected by ischemia.
Lipidoses
Deficiency of taurocholate-dependent phospholipase C acting on phosphatidylcholine in Niemann-Pick disease.
Liver Cirrhosis
Genome-wide analysis of copy number variation identifies candidate gene loci associated with the progression of non-alcoholic fatty liver disease.
Phosphodiesterase inhibition mediates matrix metalloproteinase activity and the level of collagen degradation fragments in a liver fibrosis ex vivo rat model.
Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Liver Diseases
Combined treatments with metformin and phosphodiesterase inhibitors alleviate non-alcoholic fatty liver disease in high-fat diet-fed rats: A comparative study.
Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats.
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.
Lipotoxicity-induced STING1 activation stimulates MTORC1 and restricts hepatic lipophagy.
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention.
Phosphodiesterases (PDEs) hydrolyze the 3' phosphoester bond of the purine 3',5'-cyclic monophosphates, cAMP and cGMP.
The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation.
[Symposium: Evaluation of methods of enzymatic diagnosis in various fields. A. Internal medicine. 3. Liver diseases. Diagnosis of liver diseases by means of serum phosphodiesterase.]
Liver Diseases, Alcoholic
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Liver Failure
Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors.
Tumor necrosis factor production in the perfused mouse liver and its pharmacological modulation by methylxanthines.
Liver Neoplasms
Serum 5'--nucleotide phosphodiesterase isozyme--V test for human liver cancer.
Liver Neoplasms, Experimental
A role for DNA polymerase in the specificity of nucleotide incorporation opposite N-acetyl-2-aminofluorene adducts.
Decreased activity of cytidine 3':5'-monophosphate (cyclic CMP) phosphodiesterase in the fast-growing Morris hepatoma 3924A, but not in the slow-growing Morris hepatoma 9618A.
Increased activity of low-Km cyclic adenosine 3':5'-monophosphate phosphodiesterase in plasma membranes of Morris hepatoma 5123tc (h).
The isolation and characterization of cyclic nucleotide phosphodiesterases from Morris hepatoma 5123tc(h) and rat liver.
Lordosis
Effect of guanine derivatives on lordosis behavior in estrogen primed rats.
Facilitation of progesterone induced lordosis behavior by phosphodiesterase inhibitors in estrogen primed rats.
Lung Diseases
A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-? Signaling and Activation of cAMP/PKA Signaling.
Aminophylline promotes mitochondrial biogenesis in human pulmonary bronchial epithelial cells.
Cyclic adenosine monophosphate in acute ischemic stroke: some to update, more to explore.
Future developments in the pharmacotherapy of lung disease.
Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies.
Immunoreactivity of S100 beta in heart, skeletal muscle, and kidney in chronic lung disease: possible induction by cAMP.
Lung injury after simulated cardiopulmonary bypass in an isolated perfused rat lung preparation: Role of mitogen-activated protein kinase/Akt signaling and the effects of theophylline.
New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease.
Selective potentiating effect of RS14203 on a serotoninergic pathway in anesthetized rats.
Treatment initiation in paediatric pulmonary hypertension: insights from a multinational registry.
Lung Diseases, Interstitial
Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
[Effect of selective phosphodiesterase 4 inhibitors on nuclear factor kappa B, tumor necrosis factor-? and interleukin-8 expression in peripheral blood mononuclear cells in rheumatoid arthritis with interstitial lung disease].
Lung Diseases, Obstructive
Clinical Pharmacology of Oral Maintenance Therapies for Obstructive Lung Diseases.
Phosphodiesterase isoforms and cAMP compartments in the development of new therapies for obstructive pulmonary diseases.
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
Lung Injury
A novel fluid resuscitation strategy modulates pulmonary transcription factor activation in a murine model of hemorrhagic shock.
A possible involvement of oxidative lung injury in endotoxin-induced bronchial hyperresponsiveness to substance P in guinea pigs.
Attenuation of pulmonary fibrosis in mice by aminophylline.
DSM-RX78, a new phosphodiesterase inhibitor, suppresses superoxide anion production in activated human neutrophils and attenuates hemorrhagic shock-induced lung injury in rats.
Effects of pentoxifylline on inflammatory cytokine expression and acute pleuropneumonia in swine.
Inhibition of chlorine-induced lung injury by the type 4 phosphodiesterase inhibitor rolipram.
Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury.
Pharmacokinetics, biodistribution and toxicology following intravenous and oral administration of DSM-RX78 and EFB-1, two new 2-(2-fluorobenzamido)benzoate-based PDE4 inhibitors, to rats.
Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.
Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect.
Resolution acute respiratory distress syndrome through reversing the imbalance of Treg/Th17 by targeting the cAMP signaling pathway.
Science review: Redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: role for nuclear factor-kappaB.
Selective phosphodiesterase 3 inhibitor olprinone attenuates meconium-induced oxidative lung injury.
Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury.
Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4.
[Effect of inhaling specific phosphodiesterase inhibitor on lung injury induced by cardiopulmonary bypass].
Lung Neoplasms
A Double-Blind Placebo-Controlled Study of the Effects of Olprinone, a Specific Phosphodiesterase III Inhibitor, for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer.
A Novel Flavonoid Kushenol Z from Sophora flavescens Mediates mTOR Pathway by Inhibiting Phosphodiesterase and Akt Activity to Induce Apoptosis in Non-Small-Cell Lung Cancer Cells.
A study on the levels of calmodulin and DNA in human lung cancer cells.
DAXAS and COPD Correlation with Cancer.
ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells.
Genetic risk of lung cancer associated with a single nucleotide polymorphism from EXO1: a meta analysis.
Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer.
Lupus Erythematosus, Cutaneous
Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.
Lupus Erythematosus, Systemic
Loss of Trex1 in Dendritic Cells Is Sufficient To Trigger Systemic Autoimmunity.
T Cells Produce IFN-? in the TREX1 D18N Model of Lupus-like Autoimmunity.
TREX1 variants in Sjogren's syndrome related lymphomagenesis.
Lyme Disease
The proofreading domain of Escherichia coli DNA polymerase I and other DNA and/or RNA exonuclease domains.
Lymphoma
A role for DNA polymerase in the specificity of nucleotide incorporation opposite N-acetyl-2-aminofluorene adducts.
cAMP metabolism in an S49 mouse lymphoma variant with diminished phosphodiesterase activity.
Cyclic AMP-dependent protein kinase: pivotal role in regulation of enzyme induction and growth.
Identification by direct photoaffinity labeling of an altered phosphodiesterase in a mutant S49 lymphoma cell.
Poly (ADP-ribose) metabolism in alkylated mouse L5178Y cells.
[Effects of aminophylline on proliferation and apoptosis in Raji lympho-blastoid cell line]
Lymphoma, B-Cell
A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multi-target mechanism discovered through systematic combination screening in B-cell malignancies.
No donor KMUP-1 improves hepatic ischemia-reperfusion and hypoxic cell injury by inhibiting oxidative stress and pro-inflammatory signaling.
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
Lymphoma, Follicular
Sleeping Beauty Screen Identifies RREB1 and Other Genetic Drivers in Human B-cell Lymphoma.
Lymphoma, Large B-Cell, Diffuse
Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multi-target mechanism discovered through systematic combination screening in B-cell malignancies.
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
Malaria
cAMP-Signalling Regulates Gametocyte-Infected Erythrocyte Deformability Required for Malaria Parasite Transmission.
Phosphodiesterase beta is the master regulator of cAMP signalling during malaria parasite invasion.
Plasmodium falciparum STEVOR phosphorylation regulates host erythrocyte deformability enabling malaria parasite transmission.
Malaria, Cerebral
Selective damage of hippocampal neurons in murine cerebral malaria prevented by pentoxifylline.
Malnutrition
An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
Mandibular Fractures
The effect of two phosphodiesterase inhibitors on bone healing in mandibular fractures (animal study in rats).
Mastocytoma
Differential effect of sodium butyrate on cyclic AMP phosphodiesterase activities in butyrate sensitive and resistant mastocytoma cells.
Inhibition of salvage synthesis of nucleic acid by adenosine 3',5'-cyclic decylphosphoramidate in mastocytoma P-815 cells.
Measles
[The influence of L-dopa and of thymus fraction on the survival rate of whole-body-irradiated mice]
Meconium Aspiration Syndrome
Effects of intravenous phosphodiesterase inhibitors and corticosteroids on severe meconium aspiration syndrome.
Melanoma
Antitumor efficacy of reticulol from Streptoverticillium against the lung metastasis model B16F10 melanoma. Lung metastasis inhibition by growth inhibition of melanoma.
Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid.
Calmodulin activation of cyclic AMP phosphodiesterase in the B16 mouse melanoma.
Characterization of a human melanoma cell line (KHm-1) containing phosphodiesterase activity only for cyclic adenosine 3':5'-monophosphate.
Characterization of phosphodiesterase 3 in human malignant melanoma cell line.
Effect of theophylline on the transport of tyrosine in cultured B-16 mouse melanoma cells.
Exonuclease 1 (EXO1) gene variation and melanoma risk.
Growth and pigmentation in genetically related Cloudman S91 melanoma cell lines treated with 3-isobutyl-1-methyl-xanthine and beta-melanocyte-stimulating hormone.
Hard times for oncogenic BRAF-expressing melanoma cells.
Induction of differentiated phenotypes in melanoma cells by a combination of an adenosine 3',5'-cyclic monophosphate stimulating agent and D-alpha tocopheryl succinate.
Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma.
Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation.
Pentoxifylline inhibits integrin-mediated adherence of 12(S)-HETE and TNFalpha-activated B16F10 cells to fibronectin and endothelial cells.
Pentoxifylline Modulates Cell Surface Integrin Expression and Integrin Mediated Adhesion of B16F10 Cells to Extracellular Matrix Components.
Pentoxifylline triggers autophagy via ER stress response that interferes with Pentoxifylline induced apoptosis in human melanoma cells.
Phosphodiesterase inhibitors such as Viagra do not increase melanoma risk, review finds.
PRESM: Personalized Reference Editor for Somatic Mutation discovery in cancer genomics.
Stimulation of cyclic GMP efflux in human melanocytes by hypergravity generated by centrifugal acceleration.
Stimulation of melanotic expression in a melanoma cell line by theophylline.
Theophylline incorporation into the nucleic acids of theophylline-stimulated melanoma cells.
Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma.
Words of Wisdom. RE: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Words of Wisdom. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
[Regulatory role of DOPA and components of the cyclic adenosine-3',5'-monophosphate system]
Melanoma, Experimental
Calmodulin activation of cyclic AMP phosphodiesterase in the B16 mouse melanoma.
Growth and pigmentation in genetically related Cloudman S91 melanoma cell lines treated with 3-isobutyl-1-methyl-xanthine and beta-melanocyte-stimulating hormone.
Memory Disorders
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
Febrile seizures impair memory and cAMP response-element binding protein activation.
Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism.
Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801.
Pentoxifylline reverses age-related deficits in spatial memory.
Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.
Meningitis
Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram.
Mesenteric Ischemia
Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine.
Metabolic Syndrome
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.
Mitochondrial Diseases
Mice lacking the mitochondrial exonuclease MGME1 accumulate mtDNA deletions without developing progeria.
Mitral Valve Insufficiency
Hemodynamic efficacy of E-1020 in comparison with dopamine on acute mitral regurgitation in anesthetized dogs.
Mouth Neoplasms
Serum phosphodiesterase levels in oral cancer.
Movement Disorders
Clinical findings of autosomal-dominant striatal degeneration and PDE8B mutation screening in parkinsonism and related disorders.
Mucolipidoses
Radiometric assays of N-acetylglucosaminylphosphotransferase and alpha-N-acetylglucosaminyl phosphodiesterase with substrates labeled in the glucosamine moiety.
Multiple Myeloma
Chronicles in drug discovery.
Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death.
Multiple Sclerosis
Dual implication of 2',3'-cyclic nucleotide 3' phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis.
Epstein-Barr virus, 9.4 T MRI and phosphodiesterase inhibitors in multiple sclerosis.
Glycerylphosphocholine phosphocholine phosphodiesterase activity is reduced in multiple sclerosis plaques.
Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis.
Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis.
Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis.
Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats.
Simultaneous measurement of 2':3' cyclic-nucleotide 3' phosphodiesterase and RNase activities in sera and spinal fluids of multiple sclerosis patients.
The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-beta 1b treatment in patients with multiple sclerosis.
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis.
Vinpocetine inhibits oligodendroglial precursor cell differentiation.
Multiple Sclerosis, Relapsing-Remitting
Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
Muscular Atrophy
Phosphodiesterase 4 inhibition restrains muscle proteolysis in diabetic rats by activating PKA and EPAC/Akt effectors and inhibiting FoxO factors.
Phosphodiesterase-4 inhibition reduces proteolysis and atrogenes expression in rat skeletal muscles.
Muscular Diseases
Imidazole myopathy. Production of the myopathy and its dependence on acetylcholine.
[Cyclic 3',5'-AMP metabolism in progressive muscular dystrophy patients]
[Pathogenesis of several forms of progressive muscular dystrophy]
Muscular Dystrophies
NO more muscle fatigue.
Muscular Dystrophy, Duchenne
Calcium, calmodulin and 3',5'-cyclic nucleotide phosphodiesterase activity in human muscular disorders.
Chronicles in drug discovery.
Evaluation of the Therapeutic Utility of Phosphodiesterase 5A Inhibition in the mdx Mouse Model of Duchenne Muscular Dystrophy.
Myasthenia Gravis
Involvement of phosphodiesterases in autoimmune diseases.
Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor.
The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Myocardial Infarction
Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction.
Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor.
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Effects of milrinone on left ventricular remodeling after acute myocardial infarction.
Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion.
Impact of chronotropic effect of cilostazol after acute myocardial infarction: insights from change in left ventricular volume and function.
Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction.
Modulation of inotropic therapy by venodilation in acute heart failure: a randomised comparison of four inotropic agents, alone and combined with isosorbide dinitrate.
Molecular genetics of coronary artery disease.
Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway.
Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction.
Phosphodiesterase 5a Inhibition with Adenoviral Short Hairpin RNA Benefits Infarcted Heart Partially through Activation of Akt Signaling Pathway and Reduction of Inflammatory Cytokines.
Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors.
Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction.
The phosphodiesterase 8B gene rs4704397 is associated with thyroid function, risk of myocardial infarction and body height. The Tromsø Study.
[Cyclic adenosine monophosphate and atherogenic factors]
[Early echocardiographic identification of viable myocardium after acute myocardial infarct using inotropic agents: comparison of dobutamine and enoximone]
[Systems for regulating the level of Ca2+, cyclic nucleotides, and reverse absorption of neurotransmitters in isolated nerve endings of the rat brain during development of myocardial infarct]
Myocardial Ischemia
Cardiac and hemodynamic effects of intravenous R80122, a new phosphodiesterase III inhibitor, in a canine model of myocardial ischemia and heart failure.
Cardiac drugs: new inotropes.
Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction.
Effect of isometric handgrip on systolic time intervals in patients with ischemic heart disease and cyclic amp phosphodiesterase inhibitor pretreatment.
Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs.
Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs.
Effects of enoximone and R 80122, a new selective phosphodiesterase III inhibitor, on hemodynamics and myocardial energetics in patients with ischemic heart disease.
Effects of the antianginal drug trapidil on atrioventricular conduction disturbances during acute myocardial ischemia.
Inhibition of phosphodiesterase type III before aortic cross-clamping preserves intramyocardial cyclic adenosine monophosphate during cardiopulmonary bypass.
Inotropic support of the heart that fails to successfully wean from cardiopulmonary bypass: the Montreal Heart Institute experience.
Newer treatments for decompensated heart failure: focus on levosimendan.
[Effects of the phosphodiesterase III inhibitor in ischemic heart disease]
Myocardial Reperfusion Injury
Effect of a cyclic adenosine monophosphate phosphodiesterase inhibitor, DN-9693, on myocardial reperfusion injury.
Myocardial Stunning
Ca(2+) sensitization and diastolic function of normal and stunned porcine myocardium.
Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs.
Comparison between the effects of a novel Ca++ sensitizer and a phosphodiesterase inhibitor on stunned myocardium.
Does ventricular fibrillation cause myocardial stunning during defibrillator implantation?
Effect of milrinone and atrial pacing on stunned myocardium.
Treating metabolic impairment and myocardial stunning with phosphodiesterase inhibitor type III, milrinone, administered prior to coronary artery occlusion in the presence of calcium channel blockade in pigs.
Myoma
[Peptide-activator of cyclic nucleotide phosphodiesterases in the rat and human uterus]
Neonatal Sepsis
Pentoxifylline inhibits TLR- and inflammasome-mediated in vitro inflammatory cytokine production in human blood with greater efficacy and potency in newborns.
Neoplasm Metastasis
Effect of phosphodiesterase inhibitors on platelet aggregation and tumor metastasis.
Effects of DN-9693, a new metastasis inhibitor, on murine hematogenous metastasis.
Exonuclease 1 expression is associated with clinical progression, metastasis, and survival prognosis of prostate cancer.
Inhibition of experimental metastasis of human adenocarcinoma by cilostazol, a platelet phosphodiesterase inhibitor.
Novel pyrimidopyrimidine derivatives for inhibition of cellular proliferation and motility induced by h-prune in breast cancer.
Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell-like Property and Metastasis in Breast Cancer.
Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis.
Silencing lncRNA ZFAS1 or elevated microRNA-135a represses proliferation, migration, invasion and resistance to apoptosis of osteosarcoma cells.
Studies on platelet aggregation inhibitors in vivo. VIII. Effect of pentoxifylline on spontaneous tumor metastasis.
[Effects of platelet aggregating inhibitor on pulmonary metastases of tumor cells after surgical resection]
Neoplasms
5'-nucleotide phosphodiesterase activity of floxuridine-resistant mouse glioma.
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and ?-catenin transcriptional activity.
A p97/Valosin-Containing Protein Inhibitor Drug CB-5083 Has a Potent but Reversible Off-Target Effect on Phosphodiesterase-6.
A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
A study of cyclic nucleotide metabolism and the histology of rat liver during 3'-methyl-4-dimethylamino-azobenzene carcinogenesis. II. Cyclic AMP metabolism.
Action of cAMP on expression and release of adhesion molecules in human endothelial cells.
Activation of cyclic AMP phosphodiesterase by phorbol and protein kinase C pathway: differences in normal and diabetic tissue.
Activation of the human "beta 2-interferon/hepatocyte-stimulating factor/interleukin 6" promoter by cytokines, viruses, and second messenger agonists.
Adenosine 3',5'-cyclic monophosphate and guanosine 3',5'-cyclic monophosphate phosphodiesterase activities in 1,2-dimethylhydrazine induced colon adenocarcinoma.
Adenosine 3',5'-monophosphate phosphodiesterase activity in experimental animal tumours which are either sensitive or resistant to bifunctional alkylating agents.
Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multi-target mechanism discovered through systematic combination screening in B-cell malignancies.
Adenyl cyclase and phosphodiesterase in human cerebral tumors.
Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP.
Amrinone and theophylline differentially regulate cytokine and nitric oxide production in endotoxemic mice.
Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model.
APEX1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis, and survival.
Association between three exonuclease 1 polymorphisms and cancer risks: a meta-analysis.
Association of DNA repair gene polymorphisms with response to cisplatin-based concurrent chemoradiotherapy in patients with cervical carcinoma.
Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells.
Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells.
Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
Benzoquinones and Terphenyl Compounds As Phosphodiesterase-4B Inhibitors from a Fungus of the Order Chaetothyriales (MSX 47445).
Biochemical properties of cyclic nucleotide phosphodiesterase in metastasizing and nonmetastasizing rat mammary carcinomas.
Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo.
Ca2+ and partly GTP gamma S-dependent particulate phospholipase C hydrolyzing phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate is inhibited by diacyl(acyl-acetyl) glycerols.
Caffeine and other phosphodiesterase inhibitors are potent inhibitors of the promotional effect of TPA on morphological transformation of hamster embryo cells.
Caffeine stimulates the proliferation of human lung adenocarcinoma cells and small airway epithelial cells via activation of PKA, CREB and ERK1/2.
Calmodulin activation of cyclic AMP phosphodiesterase in the B16 mouse melanoma.
Characterisation of cyclic adenosine 3':5'-monophosphate phospodiesterase from Walker carcinoma sensitive and resistant to bifunctional alkylating agents.
Characterization of phosphodiesterase 3 in human malignant melanoma cell line.
Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis.
Clinical Relevance of the Anti-inflammatory Effects of Roflumilast on Human Bronchus: Potentiation by a Long-Acting Beta-2-Agonist.
Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition.
Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages.
Constitutive activation of p70S6k in cancer cells.
Correction: Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.
Correlation between in vitro DNA synthesis, DNA strand separation and in vivo multiplication of cancer cells.
Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility.
Cyclic AMP specific, calcium independent phosphodiesterase from a malignant murine mast cell tumor.
Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death.
Cyclic nucleotide phosphodiesterase activity in muscle of patients with carcinoma.
Cyclic nucleotide phosphodiesterase activity of human normal and carcinomatous lung tissue.
Cyclic nucleotide phosphodiesterases in neoplastic and nonneoplastic human mammary tissues.
Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells.
Cyclic nucleotides in the regulation of expression of differentiated functions in neuroblastoma cells.
Cyclic-AMP phosphodiesterase activity in crown-gall tumor formation.
Cytokine-induced adhesion molecule expression on human umbilical vein endothelial cells is not regulated by cyclic adenosine monophosphate accumulation.
Design of new drug molecules to be used in reversing multidrug resistance in cancer cells.
Differential phosphodiesterase expression and cytosolic Ca2+ in human CNS tumour cells and in non-malignant and malignant cells of rat origin.
Dipyridamole Inhibits Lipogenic Gene Expression by Retaining SCAP-SREBP in the Endoplasmic Reticulum.
Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor alpha and cAMP.
Draft Genome Sequence of Marine Actinomycete Streptomyces sp. Strain NTK 937, Producer of the Benzoxazole Antibiotic Caboxamycin.
Dual regulation of tumor necrosis factor-alpha-induced CCL2/monocyte chemoattractant protein-1 expression in vascular smooth muscle cells by nuclear factor-kappaB and activator protein-1: modulation by type III phosphodiesterase inhibition.
Editorial Comment on: Effects of Phosphodiesterase Inhibitors on the Inflammatory Response of Endothelial Cells Stimulated by Myeloperoxidase-Modified Low-Density Lipoprotein or Tumor Necrosis Factor Alpha.
Effect of in vivo administration of 3-isobutyl 1-methyl xanthine (IBMX) on cyclic AMP levels, and DNA synthesis in Ehrlich ascites tumor cells.
Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188.
Effect of phosphodiesterase III inhibitor on plasma concentrations of endothelin-1 and tumour necrosis factor in patients with acute heart failure.
Effect of phosphodiesterase inhibitors on platelet aggregation and tumor metastasis.
Effect of TNF alpha production inhibitors BRL 61063 and pentoxifylline on the response of rats to poly I:C.
Effects of DN-9693, a new metastasis inhibitor, on murine hematogenous metastasis.
Effects of medroxyprogesterone acetate (MPA) on phosphodiesterase (PDE) activity in DMBA-induced rat mammary tumours.
Effects of Phosphodiesterase Inhibitors on the Inflammatory Response of Endothelial Cells Stimulated by Myeloperoxidase-Modified Low-Density Lipoprotein or Tumor Necrosis Factor Alpha.
Effects of prostacyclin analogs on the synthesis of tissue factor, tumor necrosis factor-alpha and interleukin-1 beta in human monocytic THP-1 cells.
Endogenous protein inhibitor of mitochondrial c-AMP phosphodiesterase in tumour bearing rats.
Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Evidence for a calmodulin inhibitory substance(s) isolated from human meningiomas.
Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin.
Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.
Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.
Exonuclease 1 (EXO1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Lung Adenocarcinoma.
Exonuclease 1 expression is associated with clinical progression, metastasis, and survival prognosis of prostate cancer.
Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy.
Expression of the functional cone phototransduction cascade in retinoblastoma.
Frequent Phosphodiesterase 11A Gene (PDE11A) Defects in Patients with Carney Complex (CNC) Caused by PRKAR1A Mutations: PDE11A May Contribute to Adrenal and Testicular Tumors in CNC as a Modifier of the Phenotype.
Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors.
Gene expression in thyroid autonomous adenomas provides insight into their physiopathology.
Genetics of adrenal tumors associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias.
Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers.
Germline Variants in Phosphodiesterase Genes and Genetic Predisposition to Pediatric Adrenocortical Tumors.
Growth-dependent AIB and meAIB uptake in LLC-PK1 cells: effects of differentiation inducers and of TPA.
Guanine nucleotides activate cytosolic phospholipase C of ascites tumour cells stimulated by 1-oleoyl-2-acetyl-sn-glycerol.
Hard times for oncogenic BRAF-expressing melanoma cells.
Human Exonuclease 1 (EXO1) Regulatory Functions in DNA Replication with Putative Roles in Cancer.
Human neuroblastoma in nude mice.
Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.
Ibudilast, a Phosphodiesterase Inhibitor and Toll-Like Receptor-4 Antagonist, Improves Hemorrhagic Shock and Reperfusion-Induced Left Ventricular Dysfunction by Reducing Myocardial Tumor Necrosis Factor ?.
Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat.
Identification and treatment of T2-low asthma in the era of biologics.
Identification of a functional glucocorticoid response element in the phenylethanolamine N-methyltransferase promoter using fusion genes introduced into chromaffin cells in primary culture.
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics.
Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumors.
Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells.
Inactivation of Exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility.
Increased cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in the epidermis of phorbol ester-treated mouse skin and in papillomas.
Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
Inhibition of PDE5 by Sulindac Sulfide Selectively Induces Apoptosis and Attenuates Oncogenic Wnt/{beta}-Catenin-Mediated Transcription in Human Breast Tumor Cells.
Inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1) developed by virtual screening using ligand-based pharmacophores.
Inhibitors of phosphodiesterase as cancer therapeutics.
Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-?B dependent mechanisms in apoE-/- mice.
Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition.
Is hEXO1 a cancer predisposing gene?
Isolation and characterization of calmodulin from an insulin-secreting tumour.
Isolation and characterization of the plasma membrane from Yoshida hepatoma cells.
Kinetic studies of human tyrosyl-DNA phosphodiesterase, an enzyme in the topoisomerase I DNA repair pathway.
Lack of steroidogenic response to cyclic AMP and ACTH in adrenal cells from rats bearing the MtTF4 tumor.
Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram.
Lowering of innate resistance of the lungs to the growth of blood-borne cancer cells in states of topical and systemic stress.
Management of male sexual dysfunction after cancer treatment.
Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.
MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway.
Modulation of the production of cytokines in titanium-stimulated human peripheral blood monocytes by pharmacological agents. The role of cAMP-mediated signaling mechanisms.
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia.
Novel Polyfunctional Pyridines as Anticancer and Antioxidant Agents. Synthesis, Biological Evaluation and in Silico ADME-T Study.
NSAIDs: Old Drugs Reveal New Anticancer Targets.
Overcoming of P-glycoprotein mediated vincristine resistance of L1210/VCR mouse leukemic cells could be induced by pentoxifyline but not by theophylline and caffeine.
Overexpression of autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression.
Oxpentifylline inhibits tumor necrosis factor-alpha mRNA transcription and protects against arthritis in mercuric chloride-treated brown Norway rats.
PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth.
Pentoxifylline attenuates hypoxic-ischemic brain injury in immature rats.
Pentoxifylline downregulates nitric oxide and tumor necrosis factor-alpha induced by mycobacterial lipoarabinomannan in a macrophage cell line.
Pentoxifylline fails to improve organ dysfunction and survival when used in the resuscitation of a porcine model of haemorrhage and abdominal sepsis.
Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug?
Pentoxifylline in preterm neonates: a systematic review.
Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway.
Pentoxifylline reduces acute lung injury in chronic endotoxemia.
Pentoxifylline triggers autophagy via ER stress response that interferes with Pentoxifylline induced apoptosis in human melanoma cells.
Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis.
Peripheral Enthesitis in Spondyloarthritis: Lessons from Targeted Treatments.
Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors.
Phorbol 12-myristate-13-acetate (PMA) stimulates a differential expression of cholecystokinin (CCK) and c-fos mRNA in a human neuroblastoma cell line.
Phosphodiesterase (1, 3 & 5) inhibitors attenuate diclofenac-induced acute kidney toxicity in rats.
Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors.
Phosphodiesterase 11A (PDE11A) gene defects in patients with acth-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors.
Phosphodiesterase 3A: a new player in development of interstitial cells of Cajal and a prospective target in gastrointestinal stromal tumors (GIST).
Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma.
Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression.
Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.
Phosphodiesterase inhibitors as anti-cancer drugs.
Placental extracellular vesicles-associated microRNA-519c mediates endotoxin adaptation in pregnancy.
Platyphylloside Isolated From Betula platyphylla Inhibit Adipocyte Differentiation and Induce Lipolysis Via Regulating Adipokines Including PPAR? in 3T3-L1 Cells.
Poly(ADP-ribose)-binding promotes Exo1 damage recruitment and suppresses its nuclease activities.
Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2.
Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line.
Purification and properties of Rauscher leukemia virus DNA polymerase and selective inhibition of mammalian viral reverse transcriptase by inorganic phosphate.
Quercetin inhibition of the induction and function of cytotoxic T lymphocytes.
Rare inactivating PDE11A variants associated with testicular germ cell tumors.
Regression and differentiation of neuroblastoma tumors in mice treated with differentiating agents--prostaglandin E1 and a phosphodiesterase inhibitor, RO 20-1724.
Regulation of CCK mRNA in the human neuroepithelioma cell line SK-N-MCIXC in response to second messenger activators.
Regulation of cyclic adenosine 3',5'-monophosphate in relation to growth of dimethylbenz[a]anthracene-induced mammary tumors in rats.
Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations.
Resveratrol Promotes Remyelination in Cuprizone Model of Multiple Sclerosis: Biochemical and Histological Study.
Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation.
Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model.
Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.
Serological analysis of human deoxyribonucleic acid polymerases. Preparation and properties of antiserum to deoxyribonucleic acid polymerase I from human lymphoid cells.
Significant association of the
Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice.
Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin.
Structural chemoproteomics and drug discovery.
Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase.
Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD).
Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor.
Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
Synovial fluid levels of tumor necrosis factor-alpha in the inflamed rat knee: modulation by dexamethasone and inhibitors of matrix metalloproteinase and phosphodiesterase.
Synthesis and properties of some novel anti-calmodulin drugs.
Synthesis of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and novel derivatives free of positional isomers. Potent inhibitors of cAMP-specific phosphodiesterase and of malignant tumor cell growth.
Synthesis of tumour necrosis factor-alpha in tissue culture of rat caecum: lack of suppression by phosphodiesterase inhibitors and prostanoids.
Targeting cancer with phosphodiesterase inhibitors.
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Targeting tumor cells based on Phosphodiesterase 3A expression.
Targetting cancer with Ru(III/II)-phosphodiesterase inhibitor adducts: a novel approach in the treatment of cancer.
The beta-adrenergic receptor system in human glioma-derived cell lines: the mode of phosphodiesterase induction and the macromolecules phosphorylated by cyclic AMP-dependent protein kinase.
The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis.
The exonuclease 1 Glu589Lys gene polymorphism and cancer susceptibility: evidence based on a meta-analysis.
The Human Tyrosyl-DNA Phosphodiesterase 1 (hTdp1) Inhibitor NSC120686 as an Exploratory Tool to Investigate Plant Tdp1 Genes.
The interaction between the Wnt/?-catenin signaling cascade and PKG activation in cancer.
The involvement of the 3':5'-cyclic-AMP phosphodiesterase in transformation and growth of crown-gall tumors in Bryophyllum daigremontianum.
The Molecular Organization of Human cGMP Specific Phosphodiesterase 6 (PDE6): Structural Implications of Somatic Mutations in Cancer and Retinitis Pigmentosa.
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
The proofreading domain of Escherichia coli DNA polymerase I and other DNA and/or RNA exonuclease domains.
The pyrimido-pyrimidine derivatives RA 233 and RX-RA 85 affect growth and cytoskeletal organization of rat mammary adenocarcinoma cells.
The role of tumour necrosis factor-alpha (TNF-alpha) in fever and the acute phase reaction in rabbits.
The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages.
The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity.
The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide.
The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.
The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice.
Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition.
Therapeutic options for severe asthma.
Therapeutic targets for treating fibrotic kidney diseases.
Thiazole-4-carboxamide adenine dinucleotide (TAD). Analogues stable to phosphodiesterase hydrolysis.
Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation.
TREX1 Cuts Down on Cancer Immunogenicity.
Tumor necrosis factor-alpha activates nuclear factor kappa B and induces manganous superoxide dismutase and phosphodiesterase mRNA in human papillary thyroid carcinoma cells.
Tumor vascular disrupting agent DMXAA inhibits platelet activation and thrombosis via inhibition of TXA2 signaling and phosphodiesterase.
Unraveling the molecular basis of micronodular adrenal hyperplasia.
Virtual screening using ligand-based pharmacophores for inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1).
Yessotoxin activates cell death pathways independent of Protein Kinase C in K-562 human leukemic cell line.
[adenylate cyclase system in Ehrlich ascites tumor cells sensitive and resistant to 5-fluorouracil]
[Concentration of cyclic nucleotides, activity of adenylate cyclase, 3',5'-AMP phosphodiesterase and guanylate cyclase in plasma membranes from liver and hepatomas of different degrees of malignancy]
[Effect of selective phosphodiesterase 4 inhibitors on nuclear factor kappa B, tumor necrosis factor-? and interleukin-8 expression in peripheral blood mononuclear cells in rheumatoid arthritis with interstitial lung disease].
[Effects of platelet aggregating inhibitor on pulmonary metastases of tumor cells after surgical resection]
[Insertion of mouse kappa light chain immunoglobulin gene sequences into a bacterial plasmid]
Neoplasms, Germ Cell and Embryonal
Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors.
Nephritis
Effects of TJN-598, a new selective phosphodiesterase type IV inhibitor on anti-Thy1 nephritis in rats.
Nephrotic Syndrome
Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention.
Phosphodiesterases (PDEs) hydrolyze the 3' phosphoester bond of the purine 3',5'-cyclic monophosphates, cAMP and cGMP.
Urinary excretion of sphingomyelinase phosphodiesterase acid-like 3b in children with intractable nephrotic syndrome.
Nervous System Diseases
Penile blood cyclic guanosin monophosphate level is associated with penile Doppler ultrasound findings.
Neuralgia
Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: Different inhibitory mechanism on spinal microglia from minocycline and propentofylline.
Ibudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency virus-1 Tat-mediated activation of microglial cells.
Impairment of adenylyl cyclase-mediated glutamatergic synaptic plasticity in the periaqueductal grey in a rat model of neuropathic pain.
Intrathecal injection of phosphodiesterase 4B-specific siRNA attenuates neuropathic pain in rats with L5 spinal nerve ligation.
Zaprinast diminished pain and enhanced opioid analgesia in a rat neuropathic pain model.
Neurilemmoma
Distinct isozyme patterns of cyclic nucleotide phosphodiesterase in human neuroblastoma and ganglioneuroma; a possible marker of differentiation of neural crest-derived tumors and Schwann cells.
Neuritis
Suppression of experimental autoimmune neuritis by phosphodiesterase inhibitor pentoxifylline.
Neuritis, Autoimmune, Experimental
Suppression of experimental autoimmune neuritis by phosphodiesterase inhibitor pentoxifylline.
Neuroblastoma
A further study on the regulation of cyclic nucleotide phosphodiesterase activity in neuroblastoma cells: effect of growth.
Adenosine analogues stimulate cyclic AMP-accumulation in cultured neuroblastoma and glioma cells.
Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells.
Cilostazol, a cyclic AMP phosphodiesterase inhibitor, stimulates nitric oxide production and sodium potassium adenosine triphosphatase activity in SH-SY5Y human neuroblastoma cells.
Comparison of the effect of isobutylmethylxanthine and phosphodiesterase-selective inhibitors on cAMP levels in SH-SY5Y neuroblastoma cells.
Cyclic 3',5'-AMP phosphodiesterase activity during cyclic AMP-induced differentiation of neuroblastoma cells in culture.
Cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in malignant and cyclic adenosine 3':5'-monophosphate-induced "differentiated" neuroblastoma cells.
Cyclic AMP-mediated induction of ornithine decarboxylase of glioma and neuroblastoma cells.
Cyclic nucleotide phosphodiesterase isozymes in neuroblastoma cells.
Cyclic nucleotides in the regulation of expression of differentiated functions in neuroblastoma cells.
delta-Opioid receptor activates cAMP phosphodiesterase activities in neuroblastoma x glioma NG108-15 hybrid cells.
Determination of 2-5A synthetase and 2-5A phosphodiesterase in neuroblastoma cells by analytical capillary isotachophoresis: effects of cytokines and comparison with radioenzymatic methods.
Differences and similarities between guanosine 3',5'-cyclic monophosphate phosphodiesterase and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in neuroblastoma cells in culture.
Distinct isozyme patterns of cyclic nucleotide phosphodiesterase in human neuroblastoma and ganglioneuroma; a possible marker of differentiation of neural crest-derived tumors and Schwann cells.
Effect of a phosphodiesterase inhibitor on cyclic GMP changes induced by muscarinic agonists in mouse neuroblastoma cells [proceedings]
Expression of calmodulin-dependent phosphodiesterase, calmodulin-dependent protein phosphatase, and other calmodulin-binding proteins in human SMS-KCNR neuroblastoma cells.
Glucocorticoids increase tyrosine hydroxylase activity in cultured murine neuroblastoma.
Inhibitors of cyclic-nucleotide phosphodiesterase induce morphological differentiation of mouse neuroblastoma cell culture.
Manganese inhibits adenylate cyclase activity and stimulates phosphodiesterase activity in neuroblastoma cells: its possible implication in manganese-poisoning.
Mouse neuroblastoma adenylate cyclase. Adenosine and adenosine analogues as potent effectors of adenylate cyclase activity.
Multiple forms of cyclic 3',5'-AMP phosphodiesterase of rat cerebrum and cloned astrocytoma and neuroblastoma cells.
Neuroblastoma clones: prostaglandin versus dibutyryl cyclic AMP, 8-benzylthio-cyclic AMP, phosphodiesterase inhibitors and x-rays.
Potentiation by BL191 of differentiation of neuroblastoma cells induced by dibutyryl cAMP and prostaglandin E(1).
Regression and differentiation of neuroblastoma tumors in mice treated with differentiating agents--prostaglandin E1 and a phosphodiesterase inhibitor, RO 20-1724.
Role of cyclic AMP in differentiation of human neuroblastoma cells in culture.
Rottlerin is a pan phosphodiesterase inhibitor and can induce neurodifferentiation in IMR-32 human neuroblastoma cells.
Sequence-dependent trafficking and activity of GDE2, a GPI-specific phospholipase promoting neuronal differentiation.
Stimulation by prostaglandin E1 of adenosine 3':5'-cyclic monophosphate formation in neuroblastoma cells in the presence of phosphodiesterase inhibitors.
Studies on platelet aggregation inhibitors in vivo. VIII. Effect of pentoxifylline on spontaneous tumor metastasis.
[3H]Rolipram binding and phosphodiesterase activity in neuroblastoma N18TG-2 and glioma C6Bu-1.
Neurodegenerative Diseases
cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins.
Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.
Guanosine 3',5'-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: protective effects of propentofylline.
In vitro complementation of Tdp1 deficiency indicates a stabilized enzyme-DNA adduct from tyrosyl but not glycolate lesions as a consequence of the SCAN1 mutation.
Phosphodiesterase: an interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases.
Sildenafil-evoked photoreceptor oxidative stress in vivo is unrelated to impaired visual performance in mice.
The perspective of caffeine and caffeine derived compounds in therapy.
XRCC1 protects against the lethality of induced oxidative DNA damage in nondividing neural cells.
Neuroinflammatory Diseases
Multifunctional Ligands Targeting Phosphodiesterase as the Future Strategy for the Symptomatic and Disease-Modifying Treatment of Alzheimer's Disease.
Phosphodiesterases as a New Therapeutic Targets for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases.
Phosphoinositide 3-Kinase Gamma Contributes to Neuroinflammation in a Rat Model of Surgical Brain Injury.
Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.
The phosphodiesterase 10 inhibitor papaverine exerts anti-inflammatory and neuroprotective effects via the PKA signaling pathway in neuroinflammation and Parkinson's disease mouse models.
The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.
Neurologic Manifestations
[Beta-adrenergic receptor blocker poisoning]
Neuromyelitis Optica
[Neuro-ophthalmology: the eye as a window to the brain].
Neutropenia
C16orf57, a gene mutated in poikiloderma with neutropenia, encodes a putative phosphodiesterase responsible for the U6 snRNA 3' end modification.
Niemann-Pick Disease, Type A
Deficiency of taurocholate-dependent phospholipase C acting on phosphatidylcholine in Niemann-Pick disease.
Niemann-Pick Diseases
Deficiency of taurocholate-dependent phospholipase C acting on phosphatidylcholine in Niemann-Pick disease.
Diagnosis of Niemann-Pick disease using a simple and sensitive fluorimetric assay of sphingomyelinase activity.
Fibroblast phosphodiesterase deficiency in Niemann-Pick disease.
Sphingomyelinase and nonspecific phosphodiesterase activities in Epstein-Barr virus-transformed lymphoid cell lines from Niemann-Pick disease A, B and C.
Studies on pyrophosphate diesterase activity in cultured human fibroblasts: a deficiency in Niemann-Pick disease.
Studies on sphingomyelinase and beta-glucosidase activities in Niemann-Pick disease variants. Phosphodiesterase activities measured with natural and artificial substrates.
The structure and catalytic mechanism of human sphingomyelin phosphodiesterase like 3a--an acid sphingomyelinase homologue with a novel nucleotide hydrolase activity.
Non-alcoholic Fatty Liver Disease
Combined treatments with metformin and phosphodiesterase inhibitors alleviate non-alcoholic fatty liver disease in high-fat diet-fed rats: A comparative study.
Effects of Chinese Medicinal Formula BNG-1 on Phosphodiesterase 3B Expression, Hepatic Steatosis, and Insulin Resistance in High Fat Diet-induced NAFLD Mice.
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.
Lipotoxicity-induced STING1 activation stimulates MTORC1 and restricts hepatic lipophagy.
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Obesity
A stop-codon of the phosphodiesterase 11A gene is associated with elevated blood pressure and measures of obesity.
Adenosine, prostaglandins and phosphodiesterase as targets for obesity pharmacotherapy.
Anthocyanin Bioactivity in Obesity and Diabetes: The Essential Role of Glucose Transporters in the Gut and Periphery.
Association of genetic variation in ENPP1 with obesity-related phenotypes.
Decreased expression and function of adipocyte hormone-sensitive lipase in subcutaneous fat cells of obese subjects.
Expression of ectonucleotide pyrophosphate phosphodiesterase and peroxisome proliferator activated receptor gamma in morbidly obese patients.
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Inhibitory Activities of Pancreatic Lipase and Phosphodiesterase from Korean Medicinal Plant Extracts.
Insulin resistance of fat cells from spontaneously diabetic KK mice. Analysis of insulin-sensitive phosphodiesterase.
Structural chemoproteomics and drug discovery.
The absence of evidence for major effects of the frequent SNP +299G>A in the resistin gene on susceptibility to insulin resistance syndrome associated with Japanese type 2 diabetes.
Obstetric Labor, Premature
Improving the relaxing effect of terbutaline with phosphodiesterase inhibitors: Studies on pregnant rat uteri in vitro.
In vitro study of phosphodiesterase-inhibiting drugs: a complement to beta-sympathomimetic drug therapy in premature labor?
Ocular Hypotension
Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors.
Oligohydramnios
Endocrine and pharmacological factors which influence the onset of labour in rhesus monkeys.
Oligospermia
Modulation of sperm membrane conformation by pentoxifylline in oligospermia: a biophysical investigation of sperm membrane in vitro.
Optic Nerve Diseases
The phosphodiesterase inhibitors and non-arteritic anterior ischaemic optic neuropathy: increased vigilance is necessary.
[Neuro-ophthalmology: the eye as a window to the brain].
Optic Neuropathy, Ischemic
Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
Optic neuropathy associated with the use of over-the-counter sexual enhancement supplements.
[Neuro-ophthalmology: the eye as a window to the brain].
Orchitis
Syphilitic orchitis mimicking a testicular tumor in a clinically occult HIV-infected young man: a case report with emphasis on a challenging pathological diagnosis.
Osteoarthritis
Cilostazol protects rat chondrocytes against nitric oxide-induced apoptosis in vitro and prevents cartilage destruction in a rat model of osteoarthritis.
Decreased levels of nucleotide pyrophosphatase phosphodiesterase 1 are associated with cartilage calcification in osteoarthritis and trigger osteoarthritic changes in mice.
Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4.
Osteonecrosis
Preventive Effect of Phosphodiesterase Inhibitor Pentoxifylline Against Medication-Related Osteonecrosis of the Jaw: An Animal Study.
Osteoporosis
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
KMUP-1 promotes osteoblast differentiation through cAMP and cGMP pathways and signaling of BMP-2/Smad1/5/8 and Wnt/?-catenin.
Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture.
Therapeutic potential of phosphodiesterase inhibitors in the treatment of osteoporosis: Scopes for therapeutic repurposing and discovery of new oral osteoanabolic drugs.
[Effect of phosphodiesterase IV inhibitors on bone tissue: a possibility for its use as a new agent to treat osteoporosis]
Osteosarcoma
Characterization of phosphodiesterase 3 in human malignant melanoma cell line.
Cyclic AMP-dependent and -independent effects on tissue-type plasminogen activator activity in osteogenic sarcoma cells; evidence from phosphodiesterase inhibition and parathyroid hormone antagonists.
TREX1 suppression imparts cancer-stem-cell-like characteristics to CD133- osteosarcoma cells through the activation of E2F4 signaling.
Ovarian Neoplasms
Exonuclease 1 (Exo1) Participates in Mammalian Non-Homologous End Joining and Contributes to Drug Resistance in Ovarian Cancer.
FTO-Dependent N6-Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling.
Gene expression in the spermatogenically inactive "dark" and maturing "light" testicular tissues of the prepubertal colt.
Tumor markers for ovarian cancer.
Pancreatic Neoplasms
Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells.
cAMP protection of pancreatic cancer cells against apoptosis induced by ERK inhibition.
Pancreatitis
PENTOXIFYLLINE PREVENTS LOSS OF PP2A PHOSPHATASE ACTIVITY AND RECRUITMENT OF HISTONE ACETYLTRANSFERASES TO PRO-INFLAMMATORY GENES IN ACUTE PANCREATITIS.
Rolipram and SP600125 Suppress the Early Increase in PTP1B Expression During Cerulein-Induced Pancreatitis in Rats.
Specific type IV phosphodiesterase inhibitor ameliorates cerulein-induced pancreatitis in rats.
The Selective Inhibition of Type IV Phosphodiesterase Attenuates the Severity of the Acute Pancreatitis in Rats.
Papilloma
Increased cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in the epidermis of phorbol ester-treated mouse skin and in papillomas.
Parasitic Diseases
Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases.
Parkinson Disease
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
PET Radioligands for imaging of the PDE10A in human: current status.
Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.
The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.
Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease.
Parkinsonian Disorders
PDE8B mutation is not associated with Parkinson's disease in a Taiwanese population.
Studies with bromocriptine: III. Concomitant administration of caffeine to patients with idiopathic parkinsonism.
Pediatric Obesity
Impact of phosphodiesterase 8B gene rs4704397 variation on thyroid homeostasis in childhood obesity.
Penile Induration
Biofilm and penile prosthesis infections in the era of coated implants: a review.
Conservative management options for Peyronie's disease.
Partial Priapism Treated with Pentoxifylline.
Penile blood cyclic guanosin monophosphate level is associated with penile Doppler ultrasound findings.
The Efficacy of Medical Treatment of Peyronie's Disease: Potassium Para-Aminobenzoate Monotherapy vs. Combination Therapy with Tamoxifen, L-Carnitine, and Phosphodiesterase Type 5 Inhibitor.
[Treatment of erectile dysfunction in patients with plastic induration of the penis]
Peripheral Arterial Disease
A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease.
Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.
Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study.
Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model.
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Macro- and microrheological parameters of blood in patients with cerebral and peripheral atherosclerosis: the molecular change mechanisms after pentoxifylline treatment.
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
Pentoxifylline protects against loss of function and renal interstitial fibrosis in chronic experimental partial ureteral obstruction.
Pharmacokinetic modeling analysis of cilostazol and its active metabolites (OPC-13015 and OPC-13213) after multiple oral doses of cilostazol in healthy Korean volunteers.
Progress in the Mechanism and Clinical Application of Cilostazol.
Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor.
The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.
The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow.
[Prospects of clinical application of cilostazol for peripheral artery disease].
Peripheral Nervous System Diseases
The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease.
Peripheral Vascular Diseases
Anti-inflammatory properties of cilostazol: Its interruption of DNA binding activity of NF-?B from the Toll-like receptor signaling pathways.
Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure.
Attenuation of gastric mucosal inflammation induced by aspirin through inhibition of selective type III phospshodiesterase in rats.
Cilostazol Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysms but Not Atherosclerosis in Apolipoprotein E-Deficient Mice.
Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases.
Cilostazol prevents retinal ischemic damage partly via inhibition of tumor necrosis factor-?-induced nuclear factor-kappa B/activator protein-1 signaling pathway.
Cilostazol suppresses angiotensin II?induced apoptosis in endothelial cells.
Effect of cilostazol, a selective type-III phosphodiesterase inhibitor, on water-immersion stress-induced gastric mucosal injury in rats.
Endothelium-dependent effects of pentoxifylline in rat aorta.
Improvement in the outcome of rejection with pentoxifylline in renal transplantation: a randomized controlled trial.
Pentoxifylline enhances antioxidative capability and promotes mitochondrial biogenesis for improving age-related behavioral deficits.
Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons.
Pentoxifylline inhibits neointimal formation and stimulates constrictive vascular remodeling after arterial injury.
Phosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney.
Plasma factor and platelet sensitivity to prostacyclin in patients with peripheral vascular disease before and after treatment with a combination of a cyclooxygenase and a phosphodiesterase inhibitor.
Topical cilostazol inhibits neointimal hyperplasia in a rat interposition vein graft model.
[Pentoxifylline: a cheap substitute for anti-TNFalpha agents?]
[Potential therapeutic approaches for prevention and treatment of diabetic nephropathy and neuropathy: evidences of cilostazol]
Pheochromocytoma
Activation of phosphodiesterase IV during desensitization of the A2A adenosine receptor-mediated cyclic AMP response in rat pheochromocytoma (PC12) cells.
Catecholamine-synthesizing enzymes and chromogranin proteins in drug-induced proliferative lesions of the rat adrenal medulla.
Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells.
Guanosine 3',5'-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: protective effects of propentofylline.
Mitogenic and antimitogenic effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in adult rat chromaffin cell cultures.
Photophobia
Calcium dependence of the activation and inactivation kinetics of the light-activated phosphodiesterase of retinal rods.
Engineering of a red-light-activated human cAMP/cGMP-specific phosphodiesterase.
Excised patches of plasma membrane from vertebrate rod outer segments retain a functional phototransduction enzymatic cascade.
Light-induced infrared light scattering signal in the retina: effect of phosphodiesterase inhibitors.
Pituitary Neoplasms
The pharmacodynamic action of the cyclic AMP phosphodiesterase inhibitor rolipram on prolactin producing rat pituitary adenoma (GH4C1) cells.
Thyroliberin stimulates rapid hydrolysis of phosphatidylinositol 4,5-bisphosphate by a phosphodiesterase in rat mammotropic pituitary cells. Evidence for an early Ca2+-independent action.
Pneumococcal Infections
Unique Roles for Streptococcus pneumoniae Phosphodiesterase 2 in Cyclic di-AMP Catabolism and Macrophage Responses.
Pneumonia
Administration of pentoxifylline during allergen sensitization dissociates pulmonary allergic inflammation from airway hyperresponsiveness.
Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia.
Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung.
Effects of pentoxifylline on inflammatory cytokine expression and acute pleuropneumonia in swine.
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.
Impacts of anti-inflammatory phosphodiesterase inhibitors on a murine model of chronic pulmonary inflammation.
Inhibition of phosphodiesterase suppresses allergic lung inflammation by regulating MCP-1 in an OVA-induced asthma murine model with co-exposure to lipopolysaccharide.
MicroRNA-30d-5p ameliorates lipopolysaccharide-induced acute lung injury via activating AMPK?.
Pentoxifylline or theophylline use in hospitalized COVID-19 patients requiring oxygen support.
Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor.
Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Polycystic Kidney Diseases
Phosphodiesterase Isoform Regulation of Cell Proliferation and Fluid Secretion in Autosomal Dominant Polycystic Kidney Disease.
Polycystic Kidney, Autosomal Dominant
Mapping of the familial Mediterranean fever gene to chromosome 16.
Phosphodiesterase Isoform Regulation of Cell Proliferation and Fluid Secretion in Autosomal Dominant Polycystic Kidney Disease.
Polyuria
Fluoride inhibition of the hydro-osmotic response of the toad urinary bladder to antidiuretic hormone.
Lithium-induced polyuria: effect of lithium on adenylate cyclase and adenosine 3',5'-monophosphate phosphodiesterase in medullary ascending limb of Henle's loop and in medullary collecting tubules.
Sildenafil and glyceryl trinitrate reduce tactile allodynia in streptozotocin-injected rats.
Pre-Eclampsia
Characterization of changes in mechanical responses to histamine in omental resistance arteries in pre-eclampsia.
Increased serum phosphodiesterase activity in women with pre-eclampsia.
Phosphodiesterase Inhibition in the Treatment of Preeclampsia: What Is New?
Phosphodiesterase Inhibitor Effect on Small Artery Function in Preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A heat-stable protein inhibitor of cyclic 3',5'-nucleotide phosphodiesterase.
Cyclic nucleotide phosphodiesterase and protein activator in human cancer cell lines and Brown-Pearce carcinoma.
Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells.
Premature Birth
Is the relaxing effect of beta-adrenergic agonists on the human myometrium only transitory?
Premature Ejaculation
Pharmacotherapy of sexual dysfunctions : current status.
The Control of Male Sexual Responses.
Priapism
Partial Priapism Treated with Pentoxifylline.
Pharmacologically-induced Recreational Priapism: Case Report and Review.
Priapism associated with concurrent use of phosphodiesterase inhibitor drugs and intracavernous injection therapy.
Second Pathways in the Pathophysiology of Ischemic Priapism and Treatment Alternatives.
Testosterone replacement in transgenic sickle cell mice controls priapic activity and upregulates PDE5 expression and eNOS activity in the penis.
Words of wisdom. Re: feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism.
Primary Myelofibrosis
Pulmonary hypertension in patients with hematological disorders following splenectomy.
Prostatic Hyperplasia
Chronic treatment with Sildenafil has no effect on folliculogenesis or fertility in C57BL/6 and C57BL/6 knockout for iNOS mice.
Effect of acute administration of sildenafil to rats with detrusor overactivity induced by chronic deficiency of nitric oxide.
Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway.
Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.
PDE5 inhibitors for LUTS.
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
Re: Mauro Gacci, Giovanni Corona, Matteo Salvi, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with ?-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
[Functional urology: synopsis of the 101st Congress of the French Association of Urology]
[Should we prescribe phosphodiesterase inhibitors for the treatment of symptomatic benign prostatic hyperplasia].
Prostatic Neoplasms
Biofilm and penile prosthesis infections in the era of coated implants: a review.
Erectile dysfunction.
Exonuclease 1 expression is associated with clinical progression, metastasis, and survival prognosis of prostate cancer.
Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.
Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression.
Influence of a single-nucleotide polymorphism of the DNA mismatch repair-related gene exonuclease-1 (rs9350) with prostate cancer risk among Chinese people.
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.
Phosphodiesterase 11A (PDE11A) Genetic Variants May Increase Susceptibility to Prostatic Cancer.
Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway.
Phosphodiesterase sequence variants may predispose to prostate cancer.
Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer.
Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer.
Randomised, placebo-controlled, crossover trial of sildenafil citrate in the treatment of erectile dysfunction following external beam radiation treatment of prostate cancer.
The effect of papaverine on morphologic differentiation, proliferation and invasive potential of human prostatic cancer LNCaP cells.
The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors.
Prostatitis
Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review.
Protein-Energy Malnutrition
An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
Pruritus
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
[Papaverin--effective in therapy of pruritus of atopic dermatitis?]
Pseudohypoparathyroidism
Increased urinary phosphate excretion in pseudohypoparathyroidism type II with long-term treatment with phosphodiesterase inhibitor.
Parathyroid hormone resistance syndromes - Inactivating PTH/PTHrP signaling disorders (iPPSDs).
Pseudomonas Infections
The effect of rolipram, a type IV phosphodiesterase inhibitor, on Pseudomonas aeruginosa infection of respiratory mucosa.
Pseudorabies
Activation of the human "beta 2-interferon/hepatocyte-stimulating factor/interleukin 6" promoter by cytokines, viruses, and second messenger agonists.
Psoriasis
A Phase I Randomized Trial to Assess the Effect on skin infiltrate thickness and Tolerability of Topical Phosphodiesterase Inhibitors in the Treatment of Psoriasis Vulgaris Using a Modified Psoriasis Plaque Test.
An update on the safety of apremilast for the treatment of plaque psoriasis.
Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial.
Apremilast for the management of moderate to severe plaque psoriasis.
Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
Mononuclear leukocyte cyclic adenosine monophosphate responses in psoriasis are normal.
Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects.
Pharmacology of psoriasis.
Phosphodiesterase 7A inhibitor ASB16165 impairs proliferation of keratinocytes in vitro and in vivo.
Phosphodiesterase in psoriasis.
Proximal Renal Tubular Acidosis (Fanconi syndrome) Induced by Apremilast: A Case Report.
Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of in vitro and in vivo Models.
Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
Worsening of Lymphopenia during Apremilast Treatment.
[Immediate results of treatment of psoriasis with phosphodiesterase inhibitors]
Psychomotor Agitation
Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.
Pulmonary Arterial Hypertension
Advances in the medical treatment of pulmonary hypertension.
Analysis of short-term treatment with the phosphodiesterase type 5 inhibitor tadalafil on long bone development in young rats.
Comparative Effectiveness of Pharmacological Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis.
COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors.
Curcumin analogues inhibit phosphodiesterase-5 and dilate rat pulmonary arteries.
Endothelin receptor antagonists for pulmonary arterial hypertension.
Evidence-based pharmacologic management of pulmonary arterial hypertension.
Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors.
Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration.
Long-term inhaled iloprost use in children with pulmonary arterial hypertension.
New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine.
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
Pulmonary arterial hypertension secondary to chronic lung diseases: pathogenesis and medical treatment.
Pulmonary hypertension and right ventricular function in advanced heart failure.
Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension.
Scleroderma - new aspects in pathogenesis and treatment.
Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca2+ entry.
Tadalafil as treatment for idiopathic pulmonary arterial hypertension.
[Pulmonary arterial hypertension-specific drugs - current status]
[Pulmonary hypertension and right ventricular failure. Part XII. Nitrous oxide and phosphodiesterase inhibitors in the treatment of primary pulmonary arterial hypertension]
[Pulmonary hypertension in COPD and interstitial lung diseases]
[Pulmonary hypertension. Pathophysiology and current concepts of medication therapy]
[Update in the diagnosis and therapy for pulmonary arterial hypertension]
Pulmonary Disease, Chronic Obstructive
A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD.
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy.
A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice.
A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-? Signaling and Activation of cAMP/PKA Signaling.
A Way to Increase the Bioaccesibility and Photostability of Roflumilast, a COPD Treatment, by Cyclodextrin Monomers.
ABCD of the phosphodiesterase family: interaction and differential activity in COPD.
ACP Journal Club. Review: oral phosphodiesterase 4 inhibitors reduce exacerbations but increase adverse events in COPD.
An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.
Ariflo (SmithKline Beecham plc).
Cardiac effects of current treatments of chronic obstructive pulmonary disease.
CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.
Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.
Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Clinical Considerations for Roflumilast: A New Treatment for COPD.
Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages.
Cross-talk between PKA-C? and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.
Cyclic AMP enhancing drugs modulate eicosanoid release from human alveolar macrophages.
Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors.
Direct Inhibitory Effect of the Phosphodiesterase-4 Inhibitor, Roflumilast, on Neutrophil Migration in COPD.
Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs.
Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.
Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients.
Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs.
Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction.
Efficacy and safety profile of roflumilast in a real-world experience.
Enantiomer Discrimination Illustrated by the High Resolution Crystal Structures of Type 4 Phosphodiesterase.
Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.
Evaluation of PDE4 inhibition for COPD.
Evaluation of the Effects of CHF6001, an Inhaled PDE4 Inhibitor, on Cardiac Repolarization and Cardiac Arrhythmias in Healthy Volunteers.
Evidence of oxidative stress in asthma and COPD: potential inhibitory effect of theophylline.
Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies.
Hesperetin, a Selective Phosphodiesterase 4 Inhibitor, Effectively Suppresses Ovalbumin-Induced Airway Hyperresponsiveness without Influencing Xylazine/Ketamine-Induced Anesthesia.
Impact of Phosphodiesterase 4 Inhibition on the Operational Efficacy, Response Maxima, and Kinetics of Indacaterol-Induced Gene Expression Changes in BEAS-2B Airway Epithelial Cells: A Global Transcriptomic Analysis.
In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor.
Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review.
Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker.
Modulation of Cytokine Production by Cyclic Adenosine Monophosphate Analogs in Human Leukocytes.
Novel antiinflammatory therapies for COPD.
Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models.
Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.
Phosphodiesterase 4 inhibition of beta2-integrin adhesion caused by leukotriene B4 and TNF-alpha in human neutrophils.
Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD.
Phosphodiesterase activity in neutrophils from horses with chronic obstructive pulmonary disease.
Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?
Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Phosphodiesterase inhibitors in chronic obstructive pulmonary disease.
Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
Positioning new pharmacotherapies for COPD.
Pulmonary hypertension associated with COPD.
Roflumilast for COPD.
Roflumilast for the treatment of chronic obstructive pulmonary disease.
Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.
Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes.
Roflumilast: doubtful efficacy but clear harms in COPD.
Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease.
Synthesis and biological activity of Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia.
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.
Therapeutic responses in asthma and COPD. Bronchodilators.
Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells.
[Effect of phosphodiesterase inhibitor on expression of IL-8 mRNA in peripheral blood mononuclear cells from COPD patients.]
[Pulmonary hypertension in COPD and interstitial lung diseases]
[Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD]
[Treatment of chronic obstructive pulmonary disease--traditional bronchodilatation and targeted anti-inflammatory therapy].
Pulmonary Edema
Advances in the available non-biological pharmacotherapy prevention and treatment of acute mountain sickness and high altitude cerebral and pulmonary oedema.
Are sildenafil and theophylline effective in the prevention of high-altitude pulmonary edema?
Cytokine immunopathogenesis of enterovirus 71 brain stem encephalitis.
Inhibition of lipopolysaccharide-induced pulmonary edema by isozyme-selective phosphodiesterase inhibitors in guinea pigs.
Therapeutic efficacy of milrinone in the management of enterovirus 71-induced pulmonary edema.
Pulmonary Embolism
Selective pulmonary vasodilatory effect of ZSY-27 in dogs with pulmonary hypertension due to pulmonary embolism.
Pulmonary Eosinophilia
Increased respiratory burst and phosphodiesterase activity in alveolar eosinophils in chronic eosinophilic pneumonia.
Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats.
Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.
Pulmonary Heart Disease
Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Raynaud Disease
Systemic sclerosis - focus on dermatological aspects. Part 2: diagnostics, therapy.
Renal Insufficiency
Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure.
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure.
Phosphodiesterase III inhibitor olprinone chlorate is not significantly removed by continuous venovenous hemodiafiltration.
[The etiology and management of congestive heart failure in the elderly]
Renal Insufficiency, Chronic
Effects of dopamine on kidney function and on the adenyl cyclase phosphodiesterase system in man.
Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial.
Reperfusion Injury
Combined use of adenosine and amrinone inhibits reperfusion injury of rat liver.
Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice.
Effect of olprinone, a phosphodiesterase III inhibitor, on hepatic ischemiareperfusion injury in rats.
Effects of amrinone on hepatic ischemia-reperfusion injury in rats.
Effects of amrinone on ischaemia-reperfusion injury in cirrhotic patients undergoing hepatectomy: a comparative study with prostaglandin E1.
Inotropic support of the heart that fails to successfully wean from cardiopulmonary bypass: the Montreal Heart Institute experience.
Long-acting oral phosphodiesterase inhibition preconditions against reperfusion injury in an experimental lung transplantation model.
Nebulized phosphodiesterase III inhibitor during warm ischemia attenuates pulmonary ischemia-reperfusion injury.
Pharmacological activity of cardiovascular agents from herbal medicine.
Role of cyclic nucleotides in ischemia and reperfusion injury of canine livers.
The effect of amrinone on liver regeneration in experimental hepatic resection model.
The Effect of Sildenafil and Udenafil on Testicular Damage Following Ischemia-Reperfusion Injury in Rats.
The protective effects of tadalafil on renal damage following ischemia reperfusion injury in rats.
[Anti-inflammatory effects of pentoxifylline: importance in cardiac surgery]
Respiratory Distress Syndrome
Chronicles in drug discovery.
Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition.
Respiratory Hypersensitivity
Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia.
Respiratory Insufficiency
Blockade of phosphodiesterase 4 reverses morphine-induced ventilatory disturbance without loss of analgesia.
Respiratory Tract Diseases
[Theophylline and selective phosphodiesterase inhibitor in therapy of obstructive respiratory tract diseases]
Retinal Degeneration
Activation of survival pathways in the degenerating retina of rd10 mice.
Activation of the molecular chaperone, sigma 1 receptor, preserves cone function in a murine model of inherited retinal degeneration.
Adenoviral-mediated gene transfer to retinal explants during development and degeneration.
Basic fibroblast growth factor: increased gene expression in inherited and light-induced photoreceptor degeneration.
Caspase-3 inhibitor transiently delays inherited retinal degeneration in C3H mice carrying the rd gene.
cGMP-Phosphodiesterase Inhibition Prevents Hypoxia-Induced Cell Death Activation in Porcine Retinal Explants.
Changes in morphology of retinal ganglion cells with eccentricity in retinal degeneration.
Cyclic-nucleotide phosphodiesterase: an early defect in inherited retinal degeneration of C3H mice.
Delivery of genes to the eye using lentiviral vectors.
Differential Modification of Phosducin Protein in Degenerating rd1 Retina Is Associated with Constitutively Active Ca2+/Calmodulin Kinase II in Rod Outer Segments.
Do cGMP Levels Drive the Speed of Photoreceptor Degeneration?
Linkage of photoreceptor degeneration by apoptosis with inherited defect in phototransduction.
Phosphodiesterase inhibition induces retinal degeneration, oxidative stress and inflammation in cone-enriched cultures of porcine retina.
Photoreceptor protection by mesenchymal stem cell transplantation identifies exosomal MiR-21 as a therapeutic for retinal degeneration.
Retinal degeneration in Aipl1-deficient mice: a new genetic model of Leber congenital amaurosis.
The search for mutations in the gene for the beta subunit of the cGMP phosphodiesterase (PDEB) in patients with autosomal recessive retinitis pigmentosa.
Tool from ancient pharmacopoeia prevents vision loss.
Two pathways of rod photoreceptor cell death induced by elevated cGMP.
Retinal Diseases
Photoreceptor Phosphodiesterase (PDE6): Structure, Regulatory Mechanisms, and Implications for Treatment of Retinal Diseases.
Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase.
The molecular architecture of photoreceptor phosphodiesterase 6 (PDE6) with activated G protein elucidates the mechanism of visual excitation.
Retinal Dystrophies
Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors.
Infliximab reduces Zaprinast-induced retinal degeneration in cultures of porcine retina.
Retinitis Pigmentosa
A novel mutation and phenotypes in phosphodiesterase 6 deficiency.
A novel mutation in exon 17 of the beta-subunit of rod phosphodiesterase in two RP sisters of a consanguineous family.
Adenoviral-mediated gene transfer to retinal explants during development and degeneration.
Advancing Gene Therapy for PDE6A Retinitis Pigmentosa.
An Update on Phosphodiesterase Mutations Underlying Genetic Etiology of Hearing Loss and Retinitis Pigmentosa.
Atypical retinal degeneration 3 in mice is caused by defective PDE6B pre-mRNA splicing.
Birt-Hogg-Dubé syndrome associated with chorioretinopathy and nyctalopia: a case report and review of the literature.
Delivery of genes to the eye using lentiviral vectors.
Development of photoreceptor-specific promoters and their utility to investigate EIAV lentiviral vector mediated gene transfer to photoreceptors.
Differential Modification of Phosducin Protein in Degenerating rd1 Retina Is Associated with Constitutively Active Ca2+/Calmodulin Kinase II in Rod Outer Segments.
Evaluation of the gene encoding the gamma subunit of rod phosphodiesterase in retinitis pigmentosa.
Evidence against involvement of recoverin in autosomal recessive retinitis pigmentosa in 42 Spanish families.
Functional rescue of degenerating photoreceptors in mice homozygous for a hypomorphic cGMP phosphodiesterase 6 b allele (Pde6bH620Q).
Gene Supplementation Rescues Rod Function and Preserves Photoreceptor and Retinal Morphology in Dogs, Leading the Way Towards Treating Human PDE6A-Retinitis Pigmentosa.
Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors.
Gene Therapy in a Large Animal Model of PDE6A-Retinitis Pigmentosa.
Gene therapy provides long-term visual function in a pre-clinical model of retinitis pigmentosa.
Gene therapy successfully delays degeneration in a mouse model of PDE6A-linked retinitis pigmentosa (RP 43).
Homozygous tandem duplication within the gene encoding the beta-subunit of rod phosphodiesterase as a cause for autosomal recessive retinitis pigmentosa.
Identification of a novel R552O mutation in exon 13 of the beta-subunit of rod phosphodiesterase gene in a Spanish family with autosomal recessive retinitis pigmentosa.
Increased Plasma cGMP in a Family With Autosomal Recessive Retinitis Pigmentosa Due to Homozygous Mutations in the PDE6A Gene.
Infliximab reduces Zaprinast-induced retinal degeneration in cultures of porcine retina.
Modifications of retinal neurons in a mouse model of retinitis pigmentosa.
Mutation spectrum of the gene encoding the beta subunit of rod phosphodiesterase among patients with autosomal recessive retinitis pigmentosa.
Mutations in phosphodiesterase 6 identified in familial cases of retinitis pigmentosa.
Mutations in the ?-subunit of rod phosphodiesterase identified in consanguineous Pakistani families with autosomal recessive retinitis pigmentosa.
Phosphodiesterase inhibition induces retinal degeneration, oxidative stress and inflammation in cone-enriched cultures of porcine retina.
Prenylation defects in inherited retinal diseases.
Proteomic Profiling Suggests Central Role Of STAT Signaling during Retinal Degeneration in the rd10 Mouse Model.
Recessive mutations in the gene encoding the beta-subunit of rod phosphodiesterase in patients with retinitis pigmentosa.
Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase.
Targeted next-generation sequencing reveals that a compound heterozygous mutation in phosphodiesterase 6a gene leads to retinitis pigmentosa in a Chinese family.
The Molecular Organization of Human cGMP Specific Phosphodiesterase 6 (PDE6): Structural Implications of Somatic Mutations in Cancer and Retinitis Pigmentosa.
The search for mutations in the gene for the beta subunit of the cGMP phosphodiesterase (PDEB) in patients with autosomal recessive retinitis pigmentosa.
Therapeutic Window for Phosphodiesterase 6-Related Retinitis Pigmentosa.
[A study of PDE6B gene mutation and phenotype in Chinese cases with retinitis pigmentosa]
[Identification of 2 allelic mutations of the gene of the phosphodiesterase beta subunit in a Spanish family with recessive autosomic retinitis pigmentosa]
[Molecular cloning of the genes in genetic chorioretinal diseases--positional cloning and the candidate gene approach]
[Screening gene mutations of the beta subunit of phosphodiesterase in the Chinese retinitis pigmentosa patients]
Retinoblastoma
Cyclic nucleotide phosphodiesterase and protein activator in human cancer cell lines and Brown-Pearce carcinoma.
Rheumatic Diseases
Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases.
Rhinitis, Allergic
Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Rhinitis, Allergic, Seasonal
Quercetin inhibition of the induction and function of cytotoxic T lymphocytes.
Rosacea
An oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot study.
Sarcoma
Apparent allosterism by avian myeloblastosis virus reverse transcriptase and E. coli DNA polymerase I.
Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS.
Nucleases and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in murine sarcoma virus (Moloney)-infected mice.
Properties of 2',3'-dideoxy-2',3'-dehydrothymidine 5'-triphosphate in terminating DNA synthesis catalyzed by several different DNA polymerases.
Seven loci on human chromosome 4 map onto sheep chromosome 6: a proposal to restore the original nomenclature of this sheep chromosome.
Sarcoma, Avian
Adenylate cyclase and cyclic AMP phosphodiesterase of normal and Rous sarcoma virus transformed chicken embryo fibroblasts.
An electron microscopic method for the mapping of proteins attached to nucleic acids.
Calcium-dependent regulatory protein of cyclic nucleotide metabolism in normal and transformed chicken embryo fibroblasts.
Scleroderma, Diffuse
Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil.
Scleroderma, Systemic
Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis.
Differing commissioning arrangements may contribute to geographic variation in clinical management of digital ulcers in systemic sclerosis.
Innovative therapies for systemic sclerosis.
Pulmonary arterial hypertension secondary to chronic lung diseases: pathogenesis and medical treatment.
Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options.
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.
Treatment of complications associated with systemic sclerosis.
Seizures
Biochemical aspects of pentylenetetrazole induced seizure.
Cerebral phosphoinositide, triacylglycerol and energy metabolism during sustained seizures induced by bicuculline.
Effects of pentoxifylline and H-89 on epileptogenic activity of bucladesine in pentylenetetrazol-treated mice.
Phosphodiesterase-5 inhibitors oppose hyperoxic vasoconstriction and accelerate seizure development in rats exposed to hyperbaric oxygen.
Protective effect of calmodulin inhibitors against acute cyanide-induced lethality and convulsions in mice.
Transcriptional and translational regulation of phosphodiesterase type IV isozymes in rat brain by electroconvulsive seizure and antidepressant drug treatment.
[Epileptic seizures and vardenafil]
[Seizure discharges induced by amphetamine in neuron of african snail Achatina fulica: effects of phosphodiesterase inhibitors.]
Sepsis
A Neonatal Murine Escherichia coli Sepsis Model Demonstrates That Adjunctive Pentoxifylline Enhances the Ratio of Anti- vs. Pro-inflammatory Cytokines in Blood and Organ Tissues.
Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options.
Effects of pentoxifylline on inflammatory cytokine expression and acute pleuropneumonia in swine.
Effects of pentoxifylline on tumor necrosis factor production and survival during lethal E. coli sepsis vs. disseminated candidiasis with fungal septic shock.
Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines.
Influence of amrinone on tissue oxygenation of jejunal mucosa during endotoxemia.
IV milrinone for cardiac output increase and maintenance: comparison in nonhyperdynamic SIRS/sepsis and congestive heart failure.
Lazaroid and pentoxifylline suppress sepsis-induced increases in renal vascular resistance via altered arachidonic acid metabolism.
Leukocyte phosphodiesterase expression after lipopolysaccharide and during sepsis and its relationship with HLA-DR expression.
Lipopolysaccharide attenuates mRNA levels of several adenylyl cyclase isoforms in vivo.
Olprinone improves diaphragmatic contractility and fatigability during abdominal sepsis in a rat model.
Pentoxifylline alone or in combination with gentamicin or vancomycin inhibits live microbe-induced pro-inflammatory cytokine production in human cord blood and cord blood monocytes in vitro.
Pentoxifylline fails to improve organ dysfunction and survival when used in the resuscitation of a porcine model of haemorrhage and abdominal sepsis.
The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomized laboratory investigation.
Type IV phosphodiesterase inhibition improves cardiac contractility in endotoxemic rats.
Shock, Cardiogenic
Administration of enoximone in cardiogenic shock.
Effects of concomitant usage of milrinone and catecholamine for weaning from cardiopulmonary bypass.
Efficacy of phosphodiesterase inhibitor enoximone in management of postcardiotomy cardiogenic shock.
Levosimendan in perioperative and critical care patients.
Levosimendan reversing low output syndrome after heart transplantation.
Olprinone, phosphodiesterase III inhibitor, is useful for patients with severe acute heart failure due to takotsubo cardiomyopathy accompanied by subarachnoid hemorrhage.
Post-operative effects of olprinone after coronary artery bypass grafting.
[Continuous infusion of enoximone in the treatment of acute myocardial ischemia with low output syndrome]
[Enoximone as an alternative to mechanical circulatory support prior to heart transplantation]
Shock, Septic
Amrinone administration in endotoxin shock.
Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial.
Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression.
Cytokine production and its manipulation by vasoactive drugs.
Effects of epinephrine and amrinone on contractility and cyclic adenosine monophosphate generation of tumor necrosis factor alpha-exposed cardiac myocytes.
Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock.
Lymphatic flow modulation as adjunct therapy for septic shock.
The effects of milrinone on hemodynamics in an experimental septic shock model.
Sinusitis
[Present status of the treatment for olfactory dysfunction].
Skin Diseases
Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial.
East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease.
Oleic acid as the active agent and lipid matrix in cilomilast-loaded nanocarriers to assist PDE4 inhibition of activated neutrophils for mitigating psoriasis-like lesions.
Rolipram inhibits polarization and migration of human T lymphocytes.
Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Skin Ulcer
Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options.
Sleep Apnea Syndromes
Obesity and male infertility: a practical approach.
Sleep Deprivation
Phosphodiesterase inhibitors roflumilast and vardenafil prevent sleep deprivation-induced deficits in spatial pattern separation.
Small Cell Lung Carcinoma
Reduced DNA synthesis and cell viability in small cell lung carcinoma by treatment with cyclic AMP phosphodiesterase inhibitors.
Spasm
Experimental cerebral vasospasm and cyclic adenosine monophosphate (c-AMP).
The in vitro effects of phosphodiesterase inhibitors on the human internal mammary artery.
Treatment of experiment delayed cerebral arterial spasm with a beta2-adrenergic stimulator and a phosphodiesterase inhibitor.
sphingomyelin phosphodiesterase deficiency
Deficiency of taurocholate-dependent phospholipase C acting on phosphatidylcholine in Niemann-Pick disease.
Spinal Cord Diseases
Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model.
Spinal Cord Injuries
Cilostazol, a type III phosphodiesterase inhibitor, reduces ischemia/reperfusion-induced spinal cord injury.
Erectile dysfunction.
Inhibition of phosphodiesterase IV enzyme improves locomotor and sensory complications of spinal cord injury via altering microglial activity: Introduction of Roflumilast as an alternative therapy.
Performance and safety of treatment options for erectile dysfunction in patients with spinal cord injury: A review of the literature.
Systemic administration of rolipram increases medullary and spinal cAMP and activates a latent respiratory motor pathway after high cervical spinal cord injury.
Spinocerebellar Ataxias
DNA single-strand break repair and spinocerebellar ataxia with axonal neuropathy-1.
Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes.
In vitro complementation of Tdp1 deficiency indicates a stabilized enzyme-DNA adduct from tyrosyl but not glycolate lesions as a consequence of the SCAN1 mutation.
Spinocerebellar ataxia with axonal neuropathy.
Tdp1 protects against oxidative DNA damage in non-dividing fission yeast.
TDP1 serine 81 promotes interaction with DNA ligase IIIalpha and facilitates cell survival following DNA damage.
Unrepaired oxidative DNA damage induces an ATR/ATM apoptotic-like response in quiescent fission yeast.
Starvation
Adenylate cyclase and phosphodiesterase in the rat gastric mucosa after starvation, feeding and pentagastrin.
Attenuation of phosphate starvation responses by phosphite in Arabidopsis.
Changes in phosphodiesterase activity of human subcutaneous adipose tissue during starvation.
Desynchronization of cells on the developmental path triggers the formation of spiral waves of cAMP during Dictyostelium aggregation.
Distribution of cyclic AMP phosphodiesterase in microdissected periportal and perivenous rat liver tissue with different dietary states.
Effect of nutritional status on swine adipose tissue lipolytic activities.
Induction of phosphodiesterase by cyclic adenosine 3':5'-monophosphate in differentiating Dictyostelium discoideum amoebae.
pdsA, a gene involved in the production of active phosphodiesterase during starvation of Dictyostelium discoideum amoebae.
The effect of starvation on phosphodiesterase activity and the content of adenosine 3' :5'-cyclic monophosphate in isolated mouse pancreatic islets.
The stringent response promotes biofilm dispersal in Pseudomonas putida.
YdiV: a dual function protein that targets FlhDC for ClpXP-dependent degradation by promoting release of DNA-bound FlhDC complex.
[Relation between Escherichia coli K-12 viability and mutability and the balance between DNA and protein synthesis. III. Relation between disruptions in the balance between DNA and protein synthesis and mutagenesis and viability during thymidine deprivation of thy- cells defective with respect to recB and polA genes]
Stomach Diseases
Role of nitric oxide in physiology and pathology of the gastrointestinal tract.
Stomach Neoplasms
[Relationship between cyclic nucleotide phosphodiesterases (cPDE) and some patho-biologic behaviors of stomach cancer--I. Histochemical studies of CPDE in stomach cancer tissues]
Stroke
A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats.
A PDE1 inhibitor reduces adipogenesis in mice via regulation of lipolysis and adipogenic cell signaling.
Advances in the genetic basis of coronary artery disease.
Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage.
Antiplatelet cilostazol, an inhibitor of type III phosphodiesterase, improves swallowing function in patients with a history of stroke.
Antiplatelet therapy for preventing stroke in patients with chronic kidney disease.
Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.
Cilostazol Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysms but Not Atherosclerosis in Apolipoprotein E-Deficient Mice.
Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis.
Cilostazol protects against microvascular brain injury in a rat model of type 2 diabetes.
Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study.
Cilostazol's effect on the response to perivascular nerve stimulation in isolated dog cerebral and mesenteric arteries.
Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia.
Eburnamine derivatives and the brain.
Genetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitors.
Guanosine 3',5'-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: protective effects of propentofylline.
Hemodynamic and neuroendocrine response to acute administration of the phosphodiesterase inhibitor BM14.478 in patients with congestive heart failure.
Ibudilast inhibits chemokine expression in rheumatoid synovial fibroblasts and exhibits immunomodulatory activity in experimental arthritis.
Ibudilast, a phosphodiesterase inhibitor with anti-inflammatory activity, protects against ischemic brain injury in rats.
Mixed Cerebrovascular Disease and the Future of Stroke Prevention.
Molecular genetics of coronary artery disease.
Neuroprotective effect of roflumilast under cerebral ischaemia/reperfusion injury in juvenile rats through NLRP-mediated inflammatory response inhibition.
Role of FLAP and PDE4D in Myocardial Infarction and Stroke: Target Discovery and Future Treatment Options.
Saving the ischemic penumbra: potential role for statins and phosphodiesterase inhibitors.
The phosphodiesterase puzzlebox: PDE4D and stroke.
The uncertain role for phosphodiesterase inhibitors in stroke prevention.
Vinpocetine Improves Scopolamine Induced Learning and Memory Dysfunction in C57 BL/6J Mice.
[Antiplatelet therapy: update in secondary stroke prevention].
[The hemodynamic profile of amrinone and enoximone in patients with severe heart failure]
Subarachnoid Hemorrhage
Changes of the Expression and Activity of Phosphodiesterase V in the Basilar Artery Before and After Cerebral Vasospasm in a Rabbit Model.
Dose-Dependent Inhibitory Effects of Cilostazol on Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage.
Effect of vasodilation by milrinone, a phosphodiesterase III inhibitor, on vasospastic arteries after a subarachnoid hemorrhage in vitro and in vivo: effectiveness of cisternal injection of milrinone.
Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model.
Olprinone, phosphodiesterase III inhibitor, is useful for patients with severe acute heart failure due to takotsubo cardiomyopathy accompanied by subarachnoid hemorrhage.
Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage.
The effect of phosphodiesterase inhibitor tadalafil on vasospasm following subarachnoid hemorrhage in an experimental rabbit model.
Therapeutic Benefit of Cilostazol in Patients with Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized and Nonrandomized Studies.
To evaluate the Changes of the expression and activity of Phosphodiesterase V in the Basilar Artery Before and After Cerebral Vasospasm in Rabbits model.
Type V phosphodiesterase expression in cerebral arteries with vasospasm after subarachnoid hemorrhage in a canine model.
Sunburn
PDE2 is a novel target for attenuating tumor formation in a mouse model of UVB-induced skin carcinogenesis.
Syphilis
Amplification of the DNA polymerase I gene of Treponema pallidum from whole blood of persons with syphilis.
Molecular subtyping of Treponema pallidum in an Arizona County with increasing syphilis morbidity: use of specimens from ulcers and blood.
New tests for syphilis: rational design of a PCR method for detection of Treponema pallidum in clinical specimens using unique regions of the DNA polymerase I gene.
Tachycardia
Analysis of competitive antagonism when this property occurs as part of a pharmacological resultant.
Changes in systemic haemodynamics, regional myocardial function and perfusion induced by alinidine in pigs with and without narrowed coronary arteries.
Coronary reactions to cardiac hyperactivity and to hypoxia in isolated perfused heart of rat.
Further evidence for the involvement of cAMP in central blood pressure regulation.
Phosphodiesterase-3 inhibitor (cilostazol) attenuates oxidative stress-induced mitochondrial dysfunction in the heart.
Tachycardia, Ventricular
Modulation of myocardial cyclic AMP and vulnerability to fibrillation in the rat heart.
Takotsubo Cardiomyopathy
Olprinone, phosphodiesterase III inhibitor, is useful for patients with severe acute heart failure due to takotsubo cardiomyopathy accompanied by subarachnoid hemorrhage.
Teratocarcinoma
Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells.
Testicular Neoplasms
A phosphodiesterase 11 (Pde11a) knockout mouse expressed functional but reduced Pde11a: Phenotype and impact on adrenocortical function.
Analysis of genetic variants of phosphodiesterase 11A in acromegalic patients.
Frequent Phosphodiesterase 11A Gene (PDE11A) Defects in Patients with Carney Complex (CNC) Caused by PRKAR1A Mutations: PDE11A May Contribute to Adrenal and Testicular Tumors in CNC as a Modifier of the Phenotype.
Rare inactivating PDE11A variants associated with testicular germ cell tumors.
Tetanus
Chronic hyperammonemia in vivo impairs long-term potentiation in hippocampus by altering activation of cyclic GMP-dependent-protein kinase and of phosphodiesterase 5.
Long-term potentiation in hippocampus involves sequential activation of soluble guanylate cyclase, cGMP-dependent protein kinase, and cGMP-degrading phosphodiesterase.
Sequential activation of soluble guanylate cyclase, protein kinase G and cGMP-degrading phosphodiesterase is necessary for proper induction of long-term potentiation in CA1 of hippocampus. Alterations in hyperammonemia.
Thrombocythemia, Essential
Atypical Takotsubo syndrome during anagrelide therapy.
Thrombocytopenia
Possible contribution of acetylamrinone and its enhancing effects on platelet aggregation under shear stress conditions in the onset of thrombocytopenia in patients treated with amrinone.
Thrombosis
Antiplatelet and antithrombotic effects of a novel selective phosphodiesterase 3 inhibitor, NSP-513, in mice and rats.
Antiplatelet treatment with cilostazol after stent implantation.
Antithrombotic activity of the phosphodiesterase III inhibitor pelrinone in a canine model of coronary artery thrombosis: enhancement of efficacy with concurrent alpha 2-adrenergic antagonism.
BF066, a Novel Dual Target Antiplatelet Agent without Significant Bleeding.
Cilostazol and Primary-PCI: Mirage or Good Alternative?
Cilostazol in the management of vascular disease.
Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury.
Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbits.
Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery.
Ibudilast, a Phosphodiesterase Inhibitor, in Combination with Low-dose Aspirin Potently Inhibits Guinea Pig Carotid Artery Thrombosis without Extending Bleeding Time and Causing Gastric Mucosal Injury.
Inhibition of Phosphodiesterase 3A by Cilostazol Dampens Proinflammatory Platelet Functions.
Manipulation of thrombus formation in the hamster cheek pouch with drugs that interact with PGI2 in vitro.
Partial segmental thrombosis of the corpus cavernosum presenting with perineal pain.
Potentiation of the antithrombotic effect of prostacyclin by simultaneous administration of aminophylline in a canine model of coronary artery thrombosis.
The vascular effects of cilostazol.
Tumor vascular disrupting agent DMXAA inhibits platelet activation and thrombosis via inhibition of TXA2 signaling and phosphodiesterase.
Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen.
Thyroid Cancer, Papillary
Tumor necrosis factor-alpha activates nuclear factor kappa B and induces manganous superoxide dismutase and phosphodiesterase mRNA in human papillary thyroid carcinoma cells.
Thyroid Neoplasms
Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas.
Thyroiditis, Subacute
Serum cyclic 3',5'-nucleotide phosphodiesterase in patients with various thyroid disorders.
Tics
Ovarian stanniocalcin is structurally unique in mammals and its production and release are regulated through the luteinizing hormone receptor.
Triple Negative Breast Neoplasms
Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth.
Trypanosomiasis, African
Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors (Part 2).
Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.
Tuberculosis
A novel calcium binding protein in Mycobacterium tuberculosis--potential target for trifluoperazine.
Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment.
c-di-AMP hydrolysis by the phosphodiesterase AtaC promotes differentiation of multicellular bacteria.
Cloning and sequence analysis of the gene encoding the DNA polymerase I from Mycobacterium tuberculosis.
Deletion of the cyclic di-AMP phosphodiesterase gene (cnpB) in Mycobacterium tuberculosis leads to reduced virulence in a mouse model of infection.
Deoxy- and dideoxynucleotide discrimination and identification of critical 5' nuclease domain residues of the DNA polymerase I from Mycobacterium tuberculosis.
DNA polymerase I of Mycobacterium tuberculosis: functional role of a conserved aspartate in the hinge joining the M and N helices.
Identification of a Mycobacterium tuberculosis Cyclic Dinucleotide Phosphodiesterase Inhibitor.
Inhibition of innate immune cytosolic surveillance by an M. tuberculosis phosphodiesterase.
Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis.
Phosphorylation of mycobacterial phosphodiesterase by eukaryotic-type Ser/Thr kinase controls its two distinct and mutually exclusive functionalities.
Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis.
Rv2577 of Mycobacterium tuberculosis Is a Virulence Factor With Dual Phosphatase and Phosphodiesterase Functions.
Structural and Biochemical Insight into the Mechanism of Rv2837c from Mycobacterium tuberculosis as a c-di-NMP Phosphodiesterase.
Structural and biochemical insight into the mechanism of Rv2837c from Mycobacterium tuberculosis as a c-di-NMP phosphodiesterase.
Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.
The adenylyl cyclase Rv2212 modifies the proteome and infectivity of Mycobacterium bovis BCG.
Urinary Bladder Neck Obstruction
Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor.
The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction.
Urinary Bladder Neoplasms
Phospholipase C-? regulates bladder cancer cells via ATM/EXO1.
Urinary Bladder, Overactive
An animal study to compare the degree of the suppressive effects on the afferent pathways of micturition between tamsulosin and sildenafil.
Lower Urinary Tract Symptoms: What's New in Medical Treatment?
Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast.
[Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function : An immunohistochemical and functional study.]
Urinary Calculi
Pathophysiology and symptoms of renal colic in children - a case report.
Urinary Incontinence
Expressions of vaginal endothelial nitric oxide synthase and phosphodiesterase 5 in female sexual dysfunction: a pilot study.
Urination Disorders
[Tadalafil in patients with benign prostatic hyperplasia during conservative combined therapy].
Urogenital Diseases
Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract.
Urolithiasis
Medical expulsive therapy in urolithiasis: a mixed treatment comparison network meta-analysis of randomized controlled clinical trials.
Mirabegron: A Novel and Promising Medical Expulsive Treatment for Ureteral Stones?
Urologic Diseases
Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.
Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats.
Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future.
Uterine Cervical Neoplasms
Three Prime Repair Exonuclease 1 (TREX1) expression correlates with cervical cancer cells growth in vitro and disease progression in vivo.
Uveitis
Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats.
The effects of 3-isobutyl-methyl-xanthine on experimentally induced ocular inflammation in the rabbit.
Vaccinia
Human DNA polymerase alpha gene expression is cell proliferation dependent and its primary structure is similar to both prokaryotic and eukaryotic replicative DNA polymerases.
Human DNA polymerase alpha: predicted functional domains and relationships with viral DNA polymerases.
Solution structure of a DNA duplex containing the potent anti-poxvirus agent cidofovir.
The 3'-to-5' exonuclease activity of vaccinia virus DNA polymerase is essential and plays a role in promoting virus genetic recombination.
Vascular Diseases
Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.
Vascular System Injuries
Biomarkers in peripheral blood associated with vascular injury in Sprague-Dawley rats treated with the phosphodiesterase IV inhibitors SCH 351591 or SCH 534385.
Early events in vascular injury in the rat induced by the phosphodiesterase IV inhibitor SCH 351591.
Histopathology of vascular injury in Sprague-Dawley rats treated with phosphodiesterase IV inhibitor SCH 351591 or SCH 534385.
Roflumilast-induced Local Vascular Injury Is Associated with a Coordinated Proteome and Microparticle Change in the Systemic Circulation in Pigs.
Vasculitis
Apoptosis and nitrative stress associated with phosphodiesterase inhibitor-induced mesenteric vasculitis in rats.
Metabonomic assessment of vasculitis in rats.
Vasospasm, Intracranial
Cerebral arterial spasm. II. Etiology and treatment of experimental cerebral vasospasm.
Changes of the Expression and Activity of Phosphodiesterase V in the Basilar Artery Before and After Cerebral Vasospasm in a Rabbit Model.
Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model.
Phosphodiesterase inhibitors and cerebral vasospasm.
Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage.
Therapeutic Benefit of Cilostazol in Patients with Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized and Nonrandomized Studies.
To evaluate the Changes of the expression and activity of Phosphodiesterase V in the Basilar Artery Before and After Cerebral Vasospasm in Rabbits model.
Ventilator-Induced Lung Injury
Inhibitors of myosin light chain kinase and phosphodiesterase reduce ventilator-induced lung injury.
Ventricular Dysfunction
A multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgery.
Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery.
Pharmacologic support of circulation in patients undergoing cardiac surgery.
Ventricular Dysfunction, Left
A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass.
Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor.
Ibudilast, a Phosphodiesterase Inhibitor and Toll-Like Receptor-4 Antagonist, Improves Hemorrhagic Shock and Reperfusion-Induced Left Ventricular Dysfunction by Reducing Myocardial Tumor Necrosis Factor ?.
New positive inotropic agents in the treatment of left ventricular dysfunction.
Newer oral inotropic agents: phosphodiesterase inhibitors.
[Left ventricular dysfunction while weaning from mechanical ventilation. Contribution of enoximone]
Ventricular Dysfunction, Right
Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem.
Support of the perioperative failing heart with preexisting ventricular dysfunction: currently available options.
Ventricular Fibrillation
Inhibition by simulated ischemia or hypoxia of delayed afterdepolarizations provoked by cyclic AMP: significance for ischemic and reperfusion arrhythmias.
Phosphodiesterase-5 inhibition improves macrocirculation and microcirculation during cardiopulmonary resuscitation.
Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome.
Vibrio Infections
Analysis of the replication elements of the pMJ101 plasmid from the fish pathogen Vibrio ordalii.
Vision Disorders
A p97/Valosin-Containing Protein Inhibitor Drug CB-5083 Has a Potent but Reversible Off-Target Effect on Phosphodiesterase-6.
Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction.
WAGR Syndrome
Unique Utilization of a Phosphoprotein Phosphatase Fold by a Mammalian Phosphodiesterase Associated with WAGR Syndrome.
Waldenstrom Macroglobulinemia
Novel agents in the treatment of Waldenström's macroglobulinemia.
Werner Syndrome
Biochemical mechanisms of chromosomal translocations resulting from DNA double-strand breaks.
Diverse dealings of the Werner helicase/nuclease.
Positionally cloned human disease genes: patterns of evolutionary conservation and functional motifs.
The exonucleolytic and endonucleolytic cleavage activities of human exonuclease 1 are stimulated by an interaction with the carboxyl-terminal region of the Werner syndrome protein.
Whooping Cough
5-HT1A receptor-mediated inhibition of acetylcholine release from guinea pig myenteric plexus: potential mechanisms.
A novel hypothalamic peptide, pituitary adenylate cyclase activating peptide, modulates Sertoli cell function in vitro.
Alpha 1-adrenergic regulation of TSH-stimulated cyclic AMP accumulation in rat thyroid cells.
Alpha 1-adrenoceptor-mediated inhibition of cellular cAMP accumulation in neonatal rat ventricular myocytes.
Angiotensin II (A-II) steroidogenic refractoriness in Y-1 cells in the presence of A-II receptors negatively coupled to adenylate cyclase.
Antilipolytic effects of insulin and adenylate cyclase inhibitors on isolated human fat cells.
Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells.
Curosurf modulates cAMP accumulation in human monocytes through a membrane-controlled mechanism.
Different effects of phorbol ester on angiotensin II- and stable GTP analogue-induced activation of polyphosphoinositide phosphodiesterase in membranes isolated from rat renal mesangial cells.
Differential effect of pertussis toxin on adenosine and muscarinic inhibition of cyclic AMP accumulation in canine ventricular myocytes.
Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of beta-adrenergic pathway, G(i) protein, phosphodiesterase, and phosphatases.
Divalent cations suppress 3',5'-adenosine monophosphate accumulation by stimulating a pertussis toxin-sensitive guanine nucleotide-binding protein in cultured bovine parathyroid cells.
Effect of pertussis toxin and neomycin on G-protein-regulated polyphosphoinositide phosphodiesterase. A comparison between HL60 membranes and permeabilized HL60 cells.
Effects of GTP, forskolin, sodium fluoride, serotonin, dopamine, and carbachol on adenylate cyclase in Teleost retina.
Effects of inactivated Bordetella pertussis on phosphodiesterase in the lung of ovalbumin sensitized and challenged rats.
Evidence for the presence of cholinergic muscarinic receptors negatively linked to adenylate cyclase in the iris-ciliary body.
Evidence for the presence of serotonin receptors negatively coupled to adenylate cyclase in the rabbit iris-ciliary body.
G-proteins, the inositol lipid signalling pathway, and secretion.
GLP-1-(7-36) amide, -(1-37), and -(1-36) amide: potent cAMP-dependent stimuli of rat parietal cell function.
Human immunodeficiency virus type 1 Tat protein decreases cyclic AMP synthesis in rat microglia cultures.
Inhibition by pertussis toxin of guanyl nucleotides exchange on transducin in bovine rod cell membranes.
Inhibition of cAMP accumulation by intracellular calcium mobilization in C6-2B cells stably transfected with substance K receptor cDNA.
Inhibition of cAMP production by alpha 2-adrenoceptor stimulation in rabbit retina.
Inhibition of glucagon-signaling and downstream actions by interleukin 1beta and tumor necrosis factor alpha in cultured primary rat hepatocytes.
Inhibitory effects of C4a on chemoattractant and secretagogue functions of the other anaphylatoxins via Gi protein-adenylyl cyclase inhibition pathway in mast cells.
Insulin stimulation of cyclic AMP phosphodiesterase is independent from the G-protein pathways involved in adenylate cyclase regulation.
Lidocaine enhances Galphai protein function.
Mechanism of stress-induced attenuation of the testicular response to gonadotropin: possible involvement of testicular opioids, a pertussis toxin-sensitive G-protein, and phosphodiesterase.
Mechanism of the impairment of the glucagon-stimulated phosphoenolpyruvate carboxykinase gene expression by interleukin-6 in rat hepatocytes: inhibition of the increase in cyclic 3',5' adenosine monophosphate and the downstream cyclic 3',5' adenosine monophosphate action.
Mechanisms of leptin secretion from white adipocytes.
Modulation of islet G-proteins, alpha-glucosidehydrolase inhibition and insulin release stimulated by various secretagogues.
N-acetylaspartylglutamate inhibits forskolin-stimulated cyclic AMP levels via a metabotropic glutamate receptor in cultured cerebellar granule cells.
Pertussis toxin enhances proenkephalin synthesis in bovine chromaffin cells.
Pertussis toxin stimulates cholecystokinin-induced cyclic AMP formation but is without effect on secretagogue-induced calcium mobilization in exocrine pancreas.
Pertussis toxin stimulates the secretion of [Met5]-enkephalin and the expression of proenkephalin A mRNA in bovine adrenal medullary chromaffin cells.
Photosensory transduction in ciliates. II. Possible role of G-protein and cGMP in Stentor coeruleus.
Photosensory transduction in ciliates. IV. Modulation of the photomovement response of Blepharisma japonicum by cGMP.
Protein kinase C activators sensitize cyclic AMP accumulation by intact 1321N1 human astrocytoma cells.
Purification and properties of calmodulin from adrenal cortex.
Role of G-proteins and adenylate cyclase in antinociception produced by intrathecal purines.
Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (betaTC-3) cells to glucose-dependent insulinotropic polypeptide.
Role of protein kinase C in transforming growth factor-beta 1 induction of carcinoembryonic antigen in human colon carcinoma cells.
Serum uncouples elevation of cyclic adenosine monophosphate concentration from cyclic adenosine monophosphate dependent morphological changes exhibited by cultured pituicytes.
The action of islet activating protein (pertussis toxin) on insulin's ability to inhibit adenylate cyclase and activate cyclic AMP phosphodiesterases in hepatocytes.
Thyrotropin-releasing hormone activates a Ca2+-dependent polyphosphoinositide phosphodiesterase in permeable GH3 cells. GTP gamma S potentiation by a cholera and pertussis toxin-insensitive mechanism.
[Inhibitory effect of pertussis toxin on the metabolism of guanine nucleotides in transducin from bovine outer rod segments]
Wilms Tumor
Studies on platelet aggregation inhibitors in vivo. VIII. Effect of pentoxifylline on spontaneous tumor metastasis.
Xeroderma Pigmentosum
Proximity of repair patches to persistent pyrimidine dimers in DNA of normal human and xeroderma pigmentosum cells.